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Abstract 
Over the past two decades there has been a realization of the importance of 
understanding the underlying molecular mechanism of complex neurological diseases. 
GWAS studies confirmed a significant association between SNPs and complex 
neurologic and psychiatric diseases such as Parkinson’s disease and Alzheimer’s 
disease. In this project, the impact of genetic variations on gene expression and 
alternative splicing in control post-mortem human brain tissues from twelve different 
regions were assessed. These are disease associated regions and support different 
functional roles. They are: frontal cortex, temporal cortex, occipital cortex, white 
matter, hippocampus, thalamus, hypothalamus, putamen, substantia nigra, medulla, 
cerebellum and spinal cord. 
Based on 1231 RNA human exon arrays, genotyped and imputed DNA samples 
from 137 control human brain, brain transcriptome profiles, gene and exon expression 
quantitative trait loci (QTL) were identified in multiple brain regions. 
Significant region-specific exon and gene expression QTLs were reported. 
Cerebellum and white matter show more unique expression profiles and expression 
QTLs in comparison with other brain regions. Furthermore, alternative splicing 
patterns were in a specific group of regions such as the cortical regions. In addition, 
two neurodegenerative disease related genes were investigated in detail, namely 
LRRK2 and MAPT. Significant regional differences in expression at mRNA and 
protein levels were shown. Moreover, exon QTLs correlated with the expression of 
specific exons located in functional protein domains of LRRK2. Also, an exon QTL 
has been found that shows a protective effect against Parkinson’s disease with an 
increase in the inclusion of exon 3 in grey matter for MAPT.  
This study has yielded novel regional specific expression QTLs and novel 
insights into the expression, regulation and function of specific genes in different 
regions of control human brain that are related to neurological diseases. This reference 
dataset is a valuable resource to complement other datasets for research into the 
complex genetics of neurological diseases. 
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4 repeats tau isoform 
5`UTR  5` un translated region 
AD 
 
Alzheimer’s disease 
ANOVA 
 
Analysis of variance 
bDNA 
 
Branched DNA 
BLs 
 
Blockers 
bp 
 
Base pairs 
CBD 
 
Corticobasal degeneration 
cDNA 
 
Complementary deoxyribonucleic acid 
CEs 
 
Capture Extenders 
CNS 
 
Central nervous system 
CNV 
 
Copy number variation 
CRBL 
 
Cerebellum 
cRNA 
 
Complementary ribonucleic acid 
Ct 
 
Cycle threshold 
DABG  Detection above background 
DAVID  The Database for Annotation, Visualization and Integrated Discovery 
DNA 
 
Deoxyribonucleic acid 
ELISA 
 
Enzyme-linked immunosorbent assay 
ENCODE  Encyclopaedia of DNA Elements 
FC 
 
Fold change 
FCTX  
 
Frontal Cortex 
FDR 
 
False discovery rate 
FTLD  Frontotemporal lobar degeneration 
GO  Gene ontology 
GSEA  Gene set enrichment analysis 
GWAS 
 
Genome wide associating studies 
HIPP 
 
Hippocampus 
HK  House keeping genes 
HYPO  Hypothalamus 
IgG 
 
Immunoglobulin G antibody 
IHC  Immunohistochemistry 
IVT 
 
In Vitro Transcription 
LD 
 
Linkage disequilibrium 
LEs 
 
Label Extenders 
MAF 
 
Minor allele frequency 
Mb 
 
Mega base(s) 
MEDU 
 
Medulla 
miRNA 
 
Micro ribonucleic acid 
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MJFF2  Michael J. Fox foundation antibody 2 
MRC 
 
Medical Research Council 
mRNA 
 
Messenger ribonucleic acid 
NABEC 
 
North American Brain Expression Consortium 
NFT 
 
Neurofibrillary tangles 
ng 
 
Nano gram 
nm 
 
Nano meter (wave length) 
OCTX 
 
Occipital Cortex 
OD 
 
Optical density 
OMIM  Online Mendelian Inheritance in Man 
PBS  Phosphate buffered saline 
PCA  Principal component analysis 
PCTX 
 
Parietal Parasagittal 
PD 
 
Parksinson’s disease 
PMI 
 
Post Mortem Interval 
PSP 
 
Progressive supranuclear palsy 
PUTM 
 
Putamen 
QC 
 
Quality control 
QG 
 
QuantiGene 
QTL 
 
Quantitative trait loci 
RIN 
 
RNA integrity number 
RNA 
 
Ribonucleic acid 
Rpm 
 
Revolutions per minute 
SHRI 
 
Sun Health Research Institute 
SNIG 
 
Substania nigra 
SNP 
 
Single nucleotide polymorphism 
SPCO 
 
Spinal Cord 
SSPE-T 
 
Sodium chloride + sodium phosphate + EDTA + Triton X-100 buffer 
TCTX 
 
Temporal Cortex 
THAL 
 
Thalamus 
TSS  Transcription start site 
UKBEC 
 
UK Brain Expression Consortium 
WGCNA  Weighted gene co-expression network analysis 
WHMT 
 
White Matter (Intralobular) 
WT 
 
Whole Transcript 
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Gene abbreviations 
AGTR1  Angiotensin II receptor, type 1 
ANO3  Anoctamin 3 
BACE2  Beta-site APP-cleaving enzyme 2  
BIN1 
 
Bridging integrator 1 
CBLN3  cerebellin 3 precursor 
CNTNAP2  Contactin-associated protein-like 2 
CR1 
 
Erythrocyte complement component, C3b/C4b receptor 1  
CRTM  Class I MHC-restricted T cell-associated molecule 
EN1  Engrailed homeobox 1 
GABRP  gamma-aminobutyric acid (GABA) A receptor, subunit π 
IDE  Insulin degrading enzyme 
IGFBP3 Insulin-like growth factor-binding protein 3 
IGHMBP2  immunoglobulin helicase μ- binding protein 2 
KCND3  Potassium voltage-gated channel, Shal-related subfamily, member 3 
LINGO2  Leucine rich repeat and Ig domain containing 2 
LRRK2 
 
Leucine-rich repeat kinase 2 
MAPT 
 
Microtubule-associated protein tau 
NLGN4X Neuroligin 4, X-linked 
NRK  Nik related kinase 
NRXN3 
 
Neurexin 3 
PDZK1  PDZ domain containing 1 
PICALM Phosphatidylinositol binding clathrin assembly protein 
PLP1  Proteolipid protein 1 
RPLP0 
 
ribosomal protein, large, P0  
SCN8A 
 
Sodium channel, voltage gated, type VIII, alpha subunit 
SETX  Senataxin 
SLC18A2  solute carrier family 18, member 2 
SLC6A3  solute carrier family 6, member 3 
TH  Tyrosine hydroxylase 
TMPRSS5  Transmembrane protease, serine 5 
TPM4  Tropomyosin 4 
TUBB 
 
Tubulin beta class I 
UBC 
 
Ubiquitin C 
VSIG4 
 
V-set and immunoglobulin domain containing 4 
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1 Introduction 
The human brain has a unique and a complex structure. The heterogeneous 
nature of this organ is due to different types of cells, neurons and the levels that these 
components are structured at. The knowledge about the human central nervous system 
(CNS) structure and function is increasing greatly, and this will be used to benefit 
human health. All the research efforts in the molecular and cellular neuroscience fields 
are vital to develop our understanding of the human CNS function and to dissect the 
complexity of neurological disease development. These rapid advancements were 
mainly determined by the genomic, transcriptomic and diagnostic technological 
innovations (Geschwind and Konopka 2009). These technologies are applicable at the 
genome-wide scale, and their application results in more insightful information being 
produced, and this can lead toward more informed investigations and in turn through to 
clinical applications. Until now, although these efforts have resulted in achieving some 
of the required aims, the field still lacks the knowledge and the comprehensive 
understanding of the complex machinery of the biological connections in the human 
CNS. 
It was anticipated that different morphological and cognitive features between 
human and other organisms were due to the variability in gene expression profiles 
(Enard, Khaitovich et al. 2002). Studying the transcriptome in human CNS or even in 
different organisms is a reasonable approach to dissect the functional complexity and 
the progress of the diseases.   In 2002, this concept was highlighted by the first 
microarray study that was performed to compare expression patterns between different 
tissues in different organisms (Enard, Khaitovich et al. 2002). Results demonstrated, in 
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the human brain, that there was considerable variation in gene expression profiles 
between different individuals that may contribute to the brain function processes. 
In order to create that specific knowledge, research on different cell lines and 
other model organisms was performed to understand more about the gene expression 
underlying functional regulation in these models (Ross, Scherf et al. 2000; Jin, Riley et 
al. 2001; Brem, Yvert et al. 2002; Wade, Kulbokas et al. 2002; Waterston, Lindblad-
Toh et al. 2002). This approach was applied for many different reasons, including cost, 
quality, quantity and the accessibility of tissues and samples, specifically CNS samples 
and specific cell types such as neurons. Human based research was limited for some of 
the reasons mentioned above. However, the necessity to dissect the complexity of 
human neurological diseases required researchers to perform their experiments on 
human tissues and samples rather than model organisms. At the same time, some 
transcriptomic studies revealed that the gene expression signatures are distinctive and 
different between human and chimpanzee brains even though the DNA similarity 
between them is 98.7% (Enard, Khaitovich et al. 2002). That was not the case for gene 
expression patterns in liver and lymphoblast cells as they were more similar to each 
other (Enard, Khaitovich et al. 2002; Gu and Gu 2003; Karaman, Houck et al. 2003). 
Results from these studies emphasized the importance of performing human based 
research. It is worth noting that the recent advancement of technologies has made this 
research approach achievable in a relatively short time line (Prof. John Hardy, personal 
communication).   
Focusing on the genome-wide and regional human CNS expression studies, 
previous studies demonstrated the usability of post-mortem human tissues (Franz, 
Ullmann et al. 2005) and the success of investigating and comparing gene expression 
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patterns in control versus disease human post-mortem brains or CNS samples for some 
neurological diseases (Mirnics, Middleton et al. 2001; Hodges, Strand et al. 2006). In 
the study of Hodge et al. differential gene expression profiles in control and disease 
samples were detected between different brain regions, namely caudate nucleus, motor 
cortex and cerebellum, but not in prefrontal cortex. This result raised the concept that 
some of the pathological features are not necessarily revealed by the histopathological 
assessments of the neurological diseases (Hodges, Strand et al. 2006).      
Likewise, not only were gene expression profiles investigated in detail in 
specific tissues, but also the alternative splicing profiles were closely investigated by 
different groups (Castle, Zhang et al. 2008; Xi, Feber et al. 2008; Qin, Haroutunian et 
al. 2009; Tollervey, Wang et al. 2011). The fact that 92-94 % of the human genes are 
alternatively spliced (Wang, Sandberg et al. 2008), indicates that the brain has a high 
level of alternative splicing events compared with other tissues (Yeo, Holste et al. 
2004) and there is evidence that 50% of mutations in human genetic diseases are 
driven by pre-mRNA splicing (Cartegni, Chew et al. 2002) highlighted the importance 
of these studies.  
The availability of this knowledge in addition to the development of advanced 
technology and the advanced downstream analysis tools (Clark, Schweitzer et al. 2007; 
Anton, Aramburu et al. 2010) facilitates some significant and key studies to be 
performed to discover novel expression and splicing events that are involved in the 
functional mechanisms and regulation process in diseased as well as normal human 
tissues including the brain (Haverty, Weng et al. 2002; Roth, Hevezi et al. 2006; Clark, 
Schweitzer et al. 2007; French, Peeters et al. 2007; Castle, Zhang et al. 2008; Johnson, 
Kawasawa et al. 2009; Anton, Aramburu et al. 2010; Fugier, Klein et al. 2011; Kang, 
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Kawasawa et al. 2011; Prescott and Chamberlain 2011; Tollervey, Wang et al. 2011; 
Hawrylycz, Lein et al. 2012). As a result of these developments, a few tissue specific 
databases of mRNA expression profiles from normal human tissues were created for 
the scientific community (Haverty, Weng et al. 2002; Su, Wiltshire et al. 2004; Son, 
Bilke et al. 2005). 
For example, in the study of French et al., novel differentially spliced isoforms 
and exons were identified between the subgroups of Glial brain tumour cases.  These 
novel isoforms are believed to have a role in the initiation or progression of the glioma 
(French, Peeters et al. 2007).  Another recent study by Tollervey and colleagues 
identified disease related alternative splicing events in patients with frontotemporal 
lobar degeneration (FTLD) or Alzheimer's disease (AD) (Tollervey, Wang et al. 2011). 
Furthermore, it is important to profile the normal variability of gene expression 
and splicing patterns. This will provide the complete mapping of these transcriptional 
regulation patterns in healthy tissues and cells which are not affected with the 
pathology of the disease.  These samples will not have altered composition, molecular 
mechanisms or gene function, and hence will make a useful reference sample for 
comparison with diseases samples.  There are two main recent studies that were 
performed on normal brains that this project complements.  
Firstly, in the study of Kang and colleagues, the transcriptome of 
developmental and adult brains were profiled. In total, 57 brains (40 brains 
representing different developmental stages and 17 representing adults) were included 
in this study from 16 brain regions, and the expression levels analyzed by using the 
Affymetrix GeneChip®Human Exon 1.0 ST arrays. 90 % of the genes were regionally 
differentially expressed at gene and exon usage levels (Kang, Kawasawa et al. 2011).  
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The second study of note is the anatomical atlas of the adult human brain by 
Hawrylycz and colleagues. A very precise and comprehensive neuroanatomical brain 
transcriptome evaluation from two individuals were performed. Histology and MRI 
scan analyses were also combined with the mRNA transcription data (Hawrylycz, Lein 
et al. 2012). 
These studies showed firstly, the normal and regional variability in the human 
brain transcriptome profiles; secondly, the correlation between different brain regions 
and their functional connectivity; thirdly, the ideal approach to maximize the use of the 
human brain transcriptomic data.  This last point was achieved by a) integrating the 
transcriptomic data with genomic data, expression quantitative trait loci (QTL) 
analyses, b) advanced functional analyses, using weighted gene co expression network 
analysis (WGCNA), c) functional annotations analyses, using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) and d) use of a 
bioinformatics database, Encyclopaedia of DNA Elements (ENCODE) Consortium. 
This provides a way forward to obtain more information about transcriptional 
regulation in the human CNS in order to understand the effect of genetic disorders 
targeting specific human CNS regions. 
Expression quantitative trait loci (QTL) analysis is the mapping of genetic data 
that influence the level of the expression patterns. Integrating these two types of data is 
important to understand to what extent the patterns of gene expression are under 
genetic control (Schadt, Monks et al. 2003; Morley, Molony et al. 2004; Cookson, 
Liang et al. 2009) and more importantly, to understand which groups of genes or 
biological processes are affected by specific genetic variants such as risk variants 
associated with complex diseases (Monks, Leonardson et al. 2004). 
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Performing expression QTL analysis in human is feasible approach by 
considering mRNA transcription profiles as quantitative traits or phenotypes. An initial 
study using lymphoblastoid cell lines showed significant value of using this analysis in 
normal tissues on a small cohort (56 individuals). The results showed 29% of 
differentially expressed genes had a genetic component (Schadt, Monks et al. 2003). 
Another study was performed by using lymphoblastoid cell lines from 94 normal 
individuals. This study introduced the concept of cis, trans and master genetic 
regulators. Results showed that there are many genetic variants that co-regulate the 
expression level of a gene. In addition, master regulators that affect expression levels 
of many genes were reported and genes that share the same genetic regulator are 
correlated (Morley, Molony et al. 2004). As well as the results from these studies 
shedding light on the complexity of the transcription regulation mechanisms by genetic 
variants, they also provided some insights about the variants’ contribution in biological 
processes in normal human tissues. 
Implementing an expression QTL analysis after a genome-wide association 
(GWA) study of human common complex diseases has become an essential systematic 
approach (Cookson, Liang et al. 2009). GWA studies have provided a systematic 
approach to identify common low risk variants that lead to amino acid changes in the 
protein (McCarthy, Abecasis et al. 2008; Manolio, Collins et al. 2009). However, it 
was observed that most of the identified disease associated risk variants from the 
GWA studies were in the noncoding regions of the genome and not mapped to amino 
acid code in the protein (Hardy and Singleton 2009; Manolio 2010). This highlights 
the importance of generating genome-wide data to understand the effect of common 
non coding variants on gene expression in control human CNS tissues. Expression 
QTL analysis can be applied at genome-wide scale in order to assess the functional 
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role and the biological basis of how these common variants are involved in the 
common disease pathology by affecting the gene expression and splicing patterns in 
the human CNS (Cookson, Liang et al. 2009; Hardy and Singleton 2009).  
Previous studies demonstrated the potential and feasibility of this approach in 
the human CNS and other human tissues, such as liver (Schadt, Molony et al. 2008), 
adipose (Emilsson, Thorleifsson et al. 2008), blood (Emilsson, Thorleifsson et al. 
2008; Heinzen, Ge et al. 2008), human monocytes (Zeller, Wild et al. 2010), 
lymphoblastoid cell lines (Monks, Leonardson et al. 2004) and human brain (Myers, 
Gibbs et al. 2007; Heinzen, Ge et al. 2008; Zou, Carrasquillo et al. 2010). In order to 
perform these studies, the availability of the tissues was the main consideration. For 
example most of the tissues, except for the human brain, are easy to access and collect. 
This is one of the reasons that expression QTL studies were mainly conducted using 
blood or lymphoblastoid cell lines (Emilsson, Thorleifsson et al. 2008) (Table 1.1). 
However, the study by Meyer et al. was performed using 193 of normal human brain 
samples dissected from cortical regions. The results showed significant associations 
between single variants and transcription levels, as the frequency of the common risk 
variant will be predictable in a cohort of normal individuals (Myers, Gibbs et al. 2007).  
Furthermore, Heinzen and colleagues performed a comprehensive association 
test not only with the transcript expression level, but also with the individual exon 
levels to explore exon splicing QTLs in blood and brain (Heinzen, Ge et al. 2008). 
Moreover, a case control study was performed to combine the analysis of the disease 
risk SNPs from GWAS and brain gene expression of Late-onset Alzheimer disease 
(LOAD). This study was conducted on a large cohort (~2300 AD cases – control). The 
results demonstrated an expression QTL association between a protective risk SNP 
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(rs7910977) and an increase in the expression of the IDE (Insulin degrading enzyme) 
gene. Further validations were performed on ~193 samples to confirm the association. 
This study provided strong evidence for a new candidate gene for AD (Zou, 
Carrasquillo et al. 2010). 
Performing expression QTL analyses on different tissues has its own 
advantages and disadvantages. The table below shows the key factors that affect the 
performance of this type of study (Table 1.1).  
Table 1.1: Advantages and disadvantages of using different human tissues for 
expression QTLs.  
Tissue type Advantages Disadvantages 
Cell lines High quality RNA May not be relevant to disease 
 
Specific cell type No connectivity between different cell types 
 
Large sample size Genomic instability 
 
Easy to manipulate artificial 
 
Availability  
Blood High quality RNA May not be relevant to disease 
 specific cell type No connectivity between different cell types 
 Large sample size  
 Availability  
Brain Relevant to disease Low quality RNA 
 Unique to the region Mixed cell types 
  Small sample size 
  Availability 
This table shows the different limitations and advantages when performing 
expression QTL analyses in different human tissues.  
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It is clear from Table 1.1 that each tissue type can provide a useful resource 
depending on the hypotheses of the study that will be conducted despite its own 
limitations.  
Focusing on the normal human CNS or brain studies, more recent studies were 
performed using advanced expression and genotyping platforms (Gibbs, van der Brug 
et al. 2010; Kang, Kawasawa et al. 2011).  The Gibbs et al. study was performed on 
~600 normal human brains dissected from four regions: cerebellum, frontal cortex, 
pons and temporal cortex. The results showed an abundance of cis regulation of 
mRNA expression and DNA methylation at a genome-wide scale (Gibbs, van der Brug 
et al. 2010). In addition, this study demonstrated the complexity of the expression QTL 
signals controlling the gene expression patterns in the human CNS.  
Another key study is by Kang et al. As mentioned previously, this study was 
performed on developmental and adult human brains in a relatively small cohort (57 
samples in total), dissected from 16 anatomical brain regions. The results showed that 
the expression patterns differ more during the developmental stages of the human 
brain, and that there is evidence of sex related difference in the expression and splicing 
pattern (Kang, Kawasawa et al. 2011).    
 In summary, all the studies that were performed on the human CNS tissues are 
valuable recourses in the scientific field to help understand and evaluate critical 
pathways and genes that are related to the development of neurodegenerative diseases 
such as Parkinson's disease (PD) and AD and target the molecular and cellular 
functions and connections in the human CNS. However, all these data sets cover 
different human CNS human regions, have different coverage across the genome, and 
are based on different sample sizes.  
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The importance of expanding the human tissue deposit especially in the human 
CNS is increasing. Thus, in this project the study was performed with large samples 
number (n = 137 individuals) dissected from twelve brain regions. These regions are: 
frontal cortex (FCTX) Brodmann areas 9 and 46, temporal cortex (TCTX) Brodmann 
areas 21,41 and 42, parietal parasaggital (PCTX) Brodmann areas 3,1, and 2, occipital 
cortex (specifically primary visual cortex, OCTX) Brodmann areas 17, hippocampus 
(HIPP), thalamus (THAL), hypothalamus (HYPO), putamen (PUTM), Substania nigra 
(SNIG), medulla (specifically inferior olivary nucleus, MEDU), cerebellum (CRBL), 
spinal cord (SPCO), and intralobular white matter (WHMT) below Brodmann areas 39 
and 40. Genome-wide profiling for expression and splicing was performed using the 
Affymetrix GeneChip®Human Exon 1.0 ST Arrays, which have comprehensive 
coverage for all exons as well as transcripts. In parallel, all individuals were SNP 
genotyped and imputed to perform: i) Regional differential expression patterns, ii) 
regional differential spicing patterns and finally iii) Regional expression QTL 
analyses, on human CNS samples. 
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Aims and objectives 
This project was performed to fulfil specific aims to benefit research in the 
neuroscience field. The main aims for this thesis are as follows: 
Firstly, the study aimed to provide the neuroscience community with a reliable 
human reference data set from post-mortem multiple CNS regions. Although this 
resource is unique, it is an accompaniment to other human genotypic-phenotypic data 
sets in the field. Consequently, this study aimed to provide substantial human data for 
researchers to answer long standing questions in various directions in relation to the 
neurological diseases. 
The second aim was to identify the human brain transcriptome in twelve CNS 
regions in a large cohort. This is achieved by investigating and exploring the CNS 
differentially gene expression and alternatively gene splicing profiles between 
different functional regions in control individuals. 
Thirdly and mainly, this study aims at expanding our understanding of the 
functional genomics in the human CNS. Integrating the genomic data with 
transcriptomic data is the step forward to study the functional effects of the non-coding 
genetic variants on gene expression and splicing and their contribution to the human 
neurological diseases. 
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2 Materials and Methods 
 
2.1 Characteristics of the human post-mortem tissue of the UK Brain 
Expression Consortium (UKBEC) 
The brain tissues collection and dissection were performed by Dr Colin Smith 
and Dr Robert Walker at the MRC Sudden Death Brain Bank. 
2.1.1 Human post-mortem brain tissue collection and dissection 
A total of 137 frozen human post-mortem brain and central nervous system 
(CNS) tissue samples of Caucasian controls with no neurological conditions were 
obtained from the Medical Research Council (MRC) Sudden Death Brain and Tissue 
Bank, Edinburgh, UK (Millar, Walker et al. 2007), and the Sun Health Research 
Institute (SHRI), an affiliate of Sun Health Corporation, USA (Beach, Sue et al. 2008). 
All samples had fully informed consent for retrieval and were authorized for ethically 
approved scientific investigation (UCL Research Ethics Committee number 
10/H0716/3).  Histology was performed on sections prepared from all paraffin 
embedded (FFPE) brain blocks and the neuropathological diagnosis was determined by 
a consultant neuropathologist (Trabzuni, Ryten et al. 2011). 
Brain tissues originating from 101 individuals from the MRC Sudden Death 
Brain and Tissue Bank were removed as fresh tissue. Tissue handling and dissection 
methods were applied exactly in the same way for all cases. The bodies were stored 
refrigerated and were brought up to the PM suite just prior to the start of the autopsy. 
Each post-mortem brain dissection was carried out in the same way. The whole brain 
was removed within 15 minutes and was immediately cut into coronal slices and the 
 Materials and Methods 
   38 
 
various anatomical regions of interest were immediately sampled from brain coronal 
slices at autopsy and immediately flash frozen.  These regions are: frontal cortex 
(FCTX) Brodmann areas 9 and 46, temporal cortex (TCTX) Brodmann areas 21,41 
and 42, parietal parasaggital (PCTX) Brodmann areas 3,1, and 2, occipital cortex 
(specifically primary visual cortex, OCTX) Brodmann areas 17, hippocampus (HIPP), 
thalamus (THAL), hypothalamus (HYPO), putamen (PUTM), Substania nigra (SNIG), 
medulla (specifically inferior olivary nucleus, MEDU), cerebellum (CRBL), spinal 
cord (SPCO), and intralobular white matter (WHMT) below Brodmann areas 39 and 
40.  Furthermore, the samples once removed from the coronal slices were placed in 
sealed containers which in turn were placed on cool blocks chilled to -20°C and stored 
within an insulated box. The samples were dissected into various size pieces 
approximately 250 mg – 500 mg and were placed in tubes which were immediately 
snap-frozen in liquid nitrogen. Samples were processed with every effort to ensure that 
tissue was maintained chilled, was not subjected to drying prior to preservation and 
had no extra freeze/ thaw cycles, with subsequent loss of RNA quality. 
The MRC Sudden Death Brain and Tissue Bank cohort included 23 females 
and 78 males, the age at death ranged from 16 to 83 years with a mean of 50.4 years.  
The brain pH ranged from 5.42 to 6.63 with a mean of 6.31.  The post mortem interval 
(PMI) was calculated from the time of death to the time of removal of the brain from 
the skull, and ranged from 28 to 114 hours with a mean of 52.2 hours.  The total 
number of samples was 1,844 as some regions were not available from certain 
individual brains. 
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The brain tissues collection and dissection were performed at the Sun Health 
Research Institute. 
An additional 36 frozen human post-mortem brain tissues of Caucasian 
controls were collected by the Sun Health Research Institute (SHRI), an affiliate of 
Sun Health Corporation (Beach, Sue et al. 2008).  Whole brains were removed as fresh 
tissue at autopsy and anatomical regions of interest were sampled from frozen brain 
coronal slices on pre-chilled -20°C plastic Petri dishes placed on top of -20°C ice 
packs at and were snap-frozen in liquid nitrogen with subsequent storage at -80°C. 
These regions are: FCTX, TCTX, OCTX, HIPP, THAL, PUTM, SNIG, MEDU, 
CRBL and WHMT.   
The time interval from the removal of the brain at the mortuary to the 
completion of the dissection and placement of samples within the storage freezer 
ranged from 2.5 to 4 hours.   
The SHRI cohort included 12 females and 24 males, the age at death ranged 
from 53 to 102 years with a mean of 80 years.  The PMI ranged from 1 to 5.5 hours 
with a mean of 2.6 hours.  The total number of samples was 476 as some regions were 
not available from all brains. Note that the PCTX, HYPO and SPCO regions were not 
available from the Sun Health cohort. 
The cohort of the two data sets combined is called the UK Brain Expression 
Consortium (UKBEC) and included 35 females and 102 males, the age at death ranged 
from 16 to 102 years with a mean of 59 years.  The brain pH ranged from 5.42 to 6.63 
with a mean of 6.31.  The PMI ranged from 1 to 114 hours with a mean of 42 hours. 
This is the largest sample resource of this nature described to date, totalling 2320 RNA 
samples to which RNA quality control has been applied and observed on different 
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regions from control human post-mortem brains. Detailed phenotypic information is 
described in Table 2.1.1 (Trabzuni, Ryten et al. 2011). 
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Table 2.1.1: Demographics of the samples studied. 
 
 
 
 
 
1
 PMI = post mortem interval (hours); 
2
 RIN = RNA integrity number 
This table shows the values (range, mean) for variables in the cohort from both MRC-UK and SHRI-USA data set separately and joined 
as UKBEC. Of note, however, because of the different practices of the two tissue resources, there is no overlap in the PMIs between the MRC-
UK (long PMI) and SHRI-USA (short PMI). This table is modified from (Trabzuni, Ryten et al. 2011). 
 
 Sex Age / year Brain pH PMI1 (hours) RIN2 
Brain bank individuals Male Female range mean range mean range mean range mean 
MRC-UK 101 78 23 16-83 50.4 5.42-6.31 6.3 28-114 52.2 1-8.5 4 
SHRI-USA 36 24 12 53-102 80 NA NA 1-5.5 2.6 1-8 3.6 
UKBEC 137 102 35 16-102 59 5.42-6.31 6.3 1-114 43.7 1-8.5 3.85 
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2.1.2 Post-mortem determination of brain pH from MRC Sudden Death Brain and 
Tissue Bank samples 
The brain pH from the MRC Sudden Death Brain and tissue bank was recorded 
using a Hanna HI8424 hand held pH meter with a glass bodied electrode (Fisher 
Scientific, Loughborough, UK). Consistent with previous studies, the pH did not vary 
between different CNS regions in a normal brain (Stan, Ghose et al. 2006; Monoranu, 
Apfelbacher et al. 2009).  A single pH value was used and measured at the lateral 
ventricle. The electrode was inserted into the lateral ventricle after the brain was 
coronally sliced behind the mammillary bodies.  It will be influenced by any remaining 
CSF fluid within the lateral ventricle but predominantly by the actual tissue comprising 
the wall of the lateral ventricle. 
Brain pH from SHRI samples was not available for the following reasons: 1) it 
was not part of the USA brain bank standard operating procedures; 2) the restriction of 
tissue availability for most USA samples. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
2.2 RNA extraction using single-step TRIZOL
®
Reagent based kit 
Total RNA was isolated from human post-mortem brain tissues using the 
miRNeasy 96 kit (Qiagen, UK).  Brain tissues were collected and weighed in RNAse-
free 96 -well plates; they were between 50-100 mg in weight.  Each brain tissue 
sample was subjected to a minimum of one extraction; with a number of samples 
extracted in duplicates and triplicates.  All steps were performed on dry ice prior to the 
addition of the QIAzol
®
Reagent. 
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2.2.1 Tissue homogenization 
Brain tissues from different regions were cut and weighed in RNase-free 96-
well plates.  All tissue samples were homogenized completely at 4°C using the 
TissueLyser II (Retsch, UK) for 4-5 minutes maximum at 30 Hz in 800 μl of QIAzol 
with the addition of two 3 mm stainless steel beads.   
2.2.2 Phase separation 
 The homogenized tissue samples were incubated at room temperature (15-
25°C) for 5 minutes.  After incubation, 160 μl of chloroform (CHCl3) (Sigma,UK) was 
added, the plates were mixed vigorously using the TissueLyser II for 30 seconds at 30 
Hz.  Then plates were incubated at room temperature (15-25°C) for 8-10 minutes.  The 
plates were centrifuged at 6,000 g for 45 minutes at 4°C. 
2.2.3 RNA precipitation, wash and elution 
The aqueous phase (upper layer, with approximately 60 % of the total volume 
after the QIAzol was added) was transferred to a fresh RNase-free 96-well plates.  It 
was very important not to disturb the bottom phase that contains the DNA and protein.  
RNA was precipitated by adding 800 µl of 100% ethanol to the aqueous phase (1.5 
volume of the aqueous phase), followed by mixing the samples.  The samples were 
then transferred into the wells of the RNeasy 96-well plates to allow the RNA in the 
solution to bind to the membrane and to be filtered through by centrifugation.   
The plates were centrifuged at 5600 g for 2 minutes at room temperature, and 
the supernatant was discarded.  Samples were then washed to remove salt traces and 
impurities by adding 800 µl of washing buffers and centrifuging plates for 2 minutes 
each wash, for 3 to 4 times.  Finally, RNA was eluted in two steps in 65 μl in total 
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volume of pre-heated RNase-free water to 50°C. RNA quality checks were then 
immediately performed on the samples, followed by the application of expression 
profiling by using human microarrays. 
2.2.4 RNA quality assessments  
2.2.4.1 Concentration and purity 
 The concentration and purity of each RNA sample were assessed by measuring 
the optical density (OD) of each RNA sample at a wavelength of 260 nm, using the 
NanoDrop ND-1000 Spectrophotometer V3.3.0.  The concentration of each sample 
was calculated, together with the ratio of absorbance at 260 nm/280 nm and 260 
nm/230 nm.  
2.2.4.2 RNA integrity numbers (RIN) 
After purification, all RNA samples were applied to a RNA 6000 Nano-
LabChip using Agilent 2100 bioanalyzer for electrophoresis applied lab-on-a-chip 
technology (Agilent Technologies UK Ltd, UK) to obtain RNA Integrity Numbers 
(RIN) (Schroeder, Mueller et al. 2006).  RIN and total RNA electropherograms were 
calculated automatically by the 2100 Expert Software (Agilent Technologies UK Ltd, 
UK).  Further assessment for the calculated RIN number was performed by checking 
each electropherogram visually. 
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2.3 Genome-wide expression profiling using Affymetrix GeneChip®Human 
Exon 1.0 ST Arrays 
Exon array experimental work was performed by AROS Applied 
Biotechnology AS Company as a service laboratory for the samples that I provided. 
The sent RNA samples were prepared and randomized in big batches to reduce 
the batch effect variability on the expression profiles as much as possible. 
2.3.1 Preparation of biotin labelled cDNA 
In total, 1266 total RNA samples were examined using expression arrays.  For 
each array, 200 ng of total RNA was used as starting material for the complementary 
DNA (cDNA) preparation. The procedure started with the first and second strand 
cDNA synthesis, and then the In Vitro Transcription (IVT) reaction was applied to 
generate cRNA. This was performed using the Ambion®WT Whole Transcript 
Expression Kit according to the manufacturer’s instructions. Biotin labelling was 
performed using the Terminal Labelling Kit (Affymetrix, UK Ltd.) according to the 
manufacturer’s instructions. Following the IVT reaction, the unincorporated 
nucleotides were removed using RNeasy columns (Qiagen, UK).  
2.3.2 Array hybridization and scanning 
Prior to hybridization, the fragmented cDNA sample was heated to 95°C for 5 
minutes and subsequently to 45°C for 5 minutes before loading onto the Affymetrix 
Human Exon 1.0 ST array cartridge. The probe array cartridge was then incubated for 
16 hours at 45°C at constant rotation (60 rpm). The washing and staining procedure 
was performed in the Affymetrix Fluidics Station 450. The probe array was exposed to 
10 washes in 6X SSPE-T at 25°C followed by 4 washes in 0.5SSPE-T at 50°C. The 
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biotinylated cRNA was stained with a streptavidin-phycoerythrin conjugate, final 
concentration 2 mg/ml (Affymetrix, UK Ltd.) in 6xSSPE-T for 30 minutes at 25°C 
followed by 10 washes in 6SSPE-T at 25°C. This was followed by an antibody 
amplification step using normal goat IgG as blocking reagent, final concentration 0.1 
mg/ml (Affymetrix, UK Ltd.) and biotinylated anti-streptavidin antibody (goat), final 
concentration 3 mg/ml (Affymetrix, UK Ltd.). Thena staining step took place with a 
streptavidin-phycoerythrin conjugate, final concentration 2 mg/ml (Affymetrix, UK 
Ltd.) in 6SSPE-T for 30 minutes at 25°C and 10 washes in 6SSPE-T at 25°C. The 
probe arrays were scanned at 560 nm using a confocal laser-scanning microscope 
(GeneChip® Scanner 3000 7G) and visually inspected for hybridization artefacts. 
 
2.4 Genome-wide expression profiling using Illumina HumanHT-12 v3 
Expression BeadChip 
Eighty-eight individuals of the UKBEC dataset from FCTX and CRBL regions 
were run on Illumina arrays in addition to the exon arrays.  These data will be analyzed 
and combined with the North American Brain Expression Consortium (NABEC) 
dataset (see Section 2.17 at the end of this chapter) for microtubule-associated protein 
tau (MAPT) gene analysis (see Chapter 5) to maximize the number of samples 
available for the selection of individuals with H1/H1, H1/H2 and H2/H2 haplotype 
status. 
 2.4.1 Preparation and amplification of biotin labelled cRNA 
A sample of 230 ng of total RNA was used as starting material for the first and 
second strand cDNA synthesis by using Illumina
® 
TotalPrep RNA Amplification Kit 
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(Ambion, USA).  First strand cDNA was synthesized by using oligo (dt) primers and 
incubating the reverse transcription master mix reaction at 42°C for 2 hours. Then the 
second strand master mix was added and incubated at 16°C for an additional 2 hours.  
This was followed by a cDNA purification step by using the cDNA filter cartridges.  
Finally, the cRNA synthesis was performed by incubating the samples with the In 
Vitro Transcription (IVT) master mix at 37°C overnight (14 hours).  Following the 
IVT reaction, the unincorporated nucleotides, salts and unused NTPs were removed 
using cRNA filter cartridges (Ambion, USA). 
2.4.2 cRNA quality assessments 
The concentration and purity of each cRNA sample were assessed by 
measuring the optical density (OD) of each RNA sample at a wavelength of 260 nm, 
using the NanoDrop ND-1000 Spectrophotometer V3.3.0.  The concentration of each 
sample was calculated, together with the ratio of absorbance at 260 nm/280 nm and 
260 nm/230 nm.  cRNA samples with concentrations less than 150 ng/µl were 
reprocessed for amplification to get a higher cRNA yield.  At this stage samples were 
ready for the hybridization step. 
2.4.3 Array hybridization, washing and scanning 
Prior to hybridization, the sample was heated to 65°C for 5 minutes and 
subsequently cooled down to room temperature before loading onto the Illumina 
HumanHT-12 v3 Expression BeadChip array.  After loading 15 µl of the samples, the 
array cartridge was then incubated in the Hyp chamber for 16-20 hours at 58°C at 
constant rotation (60 rpm). The washing and staining procedure for the bead chip 
arrays were performed in the slide rack.  The arrays were exposed to a first wash for 5 
minutes in pre-heated E1BC washing solution at 55°C, followed by a first room 
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temperature wash for 5 minutes in E1BC washing solution.  Then the ethanol wash in 
100% ethanol for 10 minutes at room temperature, followed by a second room 
temperature wash for 2 minutes.  The blocking and detecting steps were performed for 
10 minutes each using Block E1 buffer and streptavidin-Cy3 solution.  Last room 
temperature wash was performed for 5 minutes and arrays were dried at room 
temperature for 10 minutes by centrifugation.  The bead chip arrays were scanned 
using an Illumina
® 
BeadArray Reader to read and extract the image.  The expression 
data were normalized and analyzed using Gene Expression Module 3.2.7 in the 
Illumina
® 
BeadStudio Application in combination with the NABEC dataset (see 
Section 2.17).  
 
2.5 Affymetrix GeneChip®Human Exon 1.0 ST arrays quality control 
2.5.1 Array quality performance 
The Expression Console™ software version 1.1 (EC) (Affymetrix, UK Ltd.) 
was used to evaluate the performance quality of the arrays including the labelling, 
hybridization, scanning and background signals by probe set summarization and CHP 
file generation using the robust multichip analysis (RMA) algorithm.   
The quality assessment was performed by generating different parameters for 
all the probe sets analyzed by EC. Boxplots of the relative log expression for all the 
probe sets were obtained, as well as the present call (%P) which was the main 
parameter used for the array quality in this study. All parameters are shown in Table 
2.5.1 below. Samples that failed any one of the quality criteria cut-offs were re-run on 
arrays from different RNA aliquots.  
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In addition, cDNA and cRNA Agilent 2100 Bioanalyzer profiles were 
generated for samples with a wide range of RIN numbers (RINs from 2 to7) to assess 
the cDNA preparation and cRNA production nucleotide lengths from RNA samples 
with different levels of degradation.  
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Table 2.5.1: Arrays quality control parameters in Expression Console™ software. 
Parameter name Definition  
Boxplots The relative log expression for all the probe sets 
analyzed. 
%P ranges from (2 - 76.7).  The percent of probe sets present - For the exon 
level analysis, this is defined as the DABG 
(Detection above background) probe level P-
value is less than or equal to 0.01. 
%A ranges from (98.2 - 23.2). In 
this analysis the cut-off 65%. 
Note that %A = 100 - %P 
The percent of probe sets called present absent - 
For exon level analysis, the DABG P-value is 
greater than 0.01. 
All_probeset_mean ranges from 
(4.8 - 6.2).  
The mean signal value for all the probe sets 
analyzed. 
All_probeset_stdev ranges from 
(1.7 - 2.2).  
The standard deviation for all the probe sets 
analyzed. 
All_probeset_mad_residual_mean 
ranges from (0.2 - 1).  
The mean of the absolute deviation of the 
residuals from the median for all probe sets 
analyzed. 
All_probeset_mad_residual_stdev 
ranges from (0.16 - 0.68).  
The standard deviation of the absolute deviation 
of the residuals from the median for all probe 
sets analyzed. 
All_probeset_rle_mean ranges 
from (0.28 - 1.9).  
The mean absolute relative log expression 
(RLE) for all the probe sets analyzed. 
All_probeset_rle_stdev ranges 
from (0.27 - 1.47).  
The standard deviation of the mean absolute 
relative log expression (RLE) for all the probe 
sets analyzed. 
Pos_control_mean ranges from 
(5.2 - 8.26).  
The mean for the set of putative exon based 
probe sets from putative housekeeping genes. 
Pos_control_rle_mean ranges 
from (0.19 - 3).  
The mean absolute relative log expression 
(RLE) for the set of putative exon based probe 
sets from putative housekeeping genes. 
Pos_control_rle_stdv ranges from 
(0.17 – 1.75).  
The standard deviation absolute relative log 
expression (RLE) for the set of putative exon 
based probe sets from putative housekeeping 
genes. 
Bgrd_mean ranges from (31 – 
234).  
The mean of the raw intensity for the probes 
used to calculate background prior to any 
intensity transformations. 
bac_spike_mean ranges from (8 – 
13).  
The mean for the set of probe sets which 
hybridize to the pre-labelled bacterial spike 
controls (BioB, BioC, BioD, and Cre). 
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pos_vs_neg_auc is the area under the curve (AUC) for a receiver operator 
curve (ROC) comparing the intron controls to the exon controls by applying a 
threshold to the probe set summary. The ROC curve is generated by evaluating how 
well the probe set summary separates the positive controls from the negative controls 
(e.g., exon from intron). The assumption (which is only valid in part) is that the 
negative controls are a measure of false positives and the positive controls are a 
measure of true positives. An AUC of 1 reflects perfect separation whereas as an AUC 
value of 0.5 would reflect no separation. Note that the AUC of the ROC curve is 
equivalent to a rank sum statistic used to test for differences in the centre of two 
distributions.  
all_probeset parameters are important to assess the quality of many steps in 
the microarrays preparation including RNA, hybridization efficiency and the scanning 
quality.   
Pos_control and neg_control parameters are important to assess the true 
positive results in the pos_vs_neg_auc.  
bac_spike parameters will help to assess any possible problem with the 
hybridization and chip quality in specific. 
2.5.2 Statistical analysis for the effect of post-mortem variables on RNA and array 
quality performance 
Previous studies revealed that post-mortem variables have been considered to 
affect the RNA quality (Weis, Llenos et al. 2007). In this study the effect of post-
mortem variables such as pH of the brain tissue, PMI, cause of death, age and gender 
were investigated further with additional CNS regions in a large combined data set. 
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These variables were obtained from the sample data sheets from the brain banks.  
Linear mixed regression and analysis of variance (ANOVA) model analyses were 
performed to investigate factors affecting RIN and present call (%P).  Terms included 
in the model were age, gender, cause of death, region, PMI, pH, as well as variability 
within individuals and brain tissue blocks. Separate models were constructed for RIN 
and %P.  Statistical analyses were conducted using Partek
®
 Genomics Suite™ version 
6.6 and PASW Statistics version 18 software.  The explanatory ability of the model in 
a forwards stepwise manner was assessed, by examining the increase in variation 
explained when a new covariate or set of covariates were added to the existing model, 
together with a P-value for that increase and adjusted R
2 
measure.   
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2.6 Affymetrix GeneChip®Human Exon 1.0 ST arrays analysis  
2.6.1 Pre-processing, normalization and summarization of the raw expression 
intensity (CEL) files  
Raw signal intensities were pre-processed to generate log2 scale values by 
using robust multi-array average (RMA) quantile normalization with probe set 
summarization with median polish according to the RMA (Irizarry, Hobbs et al. 2003) 
with GC background correction (GC-RMA) algorithm in Affymetrix Power Tools 
1.14.3 software (Wu and Irizarry 2004) 
(http://www.affymetrix.com/partners_programs/programs/developer/tools/powertools.
affx). This was applied after re-mapping the Affymetrix probe sets onto human 
genome ref Sequence build 19 (GRCh37) as documented in the Netaffx annotation file 
(HuEx-1_0-st-v2 Probe set Annotations, Release 31) and restricting the analysis to ~ 
308,717 probe sets (out of a total of 1.4 million probe sets) that: i) had gene annotation 
according to RefSeq build hg19 using custom scripts, ii) did not target intronic regions 
and iii) contained at least three 25-mer probes with a unique hybridization to target 
sequence (single exon).  Each probe set in the Affymetrix exon arrays is prepared to 
measure a single exon expression level except in rare cases. 
Principal component analysis and unsupervised hierarchical clustering were 
then used to identify outliers and to visualize the clustering of all arrays samples by 
different functional regions; Partek
®
 Genomics Suite™ software was used for this step.  
At this point, the array data were ready to be used for different types of analyses such 
as differential regional expression (see Section 2.6.2) and expression QTL analysis 
(see Section 2.16) as different probe set filtering methods were applied to different 
analyses. 
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2.6.2 Region differential expression and alternative splicing profiles in 12 CNS 
regions 
After removing the outliers, 917 samples from twelve CNS regions were 
included in this analysis. The regions were as follow: FCTX, n = 96, TCTX, n = 84, 
OCTX, n = 95, HIPP, n = 93, THAL, n = 83, HYPO, n = 13, PUTM, n = 94, 
SNIG, n = 68, MEDU, n = 92, CRBL, n = 95, SPCO, n = 13 and WHMT, n = 91. 
 
2.6.2.1 Probe sets filtering using detection above background (DABG) method 
In order to reduce the back ground noise in the expression data for each case, 
the probe sets list (308,717 probe sets) was filtered further by calculating the detection-
above-background (DABG, detection metric) using Affymetrix Power Tools 
(Affymetrix) (Clark, Schweitzer et al. 2007). Thus, the regional expression analysis list 
was restricted to probe sets that have gene annotation according to RefSeq build hg19, 
contained at least 3 probes with unique hybridization and had DABG P values ≤ 0.001 
in ≥ 50% of samples in one brain region. This list contained 169,827 probe sets which 
were considered as detected. These probe sets were re-normalized and summarized 
based on the RMA quantile normalization method in Section 2.6.1. In addition they 
were summarized to a trancript-level summary for ~ 19,215 transcripts by calculating 
the 10% trimmed Winsorized mean of the expression values from the corresponding 
probe sets to each transcript.  Gene symbols for the detected transcripts were assigned 
to the transcript identification numbers using Netaffx annotation file (HuEx-1_0-st-v2 
Transcript Annotations, Release 31) to produce a list containing 18,107 detected genes 
which will be used for the rest of the analyses. 
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Furthermore, shorter lists that contain detected genes in one or multi CNS 
regions were constructed from this main list.  
2.6.3 Analysis of variance (ANOVA) statistical analysis  
The date of array hybridization (batch effects), gender, region and individual 
were included as covariates to eliminate the possibility of variability that influences the 
expression and splicing profiles.   
ANOVA modules (method of moments) were performed using Partek
®
 
Genomics Suite™ to determine differentially expressed and alternatively spliced 
transcripts amongst 12 CNS regions. All P values were corrected for multiple 
comparisons using the false discovery rate (FDR) step-up method (Benjamini and 
Hochberg 1995). This analysis was applied to the list of genes that was generated in 
the previous section 2.6.2.1 by considering only genes that were detected in all 12 
CNS regions after applying DABG filter method to reduce the probability of false 
positive results (12,790 genes). 
2.6.3.1 Analysis of differentially expressed genes  
Model 1: ANOVA 4-way model to identify differentially expressed transcripts 
between CNS regions 
Yijklm = μ + Regioni + Genderj + Scan Datek + Individual (Gender)jl + εijklm 
- Where Yijklm represents the m
th
 observation on the i
th
 Region, j
th
 Gender, k
th
 
Scan Date, and l
th
 Individual. 
- μ is the common effect for the whole experiment. 
- εijklm represents the random error present in the m
th
 observation on the i
th
 
Region, j
th
 Gender, k
th
 Scan Date, and l
th
 Individual. 
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- The errors εijklm are assumed to be normally and independently distributed with 
mean 0 and standard deviation δ for all measurements. 
- Scan Date and Individual are random effects. 
Then, a list of differentially expressed genes was identified by applying a 
statistical threshold of minimum fold change (FC) difference of ≥ 1.7 and FDR < 0.05 
to the ANOVA result sheet. This was performed using Partek
®
 Genomics Suite™ to 
compare all possible combinations between the 12 CNS regions using contrast method 
(Tamhane and Dunlop 2000) and define the differentially expressed genes lists using 
the list that was generated in the previous section 2.6.2.1 after applying the DABG 
filter method (12,790 genes). 
2.6.3.2 Analysis of differentially spliced genes 
Model 2: Alt-splicing ANOVA 4-way model to identify alternatively spliced 
transcripts between CNS regions. 
Yijklm = μ + Regioni + Genderj + Scan Datek + Marker IDl + Individual (Gender)jm 
+ Sample ID (Region * Gender * Scan Date * Individual)ijkmn + Region * Marker IDil 
+ εijklmno 
- Where Yijklmno represents the o
th
 observation on the i
th
 Region, j
th
 Gender, k
th
 
Scan Date, l
th
 Marker ID, m
th
 Individual, and n
th
 Sample ID.  
- μ is the common effect for the whole experiment. 
- εijklmno represents the random error present in the o
th
 observation on the i
th
 
Region, j
th
 Gender, k
th
 Scan Date, l
th
 Marker ID, m
th
 Individual, and n
th
 Sample 
ID. 
- The errors εijklmno are assumed to be normally and independently distributed 
with mean 0 and standard deviation δ for all measurements. 
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- Marker IDl is an exon-to-exon effect (alt-splicing independent of tissue type). 
- Region * Marker IDil represent whether an exon expresses differently in 
different levels of the specified alternative splice factor(s). 
- Sample ID (Individual * Region * Gender * Scan Date)ijkmn is a sample-to-
sample effect. 
- Scan Date, Individual and Sample ID are random effects. 
Then, a list of differentially spliced genes was identified by applying a 
statistical threshold FDR < 10
-5
 to the ANOVA result sheet. This was performed using 
Partek
®
 Genomics Suite™ to compare all possible combinations between the 12 CNS 
regions and cortical regions: FCTX, TCTX and OCTX (Tamhane and Dunlop 2000).  
 In addition, to confirm of the results of the differentially expressed and spliced 
genes, analysis of variance (ANOVA) procedures were run independently on the 
expression data for selected transcripts, using the same models as described in the 
previous section. The P values that were generated from these results were adjusted 
using a Bonferroni procedure, using the total number of tests undertaken.  
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2.7 Affymetrix arrays expression validation using a direct RNA quantification 
with branched DNA: QuantiGene®2.0 Assay (QG) 
This experimental work was performed at Affymetrix, USA Ltd. as a service 
laboratory for the samples that I provided. 
  CRBL, OCTX, PUTM and WHMT total RNA samples from 12 individuals 
that were analyzed on exon arrays were also analyzed using the QG platform for 
validation of exon array results. Three target genes were selected for validation, 
namely, leucine-rich repeat kinase 2 (LRRK2), sodium channel voltage gated type VIII 
alpha subunit (SCN8A), and microtubule-associated protein tau (MAPT).  ribosomal 
protein, large, P0 (RPLP0) and ubiquitin C (UBC) were selected as housekeeping 
genes to normalize the target genes as they showed relatively low variability in 
expression levels (i.e. low coefficient of variation) in all regions in the UKBEC 
dataset. The approach to the selection of reference genes is explained in previous 
studies (de Jonge, Fehrmann et al. 2007; Coulson, Brockbank et al. 2008). In addition, 
a recent study confirms the efficiency of using this approach in selecting housekeeping 
genes to normalize in different tissues (Chervoneva, Li et al. 2010). A summary of the 
QG probes that were used for analysis of all five genes is provided in Table 2.7.1. 
QuantiGene 2.0 Reagent System (QG) was used and the protocol in the 
QuantiGene 2.0 Reagent System User Manual was followed with the exception of the 
substrate step.  Lumigen® Lumi-Phos® Plus and 10% lithium lauryl sulphate and a 30 
minutes incubation at 46°C was used in place of the Lumigen® APS-5 substrate.  A 
Biotek ELx 405 select plate washer was used for all of the wash steps in the 
assay.  The QG 2.0 plates were then read on a Molecular Devices LMax luminometer  
(Turner BioSystems Modulus Microplate Luminometer (P/N 9300-001), Molecular 
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Devices LMAX) with the plate incubator set to 45°C to maintain the temperature of 
the Lumigen® Lumi-Phos® Plus substrate.  In total, 13 QG 2.0 plates were run to 
cover all target genes and the house keeping genes.  Both housekeeping genes (RPLP0 
and UBC) were loaded in duplicates at 12.5 ng/well.  In addition, target genes were 
loaded in duplicates at 75 ng/well. 
Table 2.7.1: Quanti-Gene’s probe sets designed and used to perform the 
validation.  
Symbol 
Part 
Catalogue 
number 
Specificity 
LRRK2  83322   SA-26988 This probe set is designed specifically to 
hybridize to human LRRK2. 
LRRK2  83326   SA-50260 This probe set is designed specifically to 
hybridize to human LRRK2, exon 33. 
LRRK2  83327   SA-50259 This probe set is designed specifically to 
hybridize to human LRRK2, exon 36. 
SCN8A 83324   SA-17320 This probe set is designed specifically to 
hybridize to human SCN8A transcript 
variants 1 and 2. 
SCN8A 83323   SA-50261 This probe set is designed specifically to 
hybridize to human SCN8A, exon 6. 
MAPT  81849   SA-15486 This probe set is designed specifically to 
hybridize to human MAPT, all six variants. 
MAPT  83321   SA-50258 This probe set is designed specifically to 
hybridize to human MAPT, exon 3 
MAPT  83325   SA-50257 This probe set is designed specifically to 
hybridize to human MAPT, exon 4. 
UBC 80041   SA-10061 This probe set is designed specifically to 
hybridize to human UBC. 
RPLP0  81152   SA-11148 This probe set is designed specifically to 
hybridize to Human RPLP0 transcript 
variants 1 and 2 
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2.8 Array expression validation using quantitative real time polymerase chain 
reaction (qRT-PCR) using the TaqMan essay  
Aliquots of the total RNA previously extracted from each brain region and 
analyzed on exon arrays were used for validation by quantitative RT-PCR analysis.  
The relative expression values were calculated using the Ct value of each target gene 
which was normalized by the subtraction of the geometric mean of the Ct values from 
the three housekeeping genes to obtain the ΔCt and ΔΔCt values. 
This work was performed at the Queen Square Brain Bank (QSBB) by Dr Jana 
Vandrovcova for the samples that I provided. 
2.8.1 MAPT and LRRK2 qRT-PCR 
MAPT transcript-specific assays used were (Hs00902188, variants 3 and 4, 
exon boundary 2-3, Hs00902978, variants 5 and 7, exon boundary 3-4 and 
Hs00902314, variants 1, 2, 6 and 8, exon boundary 3-4) (Invitrogen, UK). The LRRK2 
gene expression was quantified using the qRT-PCR technique (Invitrogen, UK) from 
30 individuals in 3 brain regions: CRBL, OCTX and WHMT. The two following 
LRRK2 specific assays which cover the exon-exon boundary were used: Hs00968193: 
exon boundary 39-40; Hs00411194: exon boundary 44-45. Fluorescence was measured 
using the MX3000P system (Agilent, UK). All runs were performed in triplicate and 
were normalized to a geometric mean of three housekeeping genes (PPIA, RPL0 and 
UBC).  Details of the assays are given in Table 2.8.1.   
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2.8.2 Selected genes for qRT-PCR validation 
This experimental work was performed by AROS Applied Biotechnology AS 
Company as a service laboratory for the samples that I provided. 
These experiments were performed using the Fluidigm BioMark system 
(Fluidigm, Europe) on a subset of samples from THAL (n = 34), WHMT (n = 37), 
HIPP (n = 29) and HYPO (n = 13) for validations. The expression selected 
genes/transcripts, including three endogenous controls, using human-specific TaqMan 
assays (Applied Biosystems UK) were obtained. Details of the assays and genes names 
are given in Table 2.8.1). RPLP0, TUBB and UBC specific assays were used as 
endogenous controls. Samples were analyzed using Fluidigm 96.96 Dynamic 
(Fluidigm Europe) arrays with assay triplicates in accordance with the manufacturer‘s 
protocol. An extract of 100 ng of total RNA was used as input and reverse 
transcription was performed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems UK) in accordance with the manufacturer‘s protocol. After 
reverse transcription the cDNA, samples were amplified as described in the Fluidigm® 
Specific Target Amplification Quick Reference Manual (Fluidigm, Europe). The Ct 
value (cycle number at threshold) was used to calculate the relative amount of mRNA 
molecules. Gene expression or splicing candidates were considered confirmed if the P-
value calculated by unpaired t-test was < 0.05. 
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Table 2.8.1: Details of the Applied Biosystem Taq Man assays for the selected 
genes. 
 
 
This table shows the selected genes and their corresponding specific Taq Man 
assays for their different transcripts/isoforms.  The last two columns show the location 
of the specific probe on the exon-exon boundary for specific and different transcripts, 
in addition, the numbers of isoforms that each assay covers, based on the human 
genome build 19. 
Gene name Assay ID Assay location 
Different targeted 
isoforms 
BIN1 Hs01120903_m1 Exon boundary 6-7 Three 
BIN1 Hs01120891_m1 Exon boundary 6-7 Seven 
CR1 Hs00559348_m1 
Exon boundary 33-34 
and 41-42 
Two 
IGFBP3 Hs00181211_m1 Exon boundary 2-3 Two 
LRRK2 Hs00968193_m1 Exon boundary 39-40 One 
LRRK2 Hs00411194_m1 Exon boundary 44-45 One 
MAPT Hs00902188_m1 Exon boundary 2-3 Two 
MAPT Hs00902978_m1 Exon boundary 3-4 Two 
MAPT Hs00902314_m1 Exon boundary 3-4 Four 
NLGN4X Hs01934144_s1 Exon boundary 6-6 Two 
NRXN3 Hs01028181_m1 Exon boundary 8-9 One 
NRXN3 Hs01031277_m1 Exon boundary 1-2 Two 
PICALM Hs00999745_m1 Exon boundary 12-13 Two 
PICALM Hs00999727_m1 Exon boundary 12-13 One 
RPLP0 Hs99999902_m1 Exon boundary 3-3 Two 
TUBB Hs03929064_g1 Exon boundary 4-4 One 
UBC Hs00824723_m1 Exon boundary 1-2 One 
VSIG4 Hs00200695_m1 Exon boundary 1-2 Four 
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2.9 MAPT protein expression (tau), extraction and Western blot analysis  
This work was performed at the Institute of Neurology by Dr Selina Wray for 
the samples I provided.  
From 12 individuals, brain tissue from five brain regions (FCTX, OCTX, 
CRBL, PUTM and WHMT) were homogenized in 10 mM Tris-HCl (pH 7.4), 0.8 M 
NaCl, 1 mM EDTA, 10% sucrose and protease inhibitor tablets (Roche, UK).  
Homogenates were clarified by centrifugation at 10,000 g for 10 minutes at 4°C prior 
to aliquoting and storage at -80°C.  Protein concentrations were measured by the 
bicinchoninic acid assay (BCA) assay and equal amounts of protein were 
dephosphorylated using λ protein phosphatase (New England Biolabs, UK) as 
described previously (Hanger, Gibb et al. 2002).  Briefly, proteins were incubated with 
λ protein phosphatase at a final concentration of 40 U/μl for 3 hours at 30°C.  
Dephosphorylation reactions were stopped by the addition of LDS buffer (Invitrogen, 
UK) followed by heating at 100°C for 10 minutes.  Samples were centrifuged at 
10,000 g prior to separation on 10% Bis-Tris gels alongside recombinant tau protein 
ladder (Sigma, UK).  Protein was transferred to nitrocellulose membrane and probed 
with rabbit polyclonal antibody to total tau (Dako, UK) and mouse monoclonal to actin 
(Sigma, UK). Blots were visualized and quantified using an Odyssey Infrared imaging 
system (LI-COR Biosciences, UK).  The levels of total tau in each brain region were 
normalized to actin protein, and the levels of individual tau isoforms were calculated 
as a percentage of total tau for the same sample. The t-test was performed to calculate 
the significance of the protein levels differences between different regions is 
significant. 
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2.10 MAPT protein isoforms expression (tau) using sandwich ELISA analysis 
This work was performed at the QSBB by Dr Connie Luk for the samples that I 
provided. 
From the homogenized samples in Section 2.12 in the five brain regions 
(CRBL, FCTX, OCTX, PUTM and WHMT), sandwich ELISAs for 3R- and 4R- tau 
were carried out as previously described by Luk et al. group (Luk, Giovannoni et al. 
2009). Briefly, microlitre plates were coated with 150 μl of 10 μg/ml of capture 
antibody (RD3 or RD4) (de Silva, Lashley et al. 2003) in coating buffer (150 μl, 
sodium tetraborate buffer, pH 9.4).  The plate was washed and 150 μl of diluent buffer 
was added into the plate after which 25 μl of diluted supernatants obtained from the 
brain homogenates (1 in 1,000 and 1 in 150 for 3R- and 4R- tau ELISAs respectively) 
were added in duplicates to the blocked plates previously coated with RD3 or RD4 
antibodies.  The plates were incubated at room temperature for 2 hours, washed and 
150 μl affinity-purified sheep anti-tau–HRP conjugates, diluted to 1 in 1,000 and 1 in 
3,500 for 3R- and 4R-tau assays, was added, respectively, and incubated for 1 hour on 
a shaker. After washing, the plates were developed with tetramethylbenzidine (TMB) 
substrate as previously described. The isoform composition in each sampled region is 
expressed as ng/µg of total brain protein. 
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2.11 LRRK2 array splicing validation using Reverse Transcriptase RT-PCR 
2.11.1 Splicing index analysis for array data 
To test for differential exon specific expression in the array data, the ratio of 
exon probe set value by overall gene/trancript expression (Winsorized mean across 
exons) was computed for each individual and brain region. Then the two linear models 
with or without the inclusion of the regions as covariates were compared and the P-
value from this F test reported was reported.  
2.11.2 Semi-quantitative Reverse-Transcriptase RT- PCR 
The validation for the array splicing events was performed by using QIAGEN 
LongRange 2stepS RT-PCR kit (Qiagen,UK). All primers for this analysis were 
designed using the Primer3 software (http://fokker.wi.mit.edu/primer3/input.htm), and 
then they were BLAST-searched against UCSC human In-silico PCR tools. The 
sequences of the PCR primers used in this study are listed in table 2.11.1 below.  
An aliquot of total RNA from 48 samples, originating from four brain regions 
(OCTX, SNIG, MEDU and CRBL) and 12 individuals were used as a subset for 
further validation. cDNA was synthesis from 1-2 µg of total RNA using gene specific 
designed primers under the following conditions: incubation at 42ºC for 90 minutes, 
followed by enzyme activation at 85°C for 5 minutes. 2.5 µl of cDNA was used to 
perform the semi-quantitative RT-PCR for the targeted exons under the following 
conditions: Initial activation at 93ºC for 3 minutes, followed by denaturation at 93°C 
for 15 seconds, annealing 59°C for 50 seconds, elongation at 68ºC for 50 seconds for 
30-40 cycles. PCR products were run on a 2% agarose gel (Invitrogen,UK) and 
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photographed using UV illumination to visualize GelRed staining. Images were 
inverted in Adobe Photoshop. 
Table 2.11.1: LRRK2 Reverse Transcriptase PCR primers.  
This table shows the sequences of the primers that were used for LRRK2 exons 
splicing validation on a subset of the human brain RNA samples.   
  
Exon Primer name Sequence (5′ >>> 3′) Location 
32-33 
LRRK2-Ex32-33 
Forward 
ACCATCATAAACGAG
AGCCTTAATTTC 
In exon 31 
32-33 
LRRK2-Ex32-33 
Reverse 
AGCAATCTGGAATTT
TTCTAGGAGCTT 
In exon 34 
33 
LRRK2-Exon-33 
Forward 
CAGCTGCAGTTAGAT
GAAAATGAGC 
In exon 32 
33 
LRRK2-Exon-33 
Reverse 
TGCCCTTAGGGTGTT
TTGGACAACCTT 
In exon 34 
42-43-44 
LRRK2-Exon43 
Forward 
AGTTTGATGAATTAG
AAATACAAGGAAAA 
In exon 42 
42-43-44 
LRRK2-Exon43 
Reverse 
TTTAGGTAATAAAAT
GCGTCTCGTCAG 
In junction 
of exon 44-
45 
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2.12 LRRK2 protein expression, extraction and Western blot analysis  
This work was performed at the Institute of Neurology by Dr Patrick Lewis 
with samples that I provided. 
From five individuals, human brain tissues were homogenized from five brain 
regions: FCTX, OCTX, CRBL, PUTM and WHMT  in phosphate buffered saline (Life 
Technologies, UK) 10% W/V using a Tissue rupture (Qiagen, UK) on ice for 30 
seconds, aliquoted and frozen prior to further use. Samples were denatured by the 
addition of LDS loading buffer with beta mercaptoethanol. Samples were denatured at 
100°C for 10 minutes and clarified by centrifugation at 12,000 g for 1 minute prior to 
loading onto 4-12% polyacrylamide gels (Life Sciences, UK), with 20 μl loaded per 
sample. Gels were run at 140 V, 4°C for 3 hours and transferred onto Polyvinalidene 
Fluoride PVDF membrane (Millipore, UK) at 25v for 24 hours. Following transfer, 
membranes were blocked in PBST plus 5% milk powder for 1 hour and probed with 
primary antibodies. For LRRK2, a rabbit monoclonal antibody (MJFF2, 
Epitomics/Michael J. Fox Foundation, USA) was used at a 1:1000 dilution in   
phosphate-buffered saline Tween 20 (PBST)/5% milk. For β Actin, a mouse 
monoclonal antibody (Sigma, UK) was used at a 1:5000 dilution. Membranes were 
probed at 4°C for 16 hours, washed three times with PBST and then probed with 
secondary horseradish peroxidase (HRP) conjugated antibodies (anti-Rabbit, 1:2000 
dilution in PBST milk, and anti-mouse 1:10000 dilution for LRRK2 and β Actin 
respectively) for 1 hour at room temperature. Membranes were washed three times in 
PBST and then immunoreactivity visualized by exposure of membranes to enhanced 
chemiluminescence (ECL) substrate (Pierce) and then photographic film (Super-RX, 
Fujifilm, UK). Films were developed using a Konica developer.  
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2.13 LRRK2 immunohistochemistry (IHC) staining analysis 
This work was performed at the Queen Square Brain Bank (QSBB) by Dr Rina 
Bandopadhyay.  
Flash-frozen sections of 12 µm thickness were cut using a cryostat (Leica 
Microsystems, UK) from three control brains (no diagnosed neurodegenerative 
disorders) which were obtained from the QSBB archive from two brain regions; CRBL 
and FCTX. Sections were air-dried for 30 minutes and fixed in 4% freshly made 
paraformaldehyde for 30 minutes followed by three 5 minute washes in 1XPBS. 
Endogenous peroxidase activity was blocked by incubating sections in methanol/0.3% 
H2O2, followed by three 5 minute washes in 1XPBS. Non-specific protein binding 
was blocked in 10% non-fat milk in 1X PBS at room temperature for 30 minutes. A 
rabbit monoclonal primary antibody to LRRK2 (MJFF2, Epitomics/Michael J. Fox 
Foundation, USA) diluted at 1:50 in 1X PBS, incubated initially for one hour at room 
temperature and then at 4°C for 16 hours. This was followed by incubations with 
biotinylated secondary antibody (anti-rabbit, Dako, UK) 1:200, and then with avidin-
biotin reagent (Vector laboratories, UK) for 30 minutes each. Bound antibody was 
visualized using the chromogen diaminobenzidine, and sections were counterstained 
with Mayer’s haematoxylin. Finally, sections were dehydrated in graded alcohols 
(70%-100%), cleared with xylene and mounted with coverslips with DPX mounting 
medium (VWR, UK). To validate specific staining, one slide without primary antibody 
was always included.  
To assess LRRK2 specific staining further, a recombinant protein block was 
included. The LRRK2 antibody in 1X PBS was incubated with 100 µg of LRRK2 
recombinant protein (Life Technologies, UK) initially at 37°C for 4 hours and then 
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overnight at 4°C. The solution was then centrifuged at 12,000 g for 30 minutes at 4°C. 
The supernatant was carefully decanted and used on a cerebellar section. 
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2.14 DNA extraction using Gentra Puregene Tissue Kit (4 g)  
In parallel, genomic DNA was extracted from sub-dissected samples (100–200 
mg) of human post-mortem brain tissue using Gentra Puregene Tissue Kit (4 g) 
(Qiagen, UK).  A single DNA extraction was performed on each brain tissue sample. 
All steps were performed on dry ice prior to the addition of the Cell Lysis Solution. 
2.14.1 Tissue homogenization and lysing  
Brain tissues from CRBL or OCTX regions were collected and weighed in 
sterilized 15 ml conical centrifuge tubes (VWR, UK); they were between 50-100 mg in 
weight.  All tissue samples were homogenized on ice using the Tissue rupture (Qiagen, 
UK) for 30 seconds at maximum speed in 4 ml of Cell Lysis Solution.  In this step, the 
tissue was homogenized until no big pieces from the tissue remained or visualized. The 
homogenized tissue samples were incubated at 55°C with 20 μl Proteinase K (Qiagen, 
UK) overnight for maximum DNA yields.  
2.14.2 RNA digestion  
 After incubation, 20 μl of RNase A solution (Qiagen, UK) was added, the tubes 
were mixed gently by inverting 25 times.  Then the tubes were incubated at 37°C for 
60 minutes.  After 3 minutes, tubes were placed on ice to quickly cool samples and 
stop the enzymatic reaction. 
2.14.3 Protein and DNA precipitation, wash and elution 
Following the incubation, 1.3 ml of Protein precipitation solution was added, 
and vortexed vigorously for 40-50 seconds at maximum speed, centrifuged for 15 
minutes at 2000 g. It was important to ensure that a tight white protein pellet was seen.  
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The supernatant was transferred to a fresh 15 ml conical centrifuge tube.  DNA 
was precipitated by adding 4 ml of 100% propanol and mixed by inverting gently 50 
times.  Tubes were centrifuged at 2000 g for 45 minutes at 4°C. The supernatant was 
discarded carefully and the DNA pellet was washed by adding 70% ethanol and 
inverted several times. After centrifugation for 1 minute at 2000 g, the supernatant was 
discarded and the pellet was air-dried for 10-15 minutes at room temperature.  Finally, 
the DNA pellet was dissolved by adding 400 μl pre-heated DNA hydration solution 
(55°C) and vortexed for 10 seconds.  DNA samples were incubated at room 
temperature overnight to ensure that all the DNA was dissolved.  The next day, DNA 
samples were ready for quality checks followed by the application of Illumina 1M 
Quad BeadChip genotyping.  
2.14.4 DNA quality assessments  
2.14.4.1 Concentration and purity 
 The concentration and purity of each DNA sample was assessed by measuring 
the optical density (OD) of each DNA sample at a wavelength of 260 nm, using the 
NanoDrop ND-1000 Spectrophotometer V3.3.0.  The concentration of each sample 
was calculated, together with the ratio of absorbance at 260 nm/280 nm and 260 nm 
/230 nm.  Samples with 260 nm/280 nm ratio lower than 1.7 were re-extracted from a 
fresh tissue block. 
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2.15 Genome-wide DNA genotyping using Illumina Human Omni1-Quad 
BeadChips and genotyping data quality control 
2.15.1 Illumina Human Omni1-Quad BeadChips and custom ImmunoChip 
This experimental work was performed by AROS Applied Biotechnology AS 
Company as a service laboratory for the samples that I provided.  
For this procedure, 4 μl of 50 ng/μl genomic DNA samples were marked on the 
Illumina Infinium Human Omni1-Quad BeadChip (Illumina, USA) according to the 
manufacturer's instructions. The BeadChips were scanned using an iScan (Illumina, 
USA) with an AutoLoader (Illumina, USA).  GenomeStudio v.1.8.X (Illumina Corp.) 
was used for analyzing the data and generating SNP calls. SNP calls were created 
using the HumanOmni1-Quad_v1-0_B (C) cluster file provided by Illumina as a 
reference. 
The following experimental work was performed by UCL Genomics as a 
service laboratory for the samples that I provided. 
In addition, all individuals were also genotyped using ImmunoChip, a custom 
genotyping array was designed for the fine-mapping of auto-immune disorders.  The 
ImmunoChip also contains 2,000 SNPs selected for replication of a Parkinson's disease 
genome-wide association study performed by the International Parkinson's Disease 
Genomics Consortium (International Parkinson's Disease Genomics Consortium and 
Wellcome Trust Case Control Consortium 2 2011; Nalls, Plagnol et al. 2011). This 
provided the resolution to fine map the LRRK2 gene (see Chapter 6).  
  
 Materials and Methods 
   73 
 
2.15.2 Genotyping data quality control 
This analysis work was performed at the Department of Medical & Molecular 
Genetics, King's College London by Dr Michael E. Weale and Dr Adaikalavan 
Ramasamy for the data that I provided. 
Standard quality control checks carried out on both datasets include: the 
removal of the genotyped markers that are labelled as monomorphic, or have less than 
95% genotyping call rate across samples, P  value for deviation from Hardy-Weinberg 
equilibrium (P < 0.0001), had no genomic position information and had less than two 
heterozygotes or redundant with an existing SNP. In addition, the reported sex status 
was checked and three Individuals were removed as they were suspected of being of 
non- Caucasian European ancestry, based on principal components projection of 
population stratification generated using HapMap3 data.  This resulted in a final 
dataset of 134 individuals. 
After quality control, 815,859 SNPs from the Illumina Omi1-Quad chip and 
137,456 from the ImmunoChip were included and obtained a total of 905,943 after 
merging the two datasets and resolving for overlapping SNPs. All manipulations of 
genotypic data were performed in PLINK version 1.07 (Purcell, Neale et al. 2007). 
Next, un-typed, missing SNPs and indels were imputed from the autosomes and 
chromosome X using the MACH (Li, Willer et al. 2009; Li, Willer et al. 2010) and 
minimac (http://genome.sph.umich.edu/wiki/Minimac)  softwares  using the European 
panel of the 1000 Genomes Project (March 2012: Integrated Phase I haplotype release 
version 3, based on the 2010-11 data freeze and 2012-03-14 haplotypes) which is 
based on 381 individuals of European descent. The genotyped and imputed data were 
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restricted to ~5.88 million SNPs that had a minor allele frequency of at least 5% and 
acceptable imputation quality (r
2
 > 0.50).  
For MAPT analysis in Chapter 5, the selection of individuals with H1/H1 
haplotype status was based on genotyped SNPs rs1800547 and rs1052553 in both 
datasets. 
 
2.16 Expression Quantitative trait loci (QTL) analysis 
This work was performed at the Department of Medical & Molecular Genetics, 
King's College London by Dr Michael E. Weale and Dr Adaikalavan Ramasamy for 
the data I provided. 
2.16.1 Identification of polymorphism-containing probes using reference datasets 
Before the expression QTL analysis was performed, probes containing 
common polymorphisms using different public datasets of genetic variation were 
identified. The main datasets that were used initially were the genotyping data from 
Illumina HumanHap550 array from the NABEC dataset, and the Illumina Omni-1M 
Quad array from the UKBEC dataset. Then the CEU panel of the final release of 
HapMap (release #28, merged Phase I+II+III data) was used. Next, the SNP and indel 
data of the European panel (n = 381) of the latest version of the 1000 Genomes Project 
(March 2012: Integrated Phase I haplotype release version 3, based on the 2010-11 
data freeze and 2012-03-14 haplotypes) was also considered.  Finally, the SNPs 
(average read depth ≥ 10) from the Exome Variant Server, NHLBI Exome Sequencing 
Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/) [accessed 11 May 
2012) which is taken from 3,510 European Americans from multiple ESP cohorts were 
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used.  SNPs that were identified with at least 1% minor allele frequency in European 
descent samples in all the datasets were included in the analysis. 
2.16.2 Masking probes that contain polymorphisms for the whole genome Affymetrix 
Exon 1.0 ST expression probe sets 
After polymorphism identification, this information was used to mask or 
discard the probes that contain the polymorphism in the expression arrays pre-
processing and normalization steps.   
The design of the Affymetrix expression exon array is made to have four 
probes which are grouped into one probe set to measure in most cases the expression 
level of a single given exon. If one or two of the four probes contain a polymorphism 
and the remainder do not, the probe set and estimated the exon signal from the 
remaining probes were included in the analysis.  If less than two probes remained 
(because one or more probes had a polymorphism or because of other quality control 
filters dropped-out of probes) then the remaining information was considered 
insufficient and the probe set was discarded. Probe masking has the advantage that 
both false positive and false negative expression QTL signals can be recovered.  The 
masking, array CEL files processing, normalization and summarization for 291,704 
probe sets were performed as in Section 2.6.1 in Affymetrix Power Tools to generate 
the whole genome expression profile intensities as log2 transformed values for the ten 
brain regions for the expression QTL analysis after correcting for the polymorphisms 
in probes.  The ten brain regions that were included for the expression QTL association 
analysis are as follow: FCTX, n = 127; TCTX, n = 119; OCTX, n = 129; HIPP, n = 
122; THAL, n = 124; CRBL, n = 130; SNIG, n = 101; PUTM, n = 129; MEDU, n = 
119; WHMT, n = 131, originating from 134.   It should be noted that SPCO and HYPO 
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regions were excluded from the expression QTL analysis, as the sample size for these 
two regions was too small (only 13 samples each).  
2.16.3 Expression QTL analysis and linkage disequilibrium (LD) signal identification  
Once the data were converted into a suitable format, the association between 
each SNP (genetic marker) and each expression profile (1231 arrays) was performed. 
The expression profile is defined as a probe set signal as covering an exon (in total 
291,704 probe sets) or a transcript set which is a group of probe sets covering the 
whole transcript (in total 26,493 transcripts), assuming an additive genetic model for 
SNPs. The computation was done using the MatrixEQTL software (Shabalin 2012) 
(http://www.bios.unc.edu/research/genomic_software/Matrix_eQTL/) and Revolution 
R (http://www.revolutionanalytics.com/) on a high performance Linux-based computer 
cluster. 
The process of imputation and linkage disequilibrium across the genome 
creates a problem in the expression QTLs from SNP-rich high LD regions, which was 
represented several times by LD proxy. Therefore, multiple associations for a given 
probe set were treated as a single signal if the associated SNPs were in LD (r
2
 > 0.5) 
with each other. For a given transcript ID/ cluster pairing, SNP with the smallest P-
value was classified as the ‘LD-resolved’ sentinel marker expression QTL.  An 
expression QTL signal was defined as cis-acting if the target SNP is located within 1 
Mb of the transcription start site of the associated transcript and trans-acting if the 
SNP is located outside the cis region on the genome.   
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2.16.4 False discovery rate (FDR) calculation 
 The results were classified by the marker type: SNP or indel, expression type: 
exon or gene/transcript-level and the distance of SNP to the transcription start site: cis 
or trans.  Then, the FDR was calculated based on these classifications. For each class, 
the number of tests was conducted and converted the nominal P values into a false 
discovery rates (FDR). Only the associations with FDR < 1% were considered for the 
subsequent analyses. 
2.16.5 SNP and functional annotations 
 The haplotype variant call format (VCF) file for SNPs and indels was 
submitted separately to the Seattle Sequence Annotation hg19 server 
(http://snp.gs.washington.edu/SeattleSeqAnnotation134/index.jsp). The Genome 
variation server functional annotation (functionGVS) and transcription factor columns 
were retained (SeattleSNPs. 2012). 
2.16.6 Integrating expression QTLs with GWAS catalogue 
 The NHGRI GWAs catalogue (Hindorff, Sethupathy et al. 2009; Hindorff, 
MacArthur et al. 2012) was downloaded from the link 
http://www.genome.gov/gwastudies/. This catalogue contained 8.922 records; 337 
records that reported haplotypes or indels (instead of SNPs) were ignored. After 
removing duplicate entries, there were 7,042 SNPs of which 6,387 (~91%) were 
identified in the imputed genotype data of UKBEC. The GWAS hits were classified as 
either brain or non-brain related according to the reported trait/diseases.  For each 
sentinel SNP or sentinel indel, the LD with these GWAS SNPs (within a 10 Mb or 
1000 SNP moving window) was calculated using the vcftools utility (version 0.1.9; 
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http://vcftools.sourceforge.net/) and haplotype data of the European panel (n = 379) 
from the 1000 Genomes Project (March 2012). If an LD between SNPs of r
2
  0.50 
was observed, the corresponding GWAS SNPs along with the LD measure was 
recorded.  
 Materials and Methods 
   79 
 
2.17 Characteristics of the human post-mortem tissue of the North American 
Brain Expression Consortium (NABEC) 
This work was performed at the Molecular Genetics Section and Laboratory of 
Neurogenetics, NIA, NIH, USA, resulting in two publications (Gibbs, van der Brug et 
al. 2010; Hernandez, Nalls et al. 2012).   
In this study, in addition to the expression profiles that were generated from 88 
individuals from the UKBEC dataset on Illumina HT-12 arrays (see Section 2.5), the 
expression profiles that were generated from 305 individuals from the NABEC dataset, 
who were expression profiled on the Illumina HumanHT-12 v3 Expression BeadChip 
arrays, were downloaded and used to increase the number of samples for MAPT 
analysis (see Chapter 5). 
 
2.17.1 Human post-mortem brain tissue collection and dissection 
CRBL and FCTX samples originating from 305 control individuals were 
collected as previously described (Gibbs, van der Brug et al. 2010; Nalls, Plagnol et al. 
2011; Hernandez, Nalls et al. 2012).  A small number of individuals were expression 
profiled by both consortia but these were removed in this study.  
 
2.18 RNA extraction using single-step TRIZOL
®
Reagent based protocol 
Total RNA was extracted from 100–200 mg of human post-mortem brain tissue 
using a glass-Teflon homogenizer and 1 ml TRIzol (Invitrogen, Carlsbad, CA) as 
described previously (Gibbs, van der Brug et al. 2010; Hernandez, Nalls et al. 2012).   
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2.19 Genome-wide expression profiling using Illumina HumanHT-12 v3 
Expression BeadChip  
RNA was biotinylated and amplified using the Illumina® TotalPrep-96 RNA 
Amplification Kit and directly hybridized onto HumanHT-12 v3 Expression 
BeadChips (Illumina Inc., USA) in accordance with the manufacturer’s instructions.  
In this section the same protocol in Section 2.5 was applied. 
 
2.20 Illumina HumanHT-12 v3 Expression BeadChip arrays analysis 
Expression data were analyzed using the Gene Expression Module 3.2.7 within 
Illumina® BeadStudio.  The raw intensity values for each probe were transformed 
using the cubic spline normalization method (Workman, Jensen et al. 2002) 
(http://www.illumina.com/documents/products/technotes/technote_beadstudio_normali
zation.pdf) and then log2 transformed for mRNA analysis. The annotations for probes 
according to ReMOAT (Barbosa-Morais, Dunning et al. 2010) were re-mapped on the 
human genome build 19 and then restricted the analysis to genes that were reliable, 
uniquely hybridized and were associated with gene descriptions. In the analysis for 
MAPT eQTL, the analyzed data that was generated by the following two probes: 
ILMN_1710903 and ILMN_2310814 was used. Prior to use in expression QTL 
analyses, data were corrected for gender, batch effects, age, post-mortem interval and 
brain bank as described previously (Gibbs, van der Brug et al. 2010). 
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2.21 Genome-wide DNA genotyping using Illumina
®
 Infinium HumanHap550-
v3 BeadChips 
The DNA extraction and imputation protocol was similar to that employed in 
UKBEC. The individuals were genotyped on Illumina
®
 Infinium HumanHap550 
v3  Genotyping BeadChips (Illumina, USA) and approximately 5.3 million SNPs were 
available after imputation and quality control (Gibbs, van der Brug et al. 2010). 
Finally, the selection of individuals with H1/H1 haplotype status for the MAPT gene 
was based on genotyped SNPs rs1800547 and rs1052553 in both datasets. 
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3 Quality control assessment on a large dataset of regionally-
dissected human control brains for genome-wide expression studies. 
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3.1 Summary 
Human brain tissue is a challenging source to perform genome-wide expression 
and splicing profiling by using advanced, high throughput techniques such as: 
expression microarrays and RNA sequencing. Several studies have previously shown 
that pre- and post-mortem variables can alter total RNA integrity in a complex manner. 
As a result, researchers need to be cautious when interpreting results that originated 
from post-mortem tissues. 
In order to investigate the viability of the post-mortem tissue data and assess 
the effect of post-mortem interval (PMI), agonal state and age on array performance 
and gene expression profiles, and the utility of pH and RNA integrity number (RIN) as 
predictors of RNA and expression quality; these variables were measured and assessed 
on 1,266 human Affymetrix Exon Arrays originating form 137 control individuals 
from thirteen CNS regions. In addition, the accuracy of the array results using 
QuantiGene (QG), as an independent non-PCR based validation method.  
The results revealed that post-mortem delay, agonal state and age have little 
impact on array performance quality, the quality of array results are robust and not 
necessarily proportionate to variable RNA integrity, and brain pH has only a small 
effect on array performance. QuantiGene, as a validation yielded very similar 
expression profiles as array results did. 
This analysis is the first step in this project to build a reliable human, regional 
brain expression open-access database that is designed to allow the genome-wide 
assessment of genetic variability of expression. These quality control parameters will 
allow dataset users to assess data accuracy from control human post-mortem tissues. 
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3.2 Introduction  
Microarray analysis and RNA sequencing of the transciptome in human post-
mortem brain tissue is a vital tool in investigating the underlying complex genetic 
mechanisms involved in neurodegenerative and psychiatric disorders (Gilbert, Brown 
et al. 1981; Glanzer, Haydon et al. 2004; Myers, Gibbs et al. 2007). The restriction of 
brain tissue availability, the fact that brain tissues can only be obtained after PMI of 
unpredictable duration, varying agonal states, medical history, cause of death, different 
procedures in tissue handling and tissue dissection accuracy are making these types of 
projects extremely challenging.  However, these variables which potentially influence 
the RNA integrity in post-mortem human brain tissues need to be accounted for in 
order for such data to be highly reliable (Sajdel-Sulkowska, Majocha et al. 1988; 
Burke, O'Malley et al. 1991; Leonard, Logel et al. 1993; Glasel 1995; Imbeaud, 
Graudens et al. 2005; Schroeder, Mueller et al. 2006; Durrenberger, Fernando et al. 
2010; Birdsill, Walker et al. 2011).  A previous study using 89 human post-mortem 
brains showed that pre- and post-mortem factors have different levels of effect on 
different locations in the mRNA transcript. For example, the 3' UTR end is more 
sensitive to post-mortem factors than other locations in the transcript (Johnston, 
Cervenak et al. 1997).  
In this project, the selection of the array type was made based on the 
advantages that the commercially available arrays were offering at the time.  
Affymetrix GeneChip
®
Human Exon 1.0 ST Arrays offered more comprehensive 
coverage of the genome, compared with different versions of previous expression 
arrays, as it was designed to contain 1.4 million probe sets covering 90% of the coding 
exons. This had been annotated from different genomic sources over the whole 
transciptome (median number of probes is 30 to 40 per transcript) (Gardina, Clark et 
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al. 2006).  This helped to eliminate RNA degradation that can occur with 3'UTR 
designed arrays. Degraded RNA will be inefficiently targeted and amplified to cDNA 
using the olig-DT priming protocol in 3'UTR arrays, and as a result, this decreases the 
ability to detect degraded and low expressed transcripts. In contrast, exon array probe 
sets target all coding exons along the targeted transcript to give higher resolution and 
more sensitivity for the exon and gene expression level analysis (Figure 3.2.1).  
Moreover, the exon array technology is designed to uncover splicing events in the 
transciptome (Clark, Schweitzer et al. 2007), such as skipping or inclusion of exons 
using ANOVA based method that is based on the Splicing Index concept (Srinivasan, 
Shiue et al. 2005).  However, every technique has its own limitations, it is noteworthy 
that the exon arrays have some restrictions with regard to their ability to detect certain 
splicing events (false negative). For example, small exons with low 
inclusion/expression rates may prove difficult to detect and thus may have a weak 
signal to detect and thus may be filtered out.  The alternative spliced mRNA exon/ 
transcript half-life is too short and is degraded before detection.  In addition, the probe 
design of this array does not include the exon-exon junctions (Clark, Schweitzer et al. 
2007). More detailed information is available about the exon array design on the 
Affymetrix website (http://www.affymetrix.com/estore/) by searching for ‘GeneChip 
Human Exon ST Array’.   
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Figure 3.2.1:  
Diagram of the exon array probes / probe sets design. 
This figure shows the coverage of the probes along the whole length of the 
transcript on the arrays.  Purple boxes are exons from different isoforms. 
Purple dashes are individual probes targeting the genomic locus, which is 
termed a probe selection region (PSR). 3-4 probes covering the same exon 
form a probe set.  The orange dash shows the probe location on the 3'UTR 
platform. Modified from the Affymetrix website, 2011. 
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Moreover, it is important to have a reliable and stable method to assess the 
quality of RNA samples that are generated from precious heterogeneous tissues, 
especially from small anatomical regions, such as the substantia nigra and 
hypothalamus. In order to prevent unnecessary costs, such assessment is important 
before samples were run through the whole experimental process.  The most 
widespread measure for estimating the integrity of RNA samples at present is the RIN 
as calculated by the Agilent 2100 Bioanalyzer for electrophoresis (Agilent 
Technologies UK Ltd, UK) (Becker, Hammerle-Fickinger et al. 2010). The RIN 
ranges from 1 (undetectable) to 10, with 1 being completely degraded and 10 being the 
most intact RNA.  
The algorithm for the RIN calculation is largely based on the ratio of ribosomal 
RNA 28S/18S signal heights, areas under the signal peaks, position and separation 
times (Figure 3.2.2). In addition, the algorithm counts for the level of the signal in the 
fast, inter-regions and post regions to look for RNA degradation products. It assigns 
relative weight to each of these factors and calculates the final RIN from the 
combination of these factors (Schroeder, Mueller et al. 2006).  
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This provides an indication that it is an indirect measure of the mRNA quality; 
and further, it has been shown to be inconsistent even for the same RNA sample that 
was measured at different times (Imbeaud, Graudens et al. 2005; Schroeder, Mueller et 
al. 2006; Sherwood, Head et al. 2011).  
  
 
 
 
 
 
 
 
 
Figure 3.2.2:  
Electrophoresis results from the bioanalyzer software clarifying the 
RIN calculation parameters. 
This figure shows all the parameters that the RIN calculation is based on 
from total RNA samples. This sample shows a high integrity RNA sample 
with RIN = 10 (Agilent Technologies, 2004).  
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This project of regional expression of control human brain expression was 
constructed to allow the assessment of the genetic variability in gene expression QTLs 
and splicing QTLs as well as detailed genome-wide and regional expression analysis in 
the adult human brain (Hardy, Trabzuni et al. 2009).  A large series of 137 control 
human brain tissues in which were dissected from thirteen different central nervous 
system (CNS) regions: FCTX, n = 124, TCTX, n = 118, PCTX, n = 19, OCTX, n = 
132, HIPP, n = 126, THAL, n = 121, HYPO, n = 14, PUTM, n = 130, SNIG, n = 104, 
MEDU, n = 116, CRBL, n = 137, SPCO, n = 14 and WHMT, n = 129. From each 
individual brain region, the RNA was isolated for whole transcriptome exon array 
analysis. This resulted in a total of 2,318 extracted RNA samples, but only 1,266 RNA 
samples analysed on Affymetrix Exon arrays and represent by far the largest single 
CNS expression dataset to date. For this quality control analysis, the factors that 
affected the reliability of the RNA samples quality were assessed. 
The assessment of the following aspects was performed; i) the effects of brain 
bank (BB), age, gender, cause of death, region of the brain, post-mortem delay and 
brain pH on RIN-based RNA quality, and, ii) the effects of RNA quality on the 
performance quality of the array experiment, which was measured by a reliable and 
widely used parameter, present call (%P) (Weis, Llenos et al. 2007). %P is the 
percentage of probe sets with signal detection above background noise. The effects of 
RNA quality on the cDNA preparation and cRNA production were examined as part of 
the quality control of the array experiment, and finally the reproducibility of array 
results using QuantiGene (QG), a novel, PCR-independent platform was confirmed 
(Canales, Luo et al. 2006; Arikawa, Sun et al. 2008; Hall, Leong et al. 2011).  
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3.3 Results 
In total, 1,302 tissue blocks were available for the analysis.  They were 
generated from 137 individuals from 13 CNS regions, as some regions were not 
available from all individuals.  In 870 tissue blocks more than one extraction was 
performed, and the RIN was measured to assess the RNA integrity.  One RNA sample 
from each tissue was selected to be run on the Affymetrix Exon arrays giving a total of 
1,266 exon array expression profiles (Figure 3.3.1). 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1:  
Diagram of the samples and data used for the quality control analysis. 
This figure shows the full process for the tissues and RNA samples through 
the extraction, quality control and array experiments (Trabzuni, Ryten et al. 
2011).  
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3.3.1 Factors affecting RIN-based RNA quality 
The dependence of RIN values on the other covariates assessed in this study 
was evaluated.  The focus was on the explanatory power of the available covariates on 
the RIN for each RNA extraction. In this study 2,318 RNA samples were assessed. 
The calculated RIN ranged from 1 to 8.5 with a mean of 3.85. 43% of the samples had 
RIN values < 3.  33% of the variation in RIN was explained by differences among 
tissue blocks (adjusted R
2
 measure), which set an upper limit for the explanatory power 
of the covariates, which all act at a between-tissue-sample level. 16% of the variation 
in RIN was explained by individual-level differences. 
Among all these factors, the most important covariates were brain region 
(explaining 9.2% of the variation in RIN, P =1.710-42), age (explaining an additional 
1.1%, P = 4.110-05) and cause of death (explaining an additional 1.9%, P = 0.022). 
Brain bank and gender together explained only an additional 0.4 % of the variation. 
pH and PMI were investigated separately, as pH was not measured in the 
SHRI-USA dataset and because the range of PMIs from the two brain banks did not 
overlap. 
In this part of the analysis 1842 RNA samples were assessed. pH explained 
2.1% of the variation in the RIN from the MRC-UK dataset (P = 1.010-4) (Figure 
3.3.2-A). Six individuals had very low pH (< 5.90) and, when excluded, the correlation 
was no longer significant (P = 0.82) (Figure 3.3.2-B).  
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The effect of PMI on RIN differed between the MRC-UK and SHRI-USA 
datasets. There was no significant correlation between PMI and RIN in the MRC-UK 
dataset (1842 samples), which had PMIs ranging from 28 to 114 hours.  In contrast, 
PMI explained 8.4% of the variation in RIN in the SHRI-USA dataset (476 samples) 
(P-value = 0.0053), which had PMIs ranging from 1 – 5.5 hours. This result was 
consistent with results from Birdsill et. al. and Kang et. al studies on control and 
diseased human post-mortem brain tissues (Birdsill, Walker et al. 2011; Kang, 
Kawasawa et al. 2011).  Longer PMI was associated with a higher RIN in this data set, 
a counterintuitive result which might represent confounding with some unmeasured 
variables in this analysis. 
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Figure 3.3.2:  
The relationship between RIN and pH. 
(A) Scatter plot for total RNA samples from 13 region of control brain tissue 
with linear regression line of RIN numbers for pH where samples with pH < 
5.9 were included. A significant correlation between PIN and pH was 
obtained (P = 1.010-4, r = 0.146. (B) Scatter plot as in (A) but where 
samples with pH < 5.9 were excluded for total RNA samples with linear 
regression line of RIN numbers for pH where samples with pH < 5.9 were 
excluded. No significant correlation was obtained (r = 0.0016 and P = 0.82) 
(Trabzuni, Ryten et al. 2011).  
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3.3.2 Factors affecting present call (%P), cDNA and cRNA profile  
The dependence of RNA array performance quality on RIN-based RNA quality 
and the other covariates available for the analysis were assessed.  A systematic 
quality control check of the arrays was performed using Expression Console™ 
software. This software produces a number of array quality measures. The most 
reliable and widely used parameter is present call (%P) (Tomita, Vawter et al. 
2004; Weis, Llenos et al. 2007). The present call is the percentage of probe sets 
with signal detection above background (DABG) probe level P-value ≤ 0.01. 
The range of %P in this study was 1.7% to 77.3% (mean of 61.4%).  36% of the 
variation in %P was explained by individual-level differences (adjusted R
2
 
measure). 
For 1,266 RNA samples, among all the factors, the most important covariates 
were brain region (explained 12.4% of the variation in %P, P = 3.610-53), followed by 
brain bank (explained an additional 4.7%, P = 9.610-6), and then RIN (explained an 
additional 2.7%, P = 9.110-5).  Age, gender, and cause of death together explained 
only an additional 2.2% of the variation. The effect of brain region on %P was most 
obvious when comparing CRBL and WHMT.  CRBL showed the highest %P (mean = 
68%) while WHMT showed the lowest %P (mean = 57.5%) (Figure 3.3.3).    
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Figure 3.3.3:  
The variation in %P by brain region. CRBL = cerebellum, WHMT = 
white matter. 
This graph shows the different performance of samples from specific brain 
regions on the array. The results from two-sample t-test are highly 
significant P = 1.310-24. The heights of the bars represent the mean. The 
error bars represent the S.E.M. (Trabzuni, Ryten et al. 2011).  
CRBL               WHMT 
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For the same reasons described previously pH and PMI were analyzed 
separately.  pH as a factor explained 12.0% of the variation in %P from the MRC-UK 
dataset (984 samples) (P = 2.310-9) (Figure 3.3.4). However as with RIN, this 
correlation was highly dependent on the six individuals with low pH (< 5.90). When 
these samples were excluded from the analysis no significant correlation was obtained. 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4:  
The linear regression of Present call (%P) for pH.  
Scatter plot shows that pH explains 12.0% of the variation in %P (P = 
2.310-9, r = 0.353), including samples with low pH values. Low pH values 
are driving the regression analysis (Trabzuni, Ryten et al. 2011). 
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Finally, no significant correlation was found between PMI and %P, either for 
the MRC-UK dataset (984 samples) or the SHRI-USA dataset (282 samples).  
Moreover, no difference was observed in the expected nucleotide lengths in cDNA (~ 
200 - 400 nt) and cRNA (ranges from 200 to 2000 nt) production in the Agilent 
profiles when different RNA samples with different RIN values (from 1- 8) were used. 
3.3.3 Validation of array results using QuantiGene, a PCR-independent platform  
QuantiGene is a technique for mRNA expression quantification using branched 
DNA (bDNA) technology. This eliminates the need to purify or amplify RNA, so it is 
a non-PCR based technique, and is therefore not subject to the systematic biases that 
PCR or reverse transcriptase could create when applied to degraded RNA samples 
(Hall, Leong et al. 2011). In addition, it is based on the cooperative hybridization of  
specifically designed probe sets for the targeted mRNA.  Lastly, the amplification and 
the detection are for the signal that represents the target quantity, and not the 
quantification of the target itself (Figure 3.3.5, modified from the Panomics website, 
2011).  This technique can therefore be used in place of qRT-PCR (Canales, Luo et al. 
2006; Hall, Leong et al. 2011).   
 Each oligonucleotide probe set contains three types of synthetic probes, 
Capture Extenders (CEs), Label Extenders (LEs), and Blockers (BLs) that hybridize to 
specific sequences of the target mRNA.  CEs are ~ 40 nucleotides long, around half of 
the CEs’ sequence is complementary to the target mRNA, and the other half is 
complementary to the capture probes that are at the bottom of the Capture Plates. The 
LEs are also ~ 40 nucleotides long and half of the LEs’ sequence is complementary to 
the target mRNA, and the other half is complementary to the branched DNA 
Amplifiers. Finally, the BLs are used to hybridize across the target mRNA sequence 
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that are not covered by CEs and LEs. These three probes hybridize contiguously to a 
region of 300 to 500 nucleotides, creating a region of a double-stranded RNA/DNA 
hybrid molecule. This double stranded molecule is stable and does not create the 
secondary structures that single stranded mRNAs can form. 
The exon array results in a subset of 12 individuals were validated by 
comparing the normalized mRNA expression level for three genes: LRRK2 (Leucine-
rich repeat kinase 2), SCN8A (Sodium channel, voltage gated, type VIII, alpha subunit) 
and MAPT (microtubule-associated protein tau), in four brain regions (CRBL, OCTX, 
PUTM, and WHMT). Similar regional patterns of expression were observed across the 
two platforms for both high (SCN8A, MAPT) (Figure 3.3.6) and low expression 
transcripts in brain (LRRK2) (Figure 3.3.7). 
Furthermore, there was a very high correlation in fold change (r
 
= 0.92) at both 
the gene and exon expression levels and signal intensity values (r
 
= 0.95) in the four 
brain regions that were studied by both techniques.  
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Figure 3.3.6:  
QuantiGene validation of microarray expression results for SCN8A 
and MAPT mRNA expression level in four brain regions. CRBL = 
cerebellum, OCTX = occipital cortex, PUTM = putamen, WHMT = white 
matter. 
(A) SCN8A mRNA expression level between different brain regions. The 
graph shows high expression in OCTX compared with other regions. It is 
clear that this gene in mostly not expressed in the WHMT region 
(expression level close to zero) and also has a large standard error. (B) 
MAPT, showing higher expression in OCTX compared with other brain 
regions. These results confirm the array results with significant P-values 
<0.01. The expression level is presented as the mean and the error bars is 
S.E.M. (Trabzuni, Ryten et al. 2011) 
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Figure 3.3.7:  
QuantiGene validation of microarray expression results for LRRK2    
mRNA expression level in four brain regions. CRBL = cerebellum, 
OCTX = occipital cortex, PUTM = putamen, WHMT = white matter. 
This graph shows the expression of this gene at high level in OCTX 
compared with other brain regions. Wilcoxon signed rank test was 
performed and these results confirm the difference of the expression 
between brain regions in array data is significant. The expression level is 
presented as the median and the stars indicating the significant difference in 
expression with P-values < 0.01. In this case, as LRRK2 expression level 
was very low, it was unreliable to use S.E.M. and Wilcoxon test was 
performed using the median values (Trabzuni, Ryten et al. 2011).  
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3.4 Discussion  
This study reports quality control data on the largest human control brain exon 
microarray data set generated to date. This data set was based on the analysis of tissue 
samples from 13 different CNS regions originating from 137 individuals and 
containing 2,318 processed RNA samples.  It is noteworthy that there are a number of 
previous studies of gene expression in control human post-mortem brains, however 
these used a different platform that generated only gene-level signals, a maximum of 
four brain regions were dissected and a smaller sample size was tested (Mistry and 
Pavlidis 2010).  
The results showed considerable variation in RIN values among RNA samples.  
67% of the variation resides in differences among extractions from the same tissue 
blocks, and most of the remaining variation is unexplained by the available covariate 
information. Brain pH is the most important post-mortem factor influencing RIN-
based RNA integrity, a result consistent with previous studies (Hardy, Wester et al. 
1985; Mexal, Berger et al. 2006; Chevyreva, Faull et al. 2008; Monoranu, Apfelbacher 
et al. 2009; Durrenberger, Fernando et al. 2010). Samples with very low pH values 
(ranging from 5.42 – 5.90) were responsible for the positive correlation seen between 
pH and %P (and also RIN). However, when these low pH samples were removed from 
the analysis no significant correlation was observed. This may in part explain 
contradictory observations regarding the effect of pH on RNA integrity and sample 
performance on arrays (Hardy, Wester et al. 1985; Monoranu, Apfelbacher et al. 2009; 
Birdsill, Walker et al. 2011) and confirms the findings of a recent smaller study on  
control brain tissues (Sherwood, Head et al. 2011). 
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The array-based expression data were validated by the QuantiGene PCR-
independent method, when tested on two highly expressed genes (MAPT & SCN8A) 
and one low expressed gene (LRRK2).  However, the performance quality of the array, 
as defined by %P, was not profoundly affected by age, gender, region, PMI, RIN or 
cause of death. This confirms findings from previous studies on much smaller sample 
sizes (Tomita, Vawter et al. 2004; Durrenberger, Fernando et al. 2010; Birdsill, Walker 
et al. 2011).  Only 2.7% of the variation in %P was explained by RIN. Indeed, 80 RNA 
samples with undetectable RINs performed well on the arrays with %P values ranging 
from 45% to 76%.  Thus RIN was found to be a poor predictor of array quality 
performance even at the low end of the RIN scale. Furthermore, the latter was 
confirmed since the cDNA and cRNA nucleotide length synthesis was not affected by 
the wide range of RIN-based RNA quality values (from 2 to 7) in the current study.   
Furthermore, it is important to note that the values for the RIN that were reported in 
this study are much lower than those reported for comparable samples in other 
laboratories. This is most likely due to differences in the RNA isolation kits that were 
used.  Most RNA kits, including the RNAeasy kit, encourage the loss of small or 
degraded RNA species. For this project the miRNAeasy kit was used, which 
specifically allows for the conservation of short microRNA species. When short RNA 
is present, the RIN algorithm generates lower RIN values. As a result RIN values 
generated here are not directly comparable with those reported in other studies where a 
different RNA isolation kit was used. An example of such a study was carried out on 
the Sun Health brain bank (Beach, Sue et al. 2008). 
The robust performance of the Affymetrix Exon arrays using degraded RNA 
samples was as a result of the recent modifications to the RNA amplification 
Ambion® WT Expression kit.  This kit uses both non-polyA and polyA-based mRNA 
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priming for first strand cDNA synthesis. This meant that RNA amplification did not 
need an intact polyA tail. In addition, increasing the quantity of the starting material of 
RNA from 500 ng to 750 ng during the troubleshooting of the array experiments for 
this project the array’s performance was improved. 
A number of limiting factors may have impacted on the outcomes of this study. 
For example the cause of death is an imperfect reflection of the true medical and drug 
treatment history of the individual, and that access to that history, was it available, 
would reveal other factors of greater relevance. In this study the cause of death only 
explained 1.9% of variation in RIN and there was no significant relationship with %P. 
Likewise, in the range of 28-114 hours there was no effect of PMI on either RIN or 
%P, nor a loss of RIN-based RNA quality over the 1-5 hour range was observed. It 
remains possible that there may be selective loss of RNA within an hour since the half-
life of some mRNA species has been reported to be as short as 15 minutes, while 
others may be as long as 22 days depending on the tissue type and storage conditions 
(Ross 1995; Barrachina, Castano et al. 2006; Bahar, Monahan et al. 2007; Beach, Sue 
et al. 2008; Vennemann and Koppelkamm 2010). This issue has been studied in detail 
for a range of PMIs by Harrison et al. (1995) and confirmed by a more recent study by 
Tomita et al. (2010). The same conclusion was made that a limited effect of PMI was 
observed on mRNA (Harrison, Heath et al. 1995; Tomita, Vawter et al. 2004; Kang, 
Kawasawa et al. 2011). 
Furthermore, there is a possibility that samples with the shortest PMIs (1-2.5 
hours) within the SHRI-USA sample set may originate from those individuals who 
suffered longer agonal states prior to death than individuals with longest PMIs (3-5.5 
hours) and agonal stress has been shown to affect gene expression differently in 
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different brain regions (Li, Meng et al. 2007). Other factors may contribute to this such 
as intermittent edge effects, especially on small samples during dissecting and tissue 
handling procedures. 
Finally, the brain samples were derived from two sources: one was a rapid 
death brain bank with long post-mortem intervals and the other specialises in obtaining 
very short post-mortem intervals. Both brain banks had separately optimised their 
collection and dissection protocols to facilitate gene expression studies and this may 
limit the generalisability of these conclusions. 
These results are important for several reasons.  First, they confirm the 
practical viability of using post-mortem control brain tissue to study the transcriptome 
of the human brain by array technology and RNA sequencing (Franz, Ullmann et al. 
2005).  Secondly, they show that microarrays can give reliable results over a wide 
range of RIN (1 - 8.5) and pH measurements with a drop off in array validity only 
being observed below brain pH 5.9. Thirdly, they show that the results from 
Affymetrix exon arrays are reproducible by other technologies, making it possible for 
database users to analyse the data generated with confidence.  
Furthermore, this study is the first step of an on-going multi-regional control 
human brain expression project that has been established to build an open-access 
database of identified genome-wide genetic variability in relation with gene expression 
and splicing QTLs as well as for detailed expression analysis (Hardy, Trabzuni et al. 
2009). This will move the field forward in our understanding of the underlying 
molecular mechanisms of complex neurologic diseases, and will support the 
neuroscience community with a resource which will bring functional insights.  
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The results of the work described in this chapter were published in the Journal of 
Neurochemistry:  
Trabzuni, D., Ryten, M., Walker, R., Smith, C., Imran, S., Ramasamy, A., Weale, M.E. 
and Hardy, J. (2011) Quality control parameters on a large dataset of regionally 
dissected human control brains for whole genome expression studies. Journal of 
Neurochemistry, 119, 275-282. 
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4 Regional specific transcriptome and expression quantitative trait loci 
(QTL) analyses of UKBEC dataset  
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4.1 Summary 
Different levels of complexity in the structure of the human brain are 
demonstrated and driven by the variability of the structure of different cell types, 
distinct gene expression profiles, various transcripts/exon splicing patterns and 
complex functional connections in different anatomical brain regions. Despite major 
advances in genomics and transcriptomics, it is still challenging to achieve a 
comprehensive understanding of the genetic regulation, functional mechanisms and 
transcriptome mapping of the adult control and diseased human brain.   
In order to expand our understanding of the human brain transcriptome and its 
regulation, association analyses of the QTLs with transcript and exon expression 
profiles were performed on 1231 exon arrays that were generated from ten brain 
regions in 134 individuals. In parallel, the genome-wide analyses of regional 
expression profiles of transcripts and exons levels were performed on 917 exon arrays. 
These arrays were generated from a subset of samples, which represented 101 
individuals from twelve brain regions including cortical areas, and these were obtained 
from the UKBEC.  
The results showed that 75% of the genes were expressed, and 80% of these 
genes were differentially regulated at the whole-transcript or exon level across CNS 
regions. 9% of expressed genes are specifically enriched in the CRBL region. An 
alternative splicing pattern was the dominant pattern in the cortical regions. Regional 
isoforms were identified to have a functional effect. Brain regional expression QTL 
signals were reported genome-wide.  
This study provides comprehensive information and insights into the 
transcriptional architecture of the adult human CNS in different anatomical regions, 
facilitating genomic/transcriptomic correlation investigations. It provides a valuable 
and reliable resource for future focused cell biology and functional studies.  
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4.2 Introduction  
The difficulty and complexity of studying the brain transcriptome architecture 
arises from the nature of the human brain as it is a heterogeneous structure containing 
different cell types at different ratios in different anatomical regions (Azevedo, 
Carvalho et al. 2009). In addition, the vulnerability of different brain anatomical 
regions and severity of pathology in different diseases contributes an additional level 
of complication to understanding the aetiology of these diseases.    
Profiling the expression and splicing patterns will provide comprehensive 
information for different CNS regions with different cell types in relation to 
neurological diseases. Previously it was reported that the variability in the transcription 
profiles of the human CNS can lead to different functional features (Enard, Khaitovich 
et al. 2002). In addition, different mRNA isoforms have different structures and 
opposing functions. These alternative splicing patterns can promote the progress of 
human diseases (Wang, Sandberg et al. 2008). This demonstrates the importance of 
having complete coverage of the human CNS.  
The transcriptome patterns in the different regions and cells of the CNS has 
been attempted by other groups to expand the understanding of the transcriptomic 
architecture (Roth, Hevezi et al. 2006; Johnson, Kawasawa et al. 2009; Kang, 
Kawasawa et al. 2011; Hawrylycz, Lein et al. 2012). The Roth et al. study showed 
differential expression patterns between 20 CNS regions (Roth, Hevezi et al. 2006). 
Region specific changes were also apparent in a study by Hawrylycz et al. in addition 
to revealing differences at the cellular level (Hawrylycz, Lein et al. 2012). Although 
these studies provide insight into connectivity and functional regulation in the human 
CNS, they are limited by the sample size and alternative splicing detection technology 
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that was employed. Furthermore, integrating the transcriptomic data with the genomic 
data was utilized to map expression quantitative trait loci in the control human brain 
(Myers, Gibbs et al. 2007; Heinzen, Ge et al. 2008; Gibbs, van der Brug et al. 2010; 
Kang, Kawasawa et al. 2011). Expression QTL signals associated with whole 
transcript and exon levels were reported and tissue specific signals revealed the unique 
expression and splicing patterns in different regions (Heinzen, Ge et al. 2008). The 
mapping of expression QTLs was shown to be a successful approach for exploring the 
effect of genetic control on transcriptional regulation in the human CNS, in order to 
understand the molecular mechanism of this effect on gene expression and splicing 
patterns.     
Investigating and understanding the regional expression and splicing patterns in 
normal human CNS tissues are of necessity in order to make progress in this field. To 
date, all mRNA expression databases are lacking in two important ways.  Firstly, they 
are not based on a large scale cohort due to brain tissue availability, and secondly, there 
are no comprehensive investigations of different regions representing the exon level as 
well as the gene level. In order to address this challenge, data on 917 samples from 
twelve CNS regions were included in this analysis. The regions and the sample sizes 
were as follows: FCTX, n = 96, TCTX, n = 84, OCTX, n = 95, HIPP, n = 93, 
THAL, n = 83, HYPO, n = 13, PUTM, n = 94, SNIG, n = 68, MEDU, n = 92, 
CRBL, n = 95, SPCO, n = 13 and WHMT, n = 91. This part of the data set was used 
for regional differential expression and splicing analysis in 12 regions. In addition, the 
expression QTL analysis was performed genome-wide using the entire UKBEC data 
set of 134 individuals in ten regions. The number of samples in each brain region were 
FCTX, n = 127, TCTX, n = 119, OCTX, n = 129, HIPP, n = 122, THAL, n = 124, 
PUTM, n = 129, SNIG, n = 101, MEDU, n = 119, CRBL, n = 130 and WHMT, n = 
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131 (1,231 Affymetrix exon arrays) (Trabzuni, Ryten et al. 2011). This analysis was 
performed to translate the GWAS results to a functional level and to identify more 
functional loci that are involved and related to neurological diseases. 
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4.3 Results 
4.3.1 Detected transcripts in different CNS regions using detection above 
background (DABG) method 
 According to the Affyemtrix Exon arrays comprehensive design, there are a 
total of around 24,164 estimated genes on the array (~26,493 transcripts) that were 
detected and included in the analysis after considering the Affymetrix probe sets re-
mapping as described in detail in Chapter 2, Section 2.6.1.  After applying the DABG 
filtering (P values ≤ 0.001) 19,215 transcripts (~73% of ~26,493 transcripts) were 
defined as detected transcripts in at least one CNS region in at least 50% of the 
samples as explained in detail in Chapter 2, Section 2.6.2 (Clark, Schweitzer et al. 
2007). This list contained 18,107 detected genes (~75% of 24,164 genes) and was 
generated to for use in the further analyses. 
Results showed that across all CNS regions out of 24,164 genes the percentage 
of detected genes ranged from 57% (13,834 genes) in WHMT to 71% (17,259 genes) 
in CRBL (Table 4.3.1). Furthermore, out of the 18,107 detected genes, 71% (12,790) 
were detected in all twelve CNS regions and 9% (1,666) were detected only in one 
region, mainly CRBL (Table 4.3.2). More precisely, out of the 1,666 genes, 87% 
(1,456 genes) were specifically detected only in CRBL while in other CNS regions the 
number of enriched genes was lower (Table 4.3.3). These results were in agreement 
with previous studies that were performed using microarray analyses on human post-
mortem brains on a smaller sample size, different platforms and different CNS regions. 
These studies showed that gene expression patterns in human cerebellum were 
distinctive compared with other CNS regions such as cortical regions (Khaitovich, 
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Muetzel et al. 2004; Roth, Hevezi et al. 2006; Johnson, Kawasawa et al. 2009; Gibbs, 
van der Brug et al. 2010). 
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Table 4.3.1: The detected probes sets, transcripts and genes in each CNS region. 
  
This table shows the estimated numbers and percentages for the detected transcripts and genes that were used in the regional expression 
analysis across twelve CNS regions.  CRBL represents the region that has the highest number of detected genes, while WHMT shows the lowest 
numbers of detected genes compared to the other regions. 
CNS regions Total FCTX  TCTX  OCTX  HIPP  THAL  HYPO  PUTM  SNIG  MEDU  CRBL  SPCO  WHMT  
Number of samples 917 96 84 95 93 83 13 94 68 92 95 13 91 
Number of 
detected probe sets  
NA 134,002 139,521 132,396 126,446 126,727 126,392 128,862 115,029 119,000 149,762 112,501 110,751 
Number of 
detected 
transcripts 
NA 16,034 16,379 16,184 15,437 15,259 15,475 15,711 14,614 15,085 18,152 14,878 14,262 
Number of 
detected genes  
NA 15,294 15,615 15,496 14,817 14,652 14,882 15,057 14,095 14,544 17,259 14,400 13,834 
Percentage of 
detected genes of 
24,164 genes 
75% 63% 65% 64% 61% 61% 62% 62% 58% 60% 71% 60% 57% 
Percentage of 
detected genes of 
18,107 genes 
NA 84% 86% 86% 82% 81% 82% 83% 78% 80% 95% 80% 76% 
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Table 4.3.2: The detected genes in one or more CNS regions. 
 
Number of CNS regions Number of detected genes Percentage of detected genes 
1 1,666 9% 
2 453 2.5% 
3 365 2.0% 
4 332 1.8% 
5 302 1.7% 
6 268 1.5% 
7 269 1.5% 
8 279 1.5% 
9 296 1.6% 
10 384 2.1% 
11 703 3.9% 
12 12,790 71% 
Total 18107 100% 
 
This table shows the estimated numbers and percentages for the detected genes 
that were specifically detected in one CNS region up to twelve CNS regions. 
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Table 4.3.3: Specifically detected genes in a named CNS region. 
 
CNS regions Number of detected genes  Percentage of detected genes 
FCTX 5 0.30% 
MEDU 7 0.42% 
HIPP 8 0.48% 
OCTX 10 0.60% 
SNIG 11 0.66% 
THAL 18 1.0% 
HYPO 20 1.2% 
TCTX 21 1.2% 
SPCO 28 1.68% 
WHMT 38 2.28% 
PUTM 44 2.66% 
CRBL 1,456 87% 
Total 1,666 100% 
 
 This table shows the estimated numbers and percentages for the detected genes 
that were detected in a specific CNS region.  
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In the study by Roth and colleagues, tissue specific genes were named and 
validated. For example they reported that CRTM (Class I MHC-restricted T cell-
associated molecule), GABRP (gamma-aminobutyric acid (GABA) A receptor, subunit 
pi), NRK (Nik related kinase), PDZK1 (PDZ domain containing 1) and TPM4 
(Tropomyosin 4) as being specifically expressed in CRBL. In addition, they reported 
AGTR1 (Engiotensin II receptor, type 1), EN1 (Engrailed homeobox 1) and TH 
(Tyrosine hydroxylase) to be specific for the SNIG region (Simon, Saueressig et al. 
2001; Roth, Hevezi et al. 2006; Johnson, Kawasawa et al. 2009). These results were 
confirmed in this study. However, there are some differences in the gene lists provided 
by these studies and this may be due to different sample sizes, dissection protocols, 
expression techniques, platforms, quality control parameters and analytic approaches. 
In the study by Simon et al. they used RNA in situ hybridization to detect the mRNA 
expression levels of targeted genes in the mouse brain tissue (Simon, Saueressig et al. 
2001). In contrast, the Roth et al. study identified the transcriptional profiling of 20 
CNS regions in ten human post mortem tissues, using the GeneChip Human Genome 
U133 Plus 2.0 Array that targets the 3' end of transcripts (Roth, Hevezi et al. 2006). The 
study of Johnson et al. was performed on four human brains (from fatal injuries) 
dissected from 13 different regions. They used the same Human Exon 1.0 ST Array 
that was used in this study that is designed to cover the coding sequences genome-wide 
(Johnson, Kawasawa et al. 2009). These studies, in addition to this study complement 
each other by providing a complete and accurate human transcriptome map. 
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4.3.2 Examples of regional specific expression genes 
One of the specifically expressed genes in CRBL is IGHMBP2 the 
(immunoglobulin helicase μ- binding protein 2) gene. The expression results showed 
high expression in CRBL and very low expression in the SPCO (close to background 
signals) (Figure 4.3.1). Mutations in this gene are reported to be linked to spinal 
muscular atrophy with respiratory distress type 1 (SMARD1) (Grohmann, Schuelke et 
al. 2001). Although histological examination of the spinal cord was normal in two 
cases in the study of Pitt et al. (Pitt, Houlden et al. 2003), spinal muscular atrophy 
(SMA) is the most severe clinical manifestation. There is a possibility that this gene 
was not detected in SPCO in this study, because the RNA samples were extracted from 
the cell bodies and not be from the nerve axons or synaptic regions. However, having 
this gene highly expressed in CRBL might suggest that clinicians should perform brain 
scan in SMARD1 patients and look for CRBL pathology.  
One other gene that was detected only in CRBL is CBLN3 (cerebellin 3 
precursor) (Figure 4.3.2). This gene is involved in synaptic functions in the human 
CNS and it is a CRBL specific gene/protein (Mizuno, Takahashi et al. 1995).  
In addition, two genes were detected specifically in SNIG. The first is 
SLC18A2 (solute carrier family 18 (vesicular monoamine), member 2) which is the 
dopamine vesicular transporter (Roghani, Welch et al. 1996). The second gene is 
SLC6A3 (solute carrier family 6 (neurotransmitter transporter, dopamine), member 3) 
which is a member of the family of sodium- and chloride- dependent neurotransmitter 
transporters in the CNS (Schultz 1998). These two genes were expected to be 
specifically expressed in SNIG as this reflects their main functions in the human CNS. 
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Figure 4.3.1:  
Regional Distribution of IGHMBP2 mRNA expression. CRBL = 
cerebellum, OCTX = temporal cortex, FCTX = frontal cortex, TCTX = 
temporal cortex, SNIG = substantia nigra, WHMT = white matter, HIPP = 
hippocampus, PUTM = putamen, THAL = thalamus, MEDU = medulla, 
SPCO = spinal cord, HYPO = hypothalamus.  
Boxplot of mRNA expression levels for IGHMBP2 in 12 brain regions, 
from microarray experiments on a log2 scale (y-axis). This plot shows the 
enrichment of IGHMBP2 transcript expression in CRBL. Whiskers extend 
from the box to 1.5 times the inter-quartile range. 
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Figure 4.3.2:  
Enrichment of CBLN3 mRNA expression in CRBL. CRBL = cerebellum, 
SPCO = spinal cord, MEDU = medulla, WHMT = white matter, SNIG = 
substantia nigra, OCTX = temporal cortex, PUTM = putamen, HYPO = 
hypothalamus, HIPP = hippocampus, FCTX = frontal cortex, THAL = 
thalamus, TCTX = temporal cortex. 
Boxplot of mRNA expression levels for CBLN3 in 12 CNS regions, from 
microarray experiments on a log2 scale (y-axis). This plot shows the 
detection of CBLN3 transcript expression only in CRBL. Whiskers extend 
from the box to 1.5 times the inter-quartile range. 
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4.3.3 Human CNS regional differential gene expression  
In order to expand the available data and knowledge about the different human CNS 
expression profiles, the following analysis was conducted. From the genes that were detected 
in all 12 CNS regions, differentially expressed genes were identified by applying the statistical 
threshold of a minimum fold change (FC) of ≥ 1.7 and FDR < 0.05 to the genes list that 
contained 12,790 genes as explained in detail in Chapter 2, Section 2.6.3. 
The results showed that 96% of genes (12,376 of 12,790 genes) were 
differentially expressed across the 12 CNS regions at FDR < 0.05. 
In order to provide an overview of the differences in expression patterns 
between the 12 regions, principal component analysis (PCA) was performed by using 
all expressions profiles at transcript and exon levels in all regions (Figure 4.3.3). This 
analysis demonstrates that CRBL as a region has a distinctive expression pattern on the 
PC2 axis compared to other regions; this was expected, as this confirms the results 
from previous and smaller studies on human and mouse brain tissues (Haverty, Weng 
et al. 2002; Khaitovich, Muetzel et al. 2004; Roth, Hevezi et al. 2006; Gibbs, van der 
Brug et al. 2010). In addition, WHMT was the second region after CRBL to show a 
distinct expression pattern from the other 11 CNS regions (Figure 4.3.3, dark purple 
spheres). Other CNS regions displayed a greater overlap in expression patterns, this 
was especially true of the cortical regions including FCTX, TCTX and OCTX. These 
regions will be discussed in greater detail later in this section. 
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Figure 4.3.3:  
Principal component analysis (PCA) of 12 CNS regions. CRBL = 
cerebellum, FCTX = frontal cortex, HIPP = hippocampus, HYPO = 
hypothalamus, MEDU = medulla, OCTX = occipital cortex, PUTM = 
putamen, SNIG = substantia nigra, SPCO = spinal cord, TCTX = temporal 
cortex, THAL = thalamus and WHMT = white matter.  
This figure shows a three-dimensional scatterplot of the first three principal 
component scores obtained from a PCA on expression data of all CNS-
region samples. The first three components explain 41.9% of the variability 
in expression values across all transcripts.  Each point represents a single 
CNS sample from a specific region. Regions have been colour coded, to 
demonstrate regional differences in expression values. CRBL region (red 
spheres) cluster separately from the other 11 regions indicating that the 
expression pattern in this region is unique. In addition, WHMT region 
(purple spheres) also shows a separate cluster demonstrating different 
expression patterns than other regions. 
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Furthermore, focusing on the cortical regions; PCA plots showed a separate 
clustering for the OCTX region from FCTX and TCTX regions (Figure 4.3.4) 
supporting the results in Table 4.3.4 in the following section.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.4:  
Principal component analysis (PCA) of cortical regions. FCTX = frontal 
cortex, OCTX = occipital cortex and TCTX = temporal cortex. 
 
This figure shows a three-dimensional scatterplot of the first three principal 
component scores obtained from a PCA on expression data of FCTX, TCTX 
and OCTX region samples. The first three components explain 32.8% of the 
variability in expression values across all transcripts.  Each point represents 
a single sample from a specific region. Regions have been colour coded, to 
demonstrate regional differences in expression values. OCTX region is 
clustering separately from FCTX and TCTX regions, indicating that the 
expression pattern is more distinct in this region. 
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To identify and investigate the expression profiles in more detail, a comparison 
between each possible pair of regions across the 12 CNS regions was performed and 
Table 4.3.4 was generated (Table 4.3.4). This table facilitates the identification of the 
expression patterns in term of high and low expressed genes between regions based on 
the criteria of fold change (FC) difference of ≥ 1.7 or ≤ -1.7.  Furthermore, Table 4.3.5 
was generated from calculating the differences between the number of high and low 
expressed genes in each region to give more detailed information about the dominant 
patterns in each region (Table 4.3.5).  
The CRBL has the highest number of differentially expressed genes followed 
by WHMT compared with each of the other 11 regions, specifically the cortical areas, 
suggesting that CRBL and WHMT have more distinctive functions and the other 
regions might have many more functions in common. In CRBL, there were 604 genes 
having higher expression levels (Table 4.3.4, red column) and 638 genes with lower 
expression levels in comparison with the other 11 CNS regions (Table 4.3.4, red row 
and Figure 4.3.5, red circles). In addition, there were 216 genes having higher 
expression (Table 4.3.4, purple column and Figure 4.3.5, purple/pink circles) and 271 
genes having lower expression in WHMT in comparison to the other 11 regions 
(Table 4.3.4, purple row). Looking at the table for the comparison between CRBL and 
every other region in detail, it is clear that there are more genes that have lower 
expression levels in CRBL than those genes with higher expression levels (Figure 
4.3.5, red circles). However, the reverse is the case for WHMT as there are more high 
expressed genes than low expressed genes as compared with the other CNS regions 
(Figure 4.3.5, purple/pink circles) with the exception of HYPO, SNIG, MEDU and 
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SPCO where the dominant pattern was that the number of low expressed genes is more 
than the number of high expressed genes (Table 4.3.5). 
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Table 4.3.4: Differentially expressed genes across twelve CNS regions. 
CNS regions FCTX TCTX OCTX HIPP THAL HYPO PUTM SNIG MEDU CRBL SPCO WHMT 
All 
regions 
FCTX NA 1 39 427 725 989 710 1,482 1,679 1,663 1,821 2,477 1 
TCTX 2 NA 25 468 806 1,025 772 1,541 1,724 1,555 1,815 2,448 0 
OCTX 83 62 NA 743 961 1,213 992 1,677 1,822 1,395 1,889 2,466 0 
HIPP 349 329 462 NA 480 238 374 573 841 1,770 933 1,688 0 
THAL 628 623 625 517 NA 204 569 379 671 1,800 833 1,683 0 
HYPO 812 775 819 492 351 NA 526 185 414 1,671 382 1,230 0 
PUTM 715 675 727 440 600 392 NA 721 984 1,706 1,024 1,642 9 
SNIG 1,032 1,034 1,051 691 507 214 720 NA 266 1,905 292 918 0 
MEDU 1,153 1,123 1,138 800 623 321 817 224 NA 1,830 81 478 1 
CRBL 1,927 1,805 1,620 2,283 2,423 2,376 2,258 2,697 2,741 NA 2,667 2,832 638 
SPCO 1,340 1,297 1,262 887 844 329 871 369 139 1,855 NA 513 0 
WHMT 1,932 1,866 1,852 1,469 1,537 1,246 1,461 1,137 899 2,028 773 NA 271 
All regions 1 9 5 20 53 15 82 31 9 604 10 216 NA 
 The table shows the number of genes for which the region shown in the column has higher expression level compared with the region 
shown in the row.  By implication, the values also show the number of genes for which the region shown in the row has lower expression level 
compared with the region shown in the column.  So the total number of genes which show differential expression between any two regions is the 
sum of the (column, row) and (row, column) values.  The row labelled ‘All regions’ contains the number of genes for which the region shown in 
the column has higher expression compared with all 11 other regions. Similarly, the column labelled ‘All regions’ contains the number of genes 
for which the region shown in the row has lower expression compared with all 11 other regions. Genes were considered high expressed if the 
fold change ratio ≥ 1.7 and FDR < 0.05 (see Section 2.6.3). 
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Figure 4.3.5:  
Scatter plot of the number of differentially expressed genes of each pair 
of the 12 CNS regions (Table 4.3.4). CRBL = cerebellum, WHMT = white 
matter and CTX = cortical regions including frontal, temporal and occipital. 
Other = the other 7 CNS regions, these regions were not coloured as the 
focus is on the CRBL, WHMT and CTX regions.   
This graph shows the number of high expressed genes (y-axis) versus low 
expressed genes (x-axis) for each possible pair comparisons between the 12 
CNS regions. The data in this figure were derived from Table 4.3.4. The 
results are in symmetry in the scatterplot around the 45 degree line (of equal 
numbers of high and low expressed genes). In CRBL (red circles), there 
were more low expressed genes than high expressed in comparison with the 
other 11 CNS regions, while in WHMT (purple/pink circles), there were 
more high expressed genes than low expressed genes. For Cortical regions 
(green circles), it shows that the number of the differentially expressed 
genes between these regions were very small. 
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Table 4.3.5: The difference between the differentially expressed genes across twelve CNS regions. 
CNS 
regions 
FCTX TCTX OCTX HIPP THAL HYPO PUTM SNIG MEDU CRBL SPCO WHMT 
All 
regions 
FCTX NA -1 -44 78 97 177 -5 450 526 -264 481 545 0 
TCTX 1 NA -37 139 183 250 97 507 601 -250 518 582 -9 
OCTX 44 37 NA 281 336 394 265 626 684 -225 627 614 -5 
HIPP -78 -139 -281 NA -37 -254 -66 -118 41 -513 46 219 -20 
THAL -97 -183 -336 37 NA -147 -31 -128 48 -623 -11 146 -53 
HYPO -177 -250 -394 254 147 NA 134 -29 93 -705 53 -16 -15 
PUTM 5 -97 -265 66 31 -134 NA 1 167 -552 153 181 -73 
SNIG -450 -507 -626 118 128 29 -1 NA 42 -792 -77 -219 -31 
MEDU -526 -601 -684 -41 -48 -93 -167 -42 NA -911 -58 -421 -8 
CRBL 264 250 225 513 623 705 552 792 911 NA 812 804 34 
SPCO -481 -518 -627 -46 11 -53 -153 77 58 -812 NA -260 -10 
WHMT -545 -582 -614 -219 -146 16 -181 219 421 -804 260 NA 55 
All regions 0 9 5 20 53 15 73 31 8 -34 10 -55 NA 
The table shows the differences in the numbers of the high expressed and low expressed genes between the twelve CNS regions. Positive 
values showing that the number of the high expressed genes for which the region in the column is more than the low expressed genes compared 
with the region shown in the row. Negative values showing that the number of the low expressed genes for which the region in the column is 
more than the high expressed genes compared with the region shown in the row.  
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Moreover, looking in detail at the cortical regions, namely FCTX, TCTX and 
OCTX, these data showed that the lowest number of differentially expressed genes 
was between these regions (Table 4.3.4, green box and Figure 4.3.5, green circles). 
Only three genes were detected as differentially expressed between FCTX and TCTX, 
while the OCTX region showed that there are 122 genes that were differentially 
expressed in comparison to FCTX and 87 genes in comparison to TCTX. This 
highlights that, although cortical regions have different functions, they share a 
common similar expression profile except for the OCTX, as this region has a more 
distinctive pattern compared to the other two cortical regions as the PCA plot showed 
(Figure 4.3.4). It worth noting that the number of differentially expressed genes 
between the cortical regions in comparison to SNIG, MEDU, CRBL, SPCO and 
WHMT was large compared with HIPP, THAL, HYPO and PUTM, implying that the 
cortical regions have more common functions compared with the latter (Table 4.3.5).   
In summary, 72% (13,187 genes of 18,107 genes) were detected specifically in 
these three cortical regions. Out of this 72%, 1% (138 genes), 0.9% (123 genes) and 
0.7% (89 genes) were differentially expressed in OCTX, FCTX and TCTX 
respectively in comparison with the other two regions (Figure 4.3.6). Although the 
cortical regions are considered to have functions in common with each other, OCTX 
showed a small but significantly different expression pattern from FCTX and TCTX 
regions. In the study by Roth et al, although the expression patterns were compared 
using a different platform in CNS regions, it was mentioned briefly in relation to the 
PCA plot that OCTX clustered separately from other cortical regions (Roth, Hevezi et 
al. 2006). 
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Figure 4.3.6:  
Venn diagram representing the differentially expressed (DE) genes 
within the cortical regions. OCTX = occipital cortex, FCTX = frontal 
cortex and TCTX = temporal cortex. 
This figure shows the numbers and percentages of the DE genes across the 
cortical regions. The number of the DE genes between OCTX and the other 
two regions is higher in comparison with FCTX and TCTX. 
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4.3.4 Examples of human CNS regional differential expression genes 
 In this section selected genes will be presented as examples of genes with 
significant regional differences in expression. Selection of these genes was based on 
the fact that they were reported to be genetically associated with neurological diseases 
from GWAS results or they were reported in biological studies to have specific 
functions in the human CNS.  
 Because of the importance of LRRK2 (Leucine-rich repeat kinase 2) and MAPT 
(microtubule-associated protein tau) genes in relation to neurological diseases 
comprehensive investigations were performed on these two specific genes in this thesis 
(see Chapter 5 for MAPT and Chapter 6 for LRRK2). Differential expression and 
splicing patterns for these genes were further investigated and validated using two 
different platforms. Regional differences in gene expression were validated using 
Quantigene for LRRK2, MAPT and SCN8A (sodium channel, voltage gated, type VIII, 
alpha subunit) genes (see Chapter 3, Section 3.3.3), and qRT-PCRs were performed for 
LRRK2 and MAPT (see Chapter 5, Section 5.3.1 and Chapter 6, Section 6.3.1). 
ANO3 (anoctamin 3) gene expression was expressed significantly higher in 
PUTM by 4 FC (P < 1.0  10-45, at FDR 5%) (all Bonferroni adjusted P < 4.8  10-52) 
as compared with the cortical regions (FCTX, TCTX and OCTX) and 12 FC compared 
with CRBL (Bonferroni adjusted P = 2.0  10-240), the region with the lowest 
expression. Similar expression levels were observed amongst the other CNS regions 
(Figure 4.3.7). The ANO3 gene encodes for a transmemebrane protein that activates 
calcium and chloride channels. ANO3 expression is common in neuronal tissues 
(Schreiber, Uliyakina et al. 2010). This gene was reported to be associated with late-
onset Alzheimer's disease (LOAD) (Milenkovic, Brockmann et al. 2010). In addition, a 
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recent study reported that mutations in this gene cause Dominant Craniocervical 
Dystonia (Charlesworth, Plagnol et al. 2012).  
 BIN1 (Bridging integrator 1) gene was significantly differentially expressed by 
3 FC (P < 1.0  10-42, at FDR 5%) (Bonferroni adjusted P = 2.7  10-196) between 
WHMT, the region with the highest expression, and CRBL the region with the lowest 
expression. The region with the second highest expression was HIPP. There was a 1.6 
fold difference compared with WHMT. Furthermore, BIN1 was not only differentially 
expressed by CNS regions, but also was alternatively spliced by region. The 
differentially splicing results for this gene will be discussed in detail later in this 
chapter (see Section 4.3.6). BIN1 gene encodes for several isoforms of a 
nucleocytoplasmic adaptor protein involved in regulating synaptic vesicle endocytosis 
(Wigge and McMahon 1998). This gene locus was reported to be associated with 
Alzheimer’s disease (AD) (Kamboh, Demirci et al. 2012; Karch, Jeng et al. 2012).   
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Figure 4.3.7:  
Enrichment of ANO3 mRNA expression in PUTM. PUTM = putamen, 
FCTX = frontal cortex, TCTX = temporal cortex, HIPP = hippocampus, 
OCTX = temporal cortex, SPCO = spinal cord, HYPO = hypothalamus, 
SNIG = substantia nigra, MEDU = medulla, WHMT = white matter, THAL 
= thalamus, CRBL = cerebellum. 
Boxplot of mRNA expression levels for ANO3 in 12 CNS regions, from 
microarray experiments on a log2 scale (y-axis). This plot shows ANO3 
expression in PUTM is higher by 12 FC compared with CRBL. Whiskers 
extend from the box to 1.5 times the inter-quartile range. 
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CNTNAP2 (Contactin-associated protein-like 2) gene was significantly 
differentially expressed by 5.4 - 7 FC higher (P < 1.0  10-45, at FDR 5%) in the 
cortical regions and THAL compared with CRBL (Bonferroni adjusted P = 5.9       
10
-126
) and WHMT (Bonferroni adjusted P = 1.1  10-152) which showed the lowest 
expression levels (Figure 4.3.8). This result was consistent with a previous study 
(Alarcon, Abrahams et al. 2008). CNTNAP2 encodes for a protein that is a member of 
the neurexin family. This protein is in the nervous system and acts as cell adhesion 
molecules and receptors. This gene was reported to be associated with different 
diseases such as autism, epilepsy, schizophrenia, and mental retardation (Alarcon, 
Abrahams et al. 2008; Friedman, Vrijenhoek et al. 2008). 
PLP1 (proteolipid protein 1) gene was significantly differentially expressed in 
WHMT and SPCO by 6.0 FC higher (P < 1.0  10-45, at FDR 5%) compared with other 
CNS regions, especially CRBL (Bonferroni adjusted P = 1.1  10-170). PLP1 gene 
encodes for a transmembrane proteolipid protein that is the main myelin protein in the 
CNS. It is involved in the compaction, stabilization, and maintenance of myelin 
sheaths. In addition, it is involved in oligodendrocyte development and axonal survival 
(Diehl, Schaich et al. 1986). Detecting this gene as being highly expressed in WHMT 
in control individuals is expected and confirms the reliability of the array data. In 
addition, the expression of CR1 (Erythrocyte complement component, C3b/C4b 
receptor 1) (Figure 4.3.9, A and B), IGFBP3 (Insulin-like growth factor-binding 
protein 3) (Figure 4.3.9, C and D), NLGN4X (Neuroligin 4, X-linked) (Figure 4.3.10, 
A and B) and VSIG4 (V-set and immunoglobulin domain containing 4) (Figure 4.3.10, 
C and D) genes were validated on a subset of samples from selected regions (Table 
4.3.6). Results from the qRT-PCR are consistent with the array expression patterns. 
These genes were differentially expressed by ~ 2.0 FCs between the selected regions.   
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Figure 4.3.8:  
Enrichment of CNTNAP2 mRNA expression in PUTM. FCTX = frontal 
cortex, TCTX = temporal cortex, THAL = thalamus, OCTX = temporal 
cortex, MEDU = medulla, HIPP = hippocampus, SNIG = substantia nigra, 
HYPO = hypothalamus, SPCO = spinal cord, PUTM = putamen, CRBL = 
cerebellum, WHMT = white matter. 
Boxplot of mRNA expression levels for CNTNAP2 in 12 CNS regions, from 
microarray experiments on a log2 scale (y-axis). This plot shows CNTNAP2 
expression in FCTX is higher by ~ 5.4 FC compared with CRBL. Whiskers 
extend from the box to 1.5 times the inter-quartile range. 
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Table 4.3.6: Differential expression patterns validation using qRT-PCR. 
This table shows the performed qRT-PCR validations for the expression arrays results of selected genes. The validation for the expression 
patterns was performed for CR1, IGFBP3, NLGN4X and VSIG4 genes in four CNS regions. Significant fold changes were observed for both 
platforms for the selected differentially expressed genes. (This table was produced by Dr Mina Ryten). The array results P values were adjusted 
using FDR procedure. 
 
 Affymetrix exon array results qRT-PCR results 
Gene 
Symbol 
Assay ID Regions 
compared 
P values for regional-bias Fold 
change 
P values for 
regional expression 
Fold 
change Expression splicing 
CR1 Hs00559348_m1 HIPP < WHMT 7.7×10
-38
 Not validated -1.82 3.14×10
-02
 -2.01 
IGFBP3 Hs00181211_m1 HIPP > WHMT 4.2×10
-39
 Not validated 2.10 4.05×10
-02
 1.43 
NLGN4X Hs01934144_s1 THAL > WHMT 1.9 ×10
-45
 Not validated 2.68 1.41×10
-02
 1.41 
VSIG4 Hs00200695_m1 HIPP > HYPO 2.6 ×10
-06
 Not validated 2.18 4.7×10
-02
 2.45 
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Figure 4.3.9:  
Array and qRT-PCR mRNA expression of CR1 and IGFBP3. WHMT = 
white matter, HIPP = hippocampus. 
This figure shows regional variation in: (A) Boxplot of CR1 expression level 
between WHMT and HIPP as measured using arrays on a log2 scale (y-axis), (B) 
Bar chart of CR1 expression level in same regions as measured using qRT-PCR 
validation. (C) Boxplot of IGFBP3 mRNA expression level between HIPP and 
WHMT as measured using arrays on a log2 scale (y-axis), (D) Bar chart of IGFBP3 
level in the same regions as measured using qRT-PCR validation. In both cases 
expression levels were normalized to the expression of the target gene in WHMT 
(100%). Box plot whiskers extend from the box to 1.5 times the inter-quartile 
range. The error bars represent the S.E.M. 
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Figure 4.3.10:  
Array and qRT-PCR mRNA expression of NLGN4X and VSIG4. 
WHMT = white matter, HIPP = hippocampus, THAL = thalamus, HYPO = 
hypothalamus. 
This figure shows regional variation in: (A) Boxplot of NLGN4X expression level 
between THAL and WHMT as measured using arrays on a log2 scale (y-axis), (B) 
Bar chart of NLGN4X expression level in the same regions as measured using 
qRT-PCR validation. Expression levels were normalized to the expression of the 
target gene in WHMT (100%). (C) Boxplot of the VSIG4 mRNA expression level 
between HIPP and WHMT as measured using arrays on a log2 scale (y-axis), (D) 
Bar chart of VSIG4 level in the same regions as measured using qRT-PCR. 
Expression levels were normalized to the expression of the target gene in HYPO 
(100%). Box plot whiskers extend from the box to 1.5 times the inter-quartile 
range. The error bars represent the S.E.M.  
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4.3.5 Human CNS regional differential splicing (exon) expression  
Over the last decade, a number of studies have highlighted the importance of 
alternative splicing events in the human genome (Lander, Linton et al. 2001) and nervous 
system in particular (Grabowski and Black 2001; Lee and Irizarry 2003) and their role in 
human disease (Krawczak, Reiss et al. 1992; Black 2003). These studies, and many others, 
motivated the experimental design stage of this project to conduct an analysis of the CNS 
samples on a human exon array platform, allowing the identification of differential exon usage 
and by implication alternative splicing events (Clark, Schweitzer et al. 2007) (see Chapter 3, 
Section 3.2). In order to define differentially (alternative) spliced transcripts/genes across the 
12 CNS regions, the statistical threshold of  FDR < 10
-5 
was applied to the alternative splicing 
ANOVA result sheet that contained 12,790 genes as explained in detail in Chapter 2, Section 
2.6.3.1.  
The results of this filtering showed that 91% (11,655 genes) of the 12,790 
detected (expressed) genes displayed differential exon usage in different 
regions, strongly suggestive of alternative splicing patterns. Out of these 11,655 genes, 
96% (11,241 genes) were differentially expressed as well as differentially spliced. In 
addition, 3.5% (414 genes) of those genes were differentially spliced but not 
differentially expressed and 9.2% (1,135 of 12,376 genes) were differentially 
expressed but not differentially spliced across the 12 CNS regions (Figure 4.3.11). 
These results are consistent with data from a previous study, which revealed that the 
adult human brain has a very high and specific alternative splicing profile compared 
with other human tissues (Yeo, Holste et al. 2004).   
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Figure 4.3.11:  
Venn diagram representing the differentially expressed (DE) and 
spliced (DS) genes across the 12 CNS regions. 
This figure shows the numbers and percentages of the DE and DS genes 
across the 12 CNS regions, the percentage of DE and DS genes is high in 
the adult human CNS compared with genes that are only DE (9.2%). With 
regard to the expression profiles, 11,241 genes (91%) are both differentially 
expressed as well as spliced.  
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The data resulting from analysing the alternative slicing profiles from the 
different cortical regions in this study was of particular interest. The analysis was 
performed on the three regions combined together, with the results showing that 72% 
(13,187 of 18,107 genes) were detected in the three cortical regions: FCTX, TCTX and 
OCTX. Although there was a relatively small number of differentially expressed genes 
between these regions (Table 4.3.4 and Figure 4.3.5), the alternative splicing ANOVA 
detected a high number of differentially spliced genes (Figure 4.3.12). 
The three possible comparisons within the cortical regions, namely OCTX 
versus TCTX, FCTX versus OCTX, and FCTX versus TCTX, were considered in 
relation to the detection and identification of the alternative splicing patterns (Figure 
4.3.13, A-C). These results showed a similar pattern to the results when the three 
regions were combined (Figure 4.3.12).   
Out of the 13,187 detected genes, 74% of genes (9794 genes) in the 
comparison between OCTX and TCTX (Figure 4.3.13, A), 52% of genes (6890 genes) 
in the comparison between FCTX and OCTX regions (Figure 4.3.13, B) and 40% 
(5280 genes) of genes in the comparison between FCTX and TCTX (Figure 4.3.13, C) 
were identified as differentially spliced. The OCTX, displayed a different alternative 
splicing pattern compared with the other cortical regions, similar to the results for 
deferential expression pattern (Figures 4.3.4 and 4.3.6), but even more pronounced. 
FTCX and TCTX had a lower percentage (40%) of differentially spliced genes when 
compared to each other.  
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Figure 4.3.12:  
Venn diagram representing the differentially expressed (DE) and 
spliced (DS) genes across the cortical regions. 
This figure shows the numbers and percentages of the DE and DS genes 
across the cortical regions. It shows that the number of genes that are DS 
is much higher (98%) compared with the number of genes that are DE. 
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Figure 4.3.13:  
Venn diagram representing the differentially expressed (DE) and 
spliced (DS) genes across: (A) OCTX versus TCTX, (B) FCTX versus 
OCTX and (C) FCTX versus TCTX. 
This figure shows the numbers and percentages of the DE and DS genes 
across the cortical regions. In the three comparisons, the alternative 
splicing patterns are the dominant events in these regions compared with 
the differential expression patterns. 
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4.3.6 Examples of human CNS regional differential splicing (exon) expression genes 
In this section examples of genes with regional differential splicing will be 
presented. The selection of these genes was based on the fact that they were reported to 
be genetically associated with neurological diseases from the GWAS results or they 
were reported in biological studies to have specific functions in the human CNS. The 
additional examples of MAPT and LRRK2 genes which showed regional alternative 
splicing patterns will be discussed in detail later in this thesis (see Chapter 5 for MAPT 
and Chapter 6 for LRRK2), 
KCND3 (potassium voltage-gated channel, Shal-related subfamily, member 3) 
gene was not only expressed at significantly higher level in SNIG by 7 FC higher 
(ANOVA P < 1.0  10-45, at FDR 5%) (Bonferroni adjusted P = 9.9  10-47) as 
compared with CRBL, but also was differentially spliced by region.  KCND3 has two 
isoforms, a long (L) isoform (Exon 6 included, probe set 2428126) and a short (S) 
isoform (Exon 6 spliced out). The arrays detected the long isoform to be expressed 
specifically in SNIG compared with other CNS regions (ANOVA P < 1.0  10-45, at 
FDR < 10
-05
) (Figure 4.3.14). This result is consistent with a previous study that 
showed by using single-cell RT-PCR that the long isoform of this gene is only 
expressed in dopaminergic (DA) substantia nigra (SN) neurons  (Liss, Franz et al. 
2001). KCND3 gene encodes for the K+ channel that underlies the transient outward 
potassium current. It is expressed in abundance in the adult brain and its function is to 
regulate neurotransmitter release and neuronal excitability (Serodio, Vega-Saenz de 
Miera et al. 1996; Dilks, Ling et al. 1999).  
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Figure 4.3.14:  
Exon array expression data at the probe set level suggesting alternative 
splicing by CNS region of the KCND3 transcript. CRBL = cerebellum, 
FCTX = frontal cortex, HIPP = hippocampus, HYPO = hypothalamus, 
MEDU = medulla, OCTX = occipital cortex, PUTM = putamen, SNIG = 
substantia nigra, SPCO = spinal cord, TCTX = temporal cortex, THAL = 
thalamus and WHMT = white matter.  
This figure shows the alternative splicing pattern between SNIG and other CNS 
regions for exon 6 (in the dashed black box). Long and short forms of KCND3 
mRNA as measured using arrays are plotted using the mean expression levels 
(y-axis) for each probe set (x-axis) covering the KCND3 gene. Non-parallel 
probe set expression levels, in the dashed black box, suggest differences in 
the expression and splicing of the corresponding exons. Alternative splicing 
Bonferroni adjusted P = 9.9  10-47 for SNIG versus CRBL. This plot was 
generated using Partek Genomics Suite software. 
Exon6 
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NRXN3 (Neurexin) gene was significantly differentially expressed by 4 FC 
higher (P < 1.0  10-45, at FDR 5%) in the cortical regions (OCTX, FCTX and TCTX) 
as compared with WHMT the region with the lowest expression. The region with the 
second highest expression region was CRBL. Furthermore, NRXN3 was alternatively 
spliced by region. From the results of the arrays, two major isoforms of this gene were 
detected, alpha-NRXN3 (long isoform) and the beta-NRXN3 (short isoforms). Alpha-
NRXN3 is the dominant (expressed higher) isoform in all CNS regions except for the 
CRBL where beta-NRXN3 is the dominant isoform (Figure 4.3.15). A previous study 
showed a similar pattern of expression of the two isoforms (Hishimoto, Liu et al. 
2007). Further validations for these two isoforms were performed on THAL and 
WHMT regions by using the qRT-PCR platform. A similar significant difference in 
the expression pattern was observed confirming the array results (Table 4.3.7 and 
Figure 4.3.16). NRXN3 gene encodes for cell surface proteins that are expressed in 
neurons (Tabuchi and Sudhof 2002). This protein has an essential role in synaptic 
development and functions, acting as a synaptic cell-adhesion molecule that connects 
presynaptic and postsynaptic neurons at synapses (Craig and Kang 2007; Sudhof 
2008). It was reported that this locus may be involved in the development of Autism 
(Sudhof 2008; Vaags, Lionel et al. 2012).  
Regional differences in the expression of BIN1 were discussed previously in 
Section 4.3.4, and the results showed that this gene was differentially expressed 
between regions. Furthermore, the results from the arrays for BIN1 strongly suggested 
differential isoform expression amongst CNS regions (ANOVA P < 1.0  10-45, at 
FDR < 10
-05
). The results showed that the isoforms that have exon 7 spliced out (probe 
set 2574686) are expressed higher by 4 FC in WHMT as compared with CRBL 
(Bonferroni adjusted P = 3.5  10-35) (Figure 4.3.17). 
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Figure 4.3.15:  
Exon array expression data at the probe set level showing different 
isoforms of the NRXN3 transcript. CRBL = cerebellum, FCTX = frontal 
cortex, HIPP = hippocampus, HYPO = hypothalamus, MEDU = medulla, 
OCTX = occipital cortex, PUTM = putamen, SNIG = substantia nigra, 
SPCO = spinal cord, TCTX = temporal cortex, THAL = thalamus and 
WHMT = white matter.  
This figure shows the expression level of the alpha-NRXN3 and beta-NRXN3 
isoforms in all 12 CNS regions.  beta-NRXN3 mRNA expression level is 
high in CRBL (~6 FC) as compared with the other regions (in the dashed 
black box) (Bonferroni adjusted P = 4.3  10-178). In contrast, alpha-NRXN3 
mRNA expression is low in CRBL compared with other regions (in the 
dashed red box). Mean expression levels (y-axis) plotted for each probe set 
(x-axis) covering the NRXN3 gene. Non-parallel probe set expression levels, 
in the dashed black box, suggest regional differences in the expression and 
splicing of the corresponding exons. This plot was generated using Partek 
Genomics Suite software. 
 Human CNS transcriptome 
 
148 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.16:  
Exon array expression data at the probe set level suggesting alternative 
splicing by CNS region of the NRXN3 transcript. qRT-PCR validation 
of the results in WHMT and THAL. WHMT = white matter and THAL = 
thalamus. 
This figure shows the alternative splicing pattern between WHMT and THAL 
for: (A) Alpha and beta NRXN3 mRNA expression levels between WHMT and 
THAL (~2 FC) as measured using arrays, mean expression levels (y-axis) 
plotted for each probe set (x-axis) covering the NRXN3 gene. Non-parallel 
probe set expression levels, in the dashed black box, suggest regional 
differences in the expression and splicing of the corresponding exons. All the 
differentially spliced exons correspond to exons present in β-neurexins 
(Bonferroni adjusted P = 9.5  10-99). This plot was generated using Partek 
Genomics Suite software. (B) Quantitative qRT-PCR validation of NRXN3 
alpha and beta expression levels in the same regions confirms the array results. 
The expression level is presented as the mean and the error bars are S.E.M. 
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In addition, all the BIN1 isoforms that are expressed in the human CNS have 
exon 12 spliced out. Further validation for the isoforms that have exon 7 spliced out 
were performed on THAL and WHMT regions by using the qRT-PCR platform. A 
similar and significant expression pattern was observed confirming the array results 
(Table 4.3.7 and Figure 4.3.18).  
 The last example for this category is the SETX (senataxin) gene. The results 
from the arrays strongly suggested an alternative splicing event for exon 22 (probe set 
3228025) between CRBL and SPCO. In CRBL exon 22 expression was higher by 1.8 
FC (P = 2.5  10-15, at FDR < 10-05) (Bonferroni adjusted P = 1.5  10-15) as compared 
with SPCO region (Figure 4.3.19). This suggests that different isoforms are expressed 
in different CNS regions. Mutations in the SETX genes were associated with ataxia-
ocular apraxia-2 (AOA2) (Moreira, Klur et al. 2004) and an autosomal dominant form 
of juvenile amyotrophic lateral sclerosis (ALS4) (Arning, Epplen et al. 2012). It is 
involved in the regulation of transcription and RNA processing such as RNA 
polymerase II (Suraweera, Lim et al. 2009). Further validation of this splicing event 
using a different technique is required. 
 It is noteworthy the number of extremely small P values in this study. 
This may be the result of (1) sufficiently large sample size, but more importantly (2) 
small residual background variability, contributing to small standard errors of 
expression means. Pairwise comparisons of region means were assessed and 
Bonferroni adjustments were then applied to the P values generated from this manual 
analysis, as indicated in the results above. Despite the fact that the Bonferroni 
adjustment is more conservative than the FDR adjustment that was used in the Partek 
analysis, the P values were still highly significant.  
 Human CNS transcriptome 
 
150 
  
 
 
 
 
 
 
 
 
Figure 4.3.17:  
Exon array expression data at the probe set level of different isoforms 
of the BIN1 transcript. CRBL = cerebellum, FCTX = frontal cortex, HIPP 
= hippocampus, HYPO = hypothalamus, MEDU = medulla, OCTX = 
occipital cortex, PUTM = putamen, SNIG = substantia nigra, SPCO = 
spinal cord, TCTX = temporal cortex, THAL = thalamus and WHMT = 
white matter.  
This figure shows the expression level of the different isoforms in all 12 CNS 
regions.  mRNA expression levels of BIN1 isoforms that have exon 7 spliced 
out are higher in WHMT (~4 FC) as compared with other regions such as CRBL 
(In the dashed black box). All the expressed isoforms in the human CNS have 
exon 12 spliced out. Mean expression levels (y-axis) plotted for each probe set 
(x-axis) covering the BIN1 gene. Non-parallel probe set expression levels, in 
the dashed black box, suggest regional difference in the expression and 
splicing of the corresponding exons. Alternative splicing Bonferroni 
adjusted P = 3.5  10-35. This plot was generated using Partek Genomics 
Suite software. 
Exon7 
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Figure 4.3.18:  
Exon array expression data at the probe set level suggesting alternative 
splicing by CNS region of the BIN1 transcript. qRT-PCR validation of 
the results in WHMT and THAL. WHMT = white matter and THAL = 
thalamus. 
This figure shows the alternative splicing pattern between WHMT and THAL for: 
(A) Different isoforms of BIN1 mRNA expression levels between WHMT and 
THAL (~2 FC) as measured using arrays, mean expression levels (y-axis) 
plotted for each probe set (x-axis) covering the BIN1 gene. Non-parallel 
probe set expression levels, in the dashed black box, suggest regional 
difference in the expression and splicing of the corresponding exons. The 
alternative splicing Bonferroni adjusted P = 3.2  10-59. This plot was 
generated using Partek Genomics Suite software. (B) Quantitative qRT-PCR 
validation of BIN1 mRNA expression level in the same regions confirms the array 
results. The expression level is presented as the mean and the error bar are S.E.M. 
Exon7 
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Table 4.3.7: Differential splicing patterns validation using qRT-PCR. 
This table shows the qRT-PCR validations performed for the splicing array results for BIN1, NRXN3 and PICALM genes. Significant *P 
values for both platforms for the alternative splicing were observed from the arrays and the validation experiments. (This table was produced by 
Dr Mina Ryten). The array results P values were adjusted using FDR procedure. The high level of significance of the array results in comparison 
to the moderate to non-significance of the qRT-PCR results can be due to the smaller sample size in the qRT-PCR study (THAL, n = 34, WHMT, 
n = 37) as compared with the array expression study (THAL, n = 83, WHMT, n = 91) and the larger background variation in the qRT-PCR 
compared with the array platform. It is noteworthy that the direction of FC values is mostly consistent across the expression and qRT-PCR 
platforms (fold changes are based on THAL compared with WHMT). 
 Affymetrix exon array results qRT-PCR results 
Gene 
Symbol 
Assay ID Array prediction P values for regional-bias Fold 
change 
P values for 
regional expression 
Fold 
change Expression splicing 
BIN1 
Hs01120891_m1 THAL < WHMT 
NA < 1.0 ×10
-45
 NA 
*4.06×10
-02
 1.53 
Hs01120903_m1 THAL > WHMT 9.90×10
-02
 1.38 
NRXN3 
Hs01028181_m1 (alpha) THAL = WHMT 
NA < 1.0 ×10
-45
 NA 
1.53×10
-01
 1.15 
Hs01031277_m1 (beta) THAL > WHMT *1.98×10
-02
 2.14 
PICALM 
Hs00999727_m1 THAL = WHMT 
NA < 1.0 ×10
-45
 NA 
*3.90×10
-02
 1.33 
Hs00999745_m1 THAL < WHMT *3.00×10
-03
 1.40 
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Figure 4.3.19:  
Exon array expression data at the probe set level suggesting alternative 
splicing by CNS region of the SETX transcript. SPCO = spinal cord and 
CRBL = cerebellum. 
This figure shows the alternative splicing patterns for exon 22 between CRBL and 
SPCO. Exon 22 expression level was 1.5 FC higher in CRBL compared with 
SPCO as measured using arrays, mean expression levels (y-axis) plotted for 
each probe set (x-axis) covering the SETX gene. Non-parallel probe set 
expression levels, in the dashed black box, suggest regional difference in the 
expression and splicing of the corresponding exons. Alternative splicing 
Bonferroni adjusted P = 1.5  10-15. This plot was generated using Partek 
Genomics Suite software. 
 
Exon 22 
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4.3.7 Initial brain expression quantitative trait loci (QTL) analysis: toward overall 
integration of genomic information  
In order to generate the brain expression QTL results for the ten CNS regions, 
the association tests between each probe set (exon level) and each SNP/Indel were 
performed. As a result, 19,648 unique expression QTL signals reached significance 
based on an FDR < 1%. The QTL was categorized as cis or trans based on the distance 
of the SNP to the transcription start site (TSS). In this analysis the cis window was 
within 1 Mb from the TSS.  
Results showed that 84% (16,421) of the significant expression QTL signals 
were specific to only one CNS region (Table 4.3.8). Out of these 16,421 QTL signals, 
25% (4,083), 18% (2,921) and 12% (1,991) were mapped only in CRBL, TCTX and 
WHMT respectively (Table 4.3.9). These three regions showed the highest number of 
region specific QTL signals.  
In total, there was a significant difference between the cis and trans acting 
signals. The cis-acting QTL signals accounted for 69.2% while trans-acting QTL 
signals accounted for 30.8% of all expression QTL signals (Table 4.3.8). The 
enrichment pattern of cis-acting versus trans-acting signals was similar when looking 
at all region specific QTL signals (Table 4.3.9). In order to check if there was a 
constant pattern between expression and QTL signals in each pair of regions, a table 
similar to Table 4.3.5 was generated (Table 4.3.10). The expression QTL signals 
pattern was not clearly constant with the expression pattern. There was no distinctive pattern 
and difficult to interpret. 
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Table 4.3.8: The significant expression QTL signals in one or more CNS regions. 
 
  This table shows the numbers and percentages for the significant expression QTL signals in one CNS region up to ten CNS regions. 
  
Number of CNS 
regions 
Number of              
cis-acting QTLs 
Percentage of         
cis-acting QTLs 
Number of               
trans-acting QTLs 
Percentage of           
trans-acting QTLs 
Number of               
total QTLs 
Percentage of   
total QTLs            
1 10,490 63.9% 5,931 36.1% 16,421 84% 
2 990 95.2% 50 4.8% 1,040 5% 
3 594 97.5% 15 2.5% 609 3% 
4 360 97.0% 11 3.0% 371 2% 
5 273 94.5% 16 5.5% 289 1% 
6 195 96.5% 7 3.5% 202 1% 
7 160 97.0% 5 3.0% 165 1% 
8 165 94.3% 10 5.7% 175 1% 
9 143 94.1% 9 5.9% 152 1% 
10 224 100.0% 0 0.0% 224 1% 
Total 13,594 69.2% 6,054 30.8% 19,648 100% 
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Table 4.3.9: Significant expression QTL signals that were specifically mapped in a named CNS region. 
 
  This table shows the numbers and percentages for the expression QTL signals that were mapped in a specific CNS region. 
  
CNS regions 
Number of              
cis-acting QTLs 
Percentage of         
cis-acting QTLs 
Number of               
trans-acting QTLs 
Percentage of           
trans-acting QTLs 
Total number of 
QTLs 
Percentage of   
total QTLs            
CRBL 2,919 71.5% 1,164 28.5% 4,083 25% 
WHMT 1,735 87.1% 256 12.9% 1,991 12% 
TCTX 1,301 44.5% 1,620 55.5% 2,921 18% 
FCTX 994 59.7% 670 40.3% 1,664 10% 
HIPP 784 46.0% 921 54.0% 1,705 10% 
OCTX 774 69.5% 340 30.5% 1,114 7% 
THAL 630 71.4% 252 28.6% 882 5% 
MEDU 620 79.5% 160 20.5% 780 5% 
PUTM 426 57.1% 320 42.9% 746 5% 
SNIG 307 57.4% 228 42.6% 535 3% 
Total 10,490 63.9% 5,931 36.1% 16,421 100% 
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Table 4.3.10: Significant expression QTLs that were specifically mapped in two CNS regions. 
 
 
 
 
 
 
 
 
The table shows the number of significant expression QTL signals exclusively in a pair of regions. The number of mapped QTL for that pair of 
regions is specified by the row and column position in the table. The yellow diagonal cells are presenting the number of QTL signals that were 
mapped exclusively in a named region. 
CNS regions CRBL 
         
CRBL 4083 WHMT         
WHMT 91 1991 TCTX        
TCTX 71 42 2921 FCTX       
FCTX 62 23 96 1664 HIPP      
HIPP 41 47 35 23 1705 OCTX     
OCTX 57 6 33 35 4 1114 THAL    
THAL 13 23 25 19 10 8 882 MEDU   
MEDU 13 98 16 11 11 10 12 780 PUTM  
PUTM 6 8 7 11 9 9 8 1 746 SNIG 
SNIG 7 15 4 2 7 2 1 7 1 535 
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4.3.8 Examples of brain expression QTLs 
 In this section three examples were selected to be presented. The QTLs were 
selected to demonstrate an example of a region specific expression QTL and a follow 
up of GWAS associations reported for the particular gene. Expression QTLs for MAPT 
and LRRK2 genes will be investigated in detail in the next chapters.  
 The first example is a region specific expression QTL signal mapped between an 
intergenic SNP (rs4938050) at genomic position chr11:113590031 (human genome 
build 19) and TMPRSS5 (Transmembrane protease, serine 5) gene (Affymetrix 
transcript 3391724). The SNP is located 12,424 kb downstream of the 3ꞌ end of the 
TMPRSS5 gene and the minor homozygous allele of this SNP is associated with higher 
expression of the gene mainly in WHMT (P = 7.9  10-17, at FDR 1%) (Figure 
4.3.20). TMPRSS5 encodes a serine protease family protein (spinesin), which is 
expressed specifically in the human CNS and mainly in neurons and axons. In 
addition, this protein is located in synaptic regions (Yamaguchi, Okui et al. 2002).  
 The second example is a region specific expression QTL signal that was 
detected between an intronic SNP (rs6661489) at genomic position chr1:207698044 
(human genome build 19) and CR1 (complement component (3b/4b) receptor 1) gene 
(Affymetrix transcript 2377332). The SNP is within intron 6-5 of the CR1 gene and the 
minor homozygous allele of this SNP is associated with higher expression of the gene 
mainly in WHMT (P = 1.5  10-03, at FDR 1%) followed by the HIPP region (Figure 
4.3.21). From the expression results, CR1 was enriched in WHMT compared with 
other CNS regions. This QTL is in strong linkage disequilibrium (LD) (R
2
 = 0.87) with 
two intronic SNPs rs3818361, P = 4.0  10-14 and rs6701713, P = 4.6  10-10 that were 
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reported to be associated with late onset Alzaheimer’s disease (LOAD) in GWAS 
(Hollingworth, Harold et al. 2011; Naj, Jun et al. 2011). 
The last example is an expression QTL signal that was between an intergenic 
SNP (rs10968921) at genomic position chr9:29071728 (human genome build 19) and 
LINGO2 (Leucine rich repeat and Ig domain containing 2) gene (Affymetrix transcript 
3202528). The SNP is located 14,049 kb upstream of the 5` end of the LINGO2 gene 
and the minor homozygous allele of this SNP is associated with higher expression of 
the gene only in CRBL (P = 1.6  10-33, at FDR 1%) (Figure 4.3.22). This gene locus 
was reported to be associated with Parkinson’s disease from a GWAS on an Asian 
population (Wu, Prakash et al. 2011). 
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Figure 4.3.20:  
The effect of rs4938050 on the expression of TMPRSS5 transcript. 
CRBL = cerebellum, WHMT = white matter, HIPP = hippocampus, SNIG 
= substantia nigra, FCTX = frontal cortex, TCTX = temporal cortex, 
OCTX = occipital cortex, MEDU = medulla, PUTM = putamen and THAL 
= thalamus. 
TMPRSS5 expression (Affymetrix transcript 3391724) stratified by 
rs4938050 for ten brain regions in 134 brain samples. Increased expression 
was associated with the homozygous minor allele (GG) in WHMT. A 
similar pattern was observed in all brain regions, but not as significantly. 
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Figure 4.3.21:  
The effect of rs6661489 on the expression of CR1 transcript. WHMT = 
white matter, CRBL = cerebellum, MEDU = medulla, SNIG = substantia 
nigra, PUTM = putamen, HIPP = hippocampus, OCTX = occipital cortex, 
TCTX = temporal cortex, FCTX = frontal cortex and THAL = thalamus. 
CR1 expression (Affymetrix transcript 2377332) stratified by rs6661489 for 
ten brain regions in 134 brain samples. Increased expression was associated 
with the homozygous minor allele (TT) in WHMT. A similar pattern was 
observed in all brain regions, but not as significantly with the exception of 
CRBL. 
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Figure 4.3.22:  
The effect of rs10968921 on the expression of LINGO2 transcript. 
WHMT = white matter, CRBL = cerebellum, MEDU = medulla, SNIG = 
substantia nigra, PUTM = putamen, HIPP = hippocampus, OCTX = 
occipital cortex, TCTX = temporal cortex, FCTX = frontal cortex and 
THAL = thalamus. 
LINGO2 expression (Affymetrix transcript 3202528) stratified by 
rs10968921 for ten brain regions in 134 brain samples. Increased expression 
was associated with the homozygous minor allele (CC) in CRBL. A similar 
pattern, not significant was observed in all other brain regions, but not in 
THAL, PUTM and SNIG. 
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4.4 Discussion 
 In this study the transcriptome expression and splicing pattern of the human 
CNS was investigated in 12 CNS regions. This analysis was based on 101 individuals 
(917 processed Affymetrix exon arrays) which were a subset of the UKBEC. 
Furthermore, genome-wide QTL analyses were performed for 10 brain regions of 137 
individuals of the UKBEC. This data set is a unique cohort of post mortem human 
brain samples to complement the other human CNS studies in the field (Myers, Gibbs 
et al. 2007; Gibbs, van der Brug et al. 2010; Kang, Kawasawa et al. 2011; Hawrylycz, 
Lein et al. 2012). It is essential to realize that precise mapping of the human 
transcriptome in different CNS regions will greatly assist in the understanding of 
region specific pathology in neurological diseases. 
The results revealed that using the DABG method to detect region specific 
genes not only helped to reduce the background noise in the expression signals, but 
also reduced the false positive alternative splicing signals that might be over detected 
by the alternative splicing ANOVA module that was used in the downstream analysis. 
In this study although the DABG filtering threshold used is different from previous 
studies, there was an overlap in the region specific genes that were reported (Johnson, 
Kawasawa et al. 2009; Kang, Kawasawa et al. 2011; Hawrylycz, Lein et al. 2012). It is 
important to be aware that applying different statistical thresholds in these types of 
analyses will change the detected transcript list that is generated for further analysis, in 
addition to the transcript alternative splicing detection proportions (Whistler, Chiang et 
al. 2010). However, some of the examples that were discussed in the result sections 
confirmed the validity of the array results. For example, CBLN3 was specific for 
CRBL, SLC18A2 and SLC6A3 for SNIG and PLP1 for WHMT and SPCO.  
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CRBL was the region with the most distinctive gene specific and differential 
expression patterns compared with other CNS regions (Roth, Hevezi et al. 2006; 
Johnson, Kawasawa et al. 2009; Gibbs, van der Brug et al. 2010). 8% of the detected 
genes were CRBL specific. These results might be expected, considering the unique 
anatomical microscopic structure that reflects the special biochemical and cellular 
functions of CRBL (Llinas RR 2004; Azevedo, Carvalho et al. 2009). Additionally, 
WHMT is the second region after CRBL that showed a differential expression pattern, 
despite the fact that this region showed the lowest number of detected genes between 
the other 11 regions (57%, Table 4.3.1). This may be due to the nature of this region 
as the axonal mRNA expression pattern is different as compared with the neuronal 
body expression pattern (Giuditta, Chun et al. 2008).  
Region specific expression results suggest insights for certain genes in relation 
to some diseases. For example, the IGHMBP2 gene is linked with SMARD1 and the 
existing diagnostic protocol, involves a peripheral nerve biopsy with no requirement to 
scan regions other than SPCO. This gene was not detected in SPCO in this study, 
possibly because the RNA samples were extracted from the cell bodies and not from 
the nerve axons or synaptic regions. However, having this gene enriched in CRBL 
might open the way for clinicians to look at CRBL pathology and scan the patient’s 
brain for this peripheral nerve disease. A previous study highlighted the concept that 
the molecular pathology of a disease may not be manifested as or coupled with certain 
histolopathological profiles or display the usual clinical symptoms (Hodges, Strand et 
al. 2006). 
Remarkably, 96% of the detected genes were identified as alternatively spliced 
between the 12 CNS regions. However, in some cases this pattern reflects differential 
exon expression usage rather than full isoform detection.     
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Comparing the mRNA expression and splicing profiles in the cortical regions 
provided high resolution mapping between these regions, especially in the OCTX. In 
summary, the splicing patterns in these regions were the main patterns leading to 
different functions. This suggests that the pathological mechanism of diseases 
affecting cortical areas can be through the alteration of expression and/or splicing 
patterns, which leads to the alteration of the expression ratio between different 
isoforms. One of the examples provided is the CNTNAP2 gene, which was related to 
autism, epilepsy, schizophrenia, and mental retardation diseases (Alarcon, Abrahams 
et al. 2008; Friedman, Vrijenhoek et al. 2008). Considering this gene was highly 
expressed in all cortical regions (FCTX, TCTX and OCTX), the regions that are 
mainly affected by these diseases (Tan, Doke et al. 2010) and responsible for language 
processing in the human CNS, alteration of the expression patterns may contribute to 
the pathology of the cortical areas. This hypothesis needs further validation to 
understand the mechanisms underlying the pathology. Similar hypotheses can be 
applied for ANO3, CR1 and BIN1 in relation to AD as they are differentially expressed 
in different CNS regions, but their splicing patterns have not been investigated in 
detail. 
As a means of moving forward, this approach can be applied to each possible 
comparison of all other CNS regions to explore and understand how differential 
expression and splicing patterns will affect gene connection circuits and the biological 
processes. These differential expression profiles may play an important role in 
understanding the vulnerability of certain brain regions or cells in neurological 
disorders.  
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 The results of the alternative splicing patterns suggest some functional 
importance for certain isoforms in specific CNS regions. NRXN3 gene encodes for 
proteins involved in specifying synaptic functions and mediating signalling across the 
synapse. An alternation in this gene was reported to be associated with autism and 
cognitive diseases (Sudhof 2008). Different ratios of alpha-NRXN3 and beta-NRXN3 
isoforms in different brain regions suggest different functions and activities (Craig and 
Kang 2007). Therefore, any alteration in the right balance of these isoforms may 
contribute to the pathology of the disease in specific regions. A similar concept can be 
applied for the SETX gene. This gene is not differentially expressed but differentially 
spliced between CRBL and SPCO regions, which are the main regions to be affected 
in the AOA2 and ALS4. These results suggest that SETX contributes to disease 
pathology by having different spliced isoforms in the affected regions at different 
ratios, thus altering gene connectivity and function.  
  The last example of this group is the BIN1 gene. A previous study 
demonstrated that WHMT is one of the regions most involved in AD (Hua, Leow et al. 
2008). The results showed an enrichment of the gene in WHMT and different splicing 
isoforms were also demonstrated and confirmed in this region compared to other 
regions. The protein product of BIN1 is involved in regulating synaptic vesicle 
endocytosis (Wigge and McMahon 1998), so alterations in the isoform balance could 
lead to misregulation of this process and contribute to the disease aetiology.    
The initial results for the expression QTL analysis showed that region specific 
expression QTL signals accounted for 84% of the total number of expression QTLs. 
CRBL was the most enriched regions for expression QTLs signals and that is 
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consistent with the expression pattern in this region confirming the unique functions of 
the CRBL.  
Genome-wide expression QTL mapping was discussed mainly as cis-acting 
signals (69.2%). Trans-acting expression QTL signals were reported, but not 
investigated in this thesis. Although the interpretation of expression QTLs has to be 
done carefully (Peirce, Li et al. 2006), the results showed significant region specific 
expression QTL signals which are and related to neurological diseases. This was 
demonstrated by the examples that were selected in the results section. CR1 is 
associated with AD and LINGO2 is associated with development of PD, providing the 
evidence that risk SNPs for diseases have a functional impact on expression and on 
splicing. Therefore a careful investigation of this is an important step forward 
following the GWAS results. In addition, this will help to focus attention on certain 
regions for the investigation of specific diseases. However, these findings have to be 
further validated with different experimental techniques to increase our understanding 
of the molecular mechanisms underlying the expression QTLs and the impact on cell 
function.  
Furthermore, the expression mechanisms underlying QTLs are not fully 
understood and there are likely to be more expression QTLs to be found and 
investigated. More research is required with larger sample sizes to be able to capture 
more expression QTL signals with smaller effect sizes. This is also true for trans-
acting expression QTL signals. 
In conclusion, these results are considered to be the first of several stages to 
understand the genetic basis of variation in gene expression in the control human brain, 
and neurodegenerative diseases. This stage includes generating the data, applying 
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quality control parameters, performing different ANOVA modules, running 
association tests, multiple test correction, mining the data to a scalable level, and 
comprehensive investigation with specific hypotheses for genes of interest. Following 
on from this work, it is important to undertake further experiments using different 
samples, cell models, advanced techniques and bioinformatic tools, especially for the 
expression QTL signals. In this way the functional mechanisms of QTL signals will be 
understood more clearly. 
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5 Characterization of MAPT expression and splicing in control 
multiple human brain regions: in relation to neurodegenerative 
diseases 
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5.1 Summary  
The MAPT (microtubule-associated protein tau) locus is one of the most 
significant genetic markers contributing to some neurodegenerative diseases such as 
Parksinson’s disease (PD).  Moreover, the tau protein is recognized as a key 
pathological feature of neurodegenerative disorders; including progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD) and Alzheimer’s disease 
(AD).  In addition to the linkage of the MAPT locus to disease, the chromosomal region 
around MAPT has been intensely studied because of the polymorphic inversion and 
complex alternative splicing patterns that make this region of the genome particularly 
complicated with regard to its genetic architecture. Thus, generating detailed data 
regarding the expression, splicing and genetic regulation of this transcript within the 
human brain is of great importance.   
In order to generate the required data, 2,011 brain samples originating from 439 
control individuals from ten brain regions were used from both UKBEC and NABEC 
datasets to provide the most reliable and comprehensive results on the regional 
expression, splicing and regulation of MAPT to date.   
The results revealed significant regional variation in mRNA expression levels 
and splicing patterns of MAPT in the control human brain.  The gene expression level, 
the regional distribution of mRNA expression and total tau protein expression levels 
were largely in agreement, appearing to be highly correlated. Finally, the H1/H2 SNP 
showed an association with expression of exon 3-containing isoforms in the control 
human brain.   
This data suggests that the genetic risk factors for neurodegenerative diseases 
at the MAPT locus are likely to operate through changing mRNA splicing patterns in 
different brain regions, as opposed to the overall mRNA expression of the MAPT gene.  
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5.2 Introduction 
MAPT (microtubule-associated protein tau) locus is one of the most remarkable 
genes in neurogenetics due not only to its involvement in multiple neurodegenerative 
disorders such as PSP (Baker, Litvan et al. 1999; Hoglinger, Melhem et al. 2011), 
CBD (Houlden, Baker et al. 2001), PD (Golbe, Lazzarini et al. 2001; Nalls, Plagnol et 
al. 2011; Lill, Roehr et al. 2012) and possibly AD (Myers, Kaleem et al. 2005; Gerrish, 
Russo et al. 2012), but also due to its genetic evolution and complex alternative 
splicing features. These features are to some extent linked, making the role of MAPT in 
health and disease all the more intriguing (Goedert, Spillantini et al. 1989; Goedert, 
Spillantini et al. 1989; Stefansson, Helgason et al. 2005). 
The evolution of the MAPT locus has been comprehensively studied, with an 
inversion polymorphism on chromosome 17q21. While the majority of individuals 
inherit this region in the direct orientation, up to 25% of individuals of European-
Caucasian-descent have ~970 kb sequence in the inverted orientation (Stefansson, 
Helgason et al. 2005; Zody, Jiang et al. 2008), introducing a larger ~1.5 Mb region of 
linkage disequilibrium (Pittman, Myers et al. 2004; Zody, Jiang et al. 2008). This 
sequence appears, in Europeans at least, to descend from a single founder (Pittman, 
Myers et al. 2004; Fung, Evans et al. 2005).  The common haplotype clades marking 
the direct (majority) and inverted orientated sequences are termed H1 and H2, 
respectively.  It is not clear which of these sequences is the ancestral orientation 
because the polymorphism exists in other primate species and the rodent sequence is in 
the H2 orientation (Stefansson, Helgason et al. 2005). It is worth noting that since this 
inversion polymorphism excludes recombination over a region of ~1.5 Mb, haplotype-
specific polymorphisms have arisen. Genetic studies, including genome-wide 
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association, have demonstrated the importance of both the inversion polymorphism 
and inversion-independent polymorphisms in disease.  In fact, two distinct types of 
disease association have been demonstrated, of which the first is the association of the 
H1 haplotype with an increased risk of PD (odds ratio ~1.7) (Golbe, Lazzarini et al. 
2001; Nalls, Plagnol et al. 2011; Lill, Roehr et al. 2012), PSP (odds ratio 5.5) (Baker, 
Litvan et al. 1999; Hoglinger, Melhem et al. 2011) and CBD (odds ratio ~5) (Houlden, 
Baker et al. 2001). The second is the association of the H1c haplotype, one of the sub-
haplotypes within the H1 clade, with an increased risk of PSP alone (odds ratio ~1.5) 
(Pittman, Myers et al. 2005; Hoglinger, Melhem et al. 2011) 
The importance of the tau protein in neurodegenerative disease has been well 
documented even before the recognition of the genetic role of MAPT genetics in these 
diseases. Tau is expressed in the adult human central nervous system and tau 
pathology.  Specifically, neurofibrillary tangles (NFTs), are a notable pathological 
feature of a range of neurodegenerative disorders, including PSP, CBD (Feany, 
Mattiace et al. 1996) and AD (Goedert, Spillantini et al. 1989).  As well as having 
distinct clinical features, these diseases also have distinct and overlapping profiles of 
severity of tau pathology within the human brain. These profiles of severity are 
summarised in Table 5.2.1 and show that in AD, a disease characterised by early 
memory loss and difficulties in executive functions, tangle pathology is most 
prominent in brain regions that are highly associated with these processes, namely the 
hippocampus, temporal cortex and frontal cortex. These findings have led researchers 
to investigate whether basal regional expression of MAPT mRNA and protein may 
predispose some brain regions to a higher risk of tau pathology than others and there is 
evidence in support of this (Feany, Mattiace et al. 1996; Luk, Giovannoni et al. 2009). 
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Table 5.2.1: Severity distribution of tangle pathology in human brain (Trabzuni, 
Wray et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
Severity ranking of the distribution of tau pathology within the human brain in 
Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD) and Parkinson’s disease (PD). The data represent average severity 
of pathology in the following way: 0 = none, 1 = mild, 2 = moderate and 3 = severe 
(Tamas Revesz, derived from (Braak and Braak 1991; Compta, Parkkinen et al. 2011; 
Dickson, Hauw et al. 2011)). 
However, there is an increasing appreciation of the importance of not only 
assessing total MAPT expression, but also alternative splicing. The MAPT gene is 
extensively spliced to produce 12 mRNA transcripts (according to Ensembl / Havana 
annotation) and seven protein isoforms. Concentrating on the known protein products 
within human brain (of which six are recognised), cassette splicing of exons 2 and 3 
(E2 and E3), give rise to tau isoforms with 0, 1 or 2 amino-terminal repeats (0N-, 1N- 
Brain region AD PSP CBD PD 
FCTX 3 2 3 1 
TCTX 3 1 2 2 
OCTX 2 0 0 0 
WHMT 0 1 3 0 
HIPP 3 2 2 2/3 
PUTM 1 2 3 0 
THAL 2 1 2 1 
HYPO 1 2 2 1 
SNIG 1 2 3 0 
MEDU 1 2 2 0 
CRBL 0 1 1 0 
SPCO 0/1 2 2 0 
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or 2N-tau) and alternative splicing of exon 10 (E10), yields isoforms with 3- or 4-
microtubule binding repeats in the carboxy-terminal half of tau (3R- or 4R-tau) 
(Goedert, Spillantini et al. 1989). Interestingly, detailed investigations by a number of 
groups have demonstrated that neurofibrillary tangles in different diseases have a 
different isoform composition, suggesting that splicing is of key importance in the 
neuropathological process. Whereas the tangles found in PSP and CBD consist 
predominantly of 4R-tau (due to exon 10 inclusion), those found in AD contain both 
3R- and 4R-tau (Sergeant, Wattez et al. 1999; Goedert 2004). Furthermore, consistent 
with the findings on total tau, it was previously shown that regions of relatively high 
4R-tau in PSP are more susceptible to tau related pathology and neurodegeneration 
(Feany, Mattiace et al. 1996; Luk, Giovannoni et al. 2009). 
Understanding the expression, splicing and regulation of the mRNA and 
protein isoforms is of key importance to the field. At present, no comprehensive study 
of this type has been performed. In order to address this, the data from the UKBEC; 
the largest exon-specific expression data set currently available, were used (Trabzuni, 
Ryten et al. 2011), containing up to 10 distinct brain regions (including hippocampus 
and substantia nigra): FCTX, n= 127, TCTX, n= 119, OCTX, n= 129, HIPP, n= 122, 
THAL, n= 124, PUTM, n= 129, SNIG, n= 101, MEDU, n= 119, CRBL, n= 130 and 
WHMT, n= 131 (1,231 Affymetrix exon arrays) (Trabzuni, Ryten et al. 2011). In 
addition, expression QTL analysis was performed to understand the effects of both the 
H1 and H1c risk haplotypes on MAPT expression and splicing. In order to increase the 
statistical power, the analysis was performed using a second data set originating from 
390 neuropathologically normal individuals from the North American Brain 
Expression Consortium (NABEC) (See Table 5.2.2)  (Gibbs, van der Brug et al. 
2010).  
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Table 5.2.2: The number of brains studied for each major type of analysis 
conducted in both data sets. Table modified from (Trabzuni, Wray et al. 2012). 
 
  
Analysis Data set Number 
Regional distribution and splicing of MAPT mRNA 
UKBEC 134 
The effect of H1/H2 haplotypes on mRNA 
expression and splicing 
The effect of the H1c haplotype on MAPT mRNA 
expression 
NABEC 
+ 
UKBEC 
305 
 
85 
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5.3 Results 
5.3.1 Regional expression and splicing of MAPT mRNA in multiple control human 
brain regions 
The tissue samples from 10 brain regions that were originated from 134 
individuals from the UKBEC were profiled on 1,231 Affymetrix Human Exon 1.0 ST 
arrays. The regional distribution of MAPT mRNA expression at the gene level is 
shown in Figure 5.3.1.  This demonstrated significant regional differences in MAPT 
mRNA expression with a 1.5 fold difference (P = 5.7  10-49) between frontal cortex, 
the highest MAPT expressing region, and the white matter, the lowest (Figure 5.3.1). 
Regional differences in MAPT mRNA expression were validated on a subset of 12 
individuals in four brain regions (CRBL, OCTX, PUTM and WHMT) using 
QuantiGene (QG), which showed a similar pattern. The results of QG were shown in 
detail in Chapter 3 Figure 3.3.6 (Trabzuni, Ryten et al. 2011) including for MAPT 
mRNA expression. 
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Figure 5.3.1:  
Regional Distribution of MAPT mRNA expression. FCTX = frontal 
cortex, TCTX = temporal cortex, OCTX = occipital cortex, HIPP = 
hippocampus, THAL = thalamus, CRBL = cerebellum, SNIG = substantia 
nigra, PUTM = putamen, MEDU = medulla and WHMT= white matter. 
Boxplot of mRNA expression levels for MAPT in 10 brain regions, from 
microarray experiments on a log2 scale (y-axis). This plot shows the 
regional variation in MAPT transcript expression across all the regions. 
Whiskers extend from the box to 1.5 times the inter-quartile range 
(Trabzuni, Wray et al. 2012). 
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The unique design of the Affymetrix Exon arrays, with probe sets targeted 
against individual exons, also allowed us to investigate regional differences in MAPT 
mRNA exon splicing (ANOVA alternative splicing P < 110-45, Figure 5.3.2, C). This 
demonstrated a relative reduction in the expression of exon 2 in white matter as 
compared to other brain regions, suggesting lower expression of exon 2-containing 
isoforms specifically in this tissue. Similarly, there was a relative increase in the 
expression of exon 6 in cerebellum as compared to other brain regions, suggesting 
higher expression of exon 6 containing isoforms in this tissue (Figure 5.3.2, C). 
Alternate splicing of exon 2 in white matter was confirmed by TaqMan assays for 0N 
(E2-, 3-), 1N (E2+, 3-) and 2N (E2+, 3+) transcripts (Figure 5.3.3). These assays 
demonstrated a selective reduction of exon 2 containing transcripts (2N-tau and 1N-
tau) in white matter, whereas 0N-tau isoforms, which do not contain exon 2 or 3, were 
unchanged between these selected regions. 
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Figure 5.3.2:  
MAPT Gene/exon Structure, position of expression probes and array 
expression. CRBL = cerebellum and WHMT = white matter.  
(A, upper panel) The structure of the MAPT gene. The position of 
Affymetrix exon array probe sets (from probe set 3723707 to 3723753) and 
probe sets of Illumina transcript expression array (ILMN_2298727, 
ILMN_1800049, ILMN_1710903 and ILMN_2310814) are indicated 
within the MAPT exons. (B, middle panel) The tau protein isoforms 
expressed in human brain. Alternative splicing of exons 2, 3 and 10 
generates six protein isoforms of tau with either 0, 1 or 2 N-terminal repeats 
and 3 or 4 C-terminal microtubule binding repeats.  (C, lower panel) Exon 
array data shows the expression of MAPT expression at the exon level 
matching the upper panel of the exon structure. The mean expression levels 
were (y-axis, log2 scale) were plotted for each probe set (x-axis) covering 
the whole transcript. Note that levels are not absolute since they depend 
upon the hybridisation efficiency of individual probe sets.  It is, therefore, 
not possible to compare the expression between exons.  Differences in 
splicing between brain regions are manifest through the non-parallelism 
between the expression lines.  Two examples suggest evidence of splicing 
are: at exon 2, the WHMT (light green line) shows less inclusion of this 
exon than would be expected and at exon 6, CRBL (red line) shows more 
inclusion (Trabzuni, Wray et al. 2012). 
 
WHMT 
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Figure 5.3.3:  
MAPT qRT-PCR validation using TaqMan assay for different 
isoforms. CRBL = cerebellum, OCTX = occipital cortex and WHMT = 
white matter. 
This graph shows the confirmation of the differential splicing pattern of 
exon 2 in WHMT as compared to CRBL and OCTX. Whereas exon 2 
containing isoforms, 1N (exon 2+, 3-) and 2N (exon 2+, 3+), were 
expressed at significantly lower levels in white matter as compared to 
occipital cortex and cerebellar cortex, no differences in 0N (exon 2-, 3-) tau 
transcripts were observed (Trabzuni, Wray et al. 2012) (Data produced by 
Dr Jana Vandrovcova). 
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5.3.2 Regional expression of tau protein in multiple control human brain regions 
The relationship between mRNA and protein expression is complex. However, 
establishing the nature of this relationship in the case of MAPT/tau is critical in 
interpreting reported expression quantitative trait loci, which have largely depended on 
mRNA expression levels alone. The regional variability in total tau protein expression 
levels in five brain regions (CRBL, FCTX, OCTX, PUTM and WHMT) in 12 
individuals were assessed in detail (Figure 5.3.4, A and B). This analysis showed that 
the FCTX has the highest tau protein levels with decreasing levels in the following 
order: FCTX > OCTX > WHMT > PUTM > CRBL. CRBL tau protein levels were 
significantly lower than all other regions examined (Figure 5.3.4, B, P < 0.01) and tau 
protein levels in PUTM were significantly lower than FCTX and OCTX (P < 0.05).   
These findings are largely in agreement with the mRNA expression results which 
showed that cortical regions express MAPT at the highest levels and cerebellum, 
putamen and white matter all have lower levels of MAPT mRNA.   
The levels of each individual isoform of tau protein were determined relative to 
total tau protein level for the same sample (Figure 5.3.4, C-H).  1N-tau protein 
isoforms formed the majority of total tau (~50%), followed by 0N-tau isoforms 
(~40%) with 2N-tau isoforms forming the lowest proportion of tau (~10%), and levels 
of 3R-tau and 4R-tau isoforms were approximately equal, in agreement with previous 
studies (Boutajangout, Boom et al. 2004).  Protein levels of the smallest tau isoform, 
0N3R, were significantly lower in cerebellum (P < 0.05) compared to other brain 
regions, but other tau isoforms were not found to vary significantly between brain 
regions.  
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Figure 5.3.4:  
Regional expression level of tau protein within multiple human brain regions. 
CRBL = cerebellum, FCTX = frontal cortex, OCTX = occipital cortex, PUTM = 
putamen and WHMT = white matter.   
Soluble tau extracts were prepared from five different brain regions, separated by 
SDS-PAGE and detected on Western blots probed with the polyclonal antibody to 
total tau. (A) Specific tau isoforms were identified by comparing to recombinant 
tau ladder (n=13, representative image shown). (B) Comparison of total tau to 
actin revealed highest tau protein levels in the FCTX and significantly lower tau 
levels in CRBL (P <0.01) and PUTM (P< 0.05). (C) Levels of specific tau 
isoforms were determined by normalisation to total tau for the same sample and 
revealed a significantly lower amount of 0N3R in CRBL compared to other 
regions. (D-H) There was no significant variation in other tau isoforms (Trabzuni, 
Wray et al. 2012) (Data produced by Dr Selina Wray). 
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The 3R- and 4R-tau protein levels were measured in the same samples using 
sandwich ELISA assays (Luk, Giovannoni et al. 2009; Luk, Vandrovcova et al. 2010). 
Both 3R- and 4R-tau are lowest in CRBL and WHMT reflecting total transcript levels 
(Figure 5.3.5). In conclusion, whereas MAPT gene-level expression and total tau 
protein expression follow similar trends between brain regions, the relationship 
between mRNA and protein isoforms could not be determined. 
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Figure 5.3.5:  
The 3R- and 4R-tau protein levels in human brain using ELISA assay. 
WHMT = white matter, PUTM = putamen, OCTX = occipital cortex, 
FCTX = frontal cortex and CRBL = cerebellum.   
3R and 4R-tau immunoreactivity in five brain regions (x-axis) of control 
brains, measured in ng/mg of tau of total protein (y-axis) by sandwich 
ELISA. Using non-parametric Kruskall-Wallis test followed by a posthoc 
Dunn’s multiple comparisons was used to compare brain regions. (A) 3R-
tau levels show significant differences in of CRBL vs PUTM, OCTX and 
FCTX (P<0.001) and CRBLs WHMT (P<0.05). (B) 4R-tau levels show 
significant differences of WHMT vs FCTX (P<0.001); WHMT vs OCTX 
(P<0.01) and FCTX vs CRBL (P<0.05) (Data produced by Dr Connie 
Luk). 
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5.3.3 H1/H2 QTLs effect on MAPT mRNA expression and splicing  
Previous studies have demonstrated the effects of the H1/H2 haplotypes on 
MAPT mRNA expression (Myers, Gibbs et al. 2007; Myers, Pittman et al. 2007; 
Gibbs, van der Brug et al. 2010; Nalls, Plagnol et al. 2011). However, there are large 
numbers of haplotype-specific polymorphisms at the MAPT locus (both SNP and 
insertion/deletion polymorphisms), some of which have only recently been identified, 
and since expression probes have largely been designed against the H1 haplotype, 
these polymorphisms may have created false expression QTL results (Naiser, Ehler et 
al. 2008). This can occur because mRNA sequences transcribed from the H2 haplotype 
will depart from the H1 reference sequence (used to develop the probes), due to both 
the presence of different nucleotides (i.e. SNPs) and the presence or absence of 
nucleotides (i.e. indels), and so are likely to exhibit a weaker binding affinity for the 
probes in question, which are a perfect match for mRNA sequences transcribed from 
the H1 haplotype.  This results in an apparent association between genotype and 
expression, confounding expression QTL studies which are looking for just such a 
signal.  For this reason, the most recent release of the 1000 Genomes Project (March 
2012: Integrated Phase I haplotype release version 3) was used to identify and remove 
probes on the Affymetrix Exon array that map to MAPT and contain SNPs or indels 
with a minor allele frequency (MAF) of > 1 % in Europeans. This resulted in the 
removal of 8 of the 25 MAPT probe sets from further expression QTL analysis (Figure 
5.3.6 and Figure 5.3.2 (A) for positions of probe sets). Exon-specific expression data 
that were generated from the remaining 17 probe sets (using UKBEC samples) were 
tested for association against 3,547 SNPs located within ~1 Mb of the transcription 
start and end site of MAPT, and this was performed separately in each brain region.  
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Figure 5.3.6:  
Schematic view shows the process of filtering the probe sets for 
expression QTL association at MAPT transcript location. 
Comprehensive investigation for the MAPT transcript probe sets, the 
analysis was limited to selected probe sets in order to have reliable and 
reproducible results. 
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The most significant expression QTL identified was between SNP 
rs111522045 (rs118049839) at genomic position chr17:44357157 (250 kilo-bases 
downstream the 3` end of the MAPT gene) from human genome build 19 and exon 3 
(Affymetrix probe set 3723712). Since this SNP is in strong linkage disequilibrium 
(LD) with SNPs that tag the H1/H2 haplotypes, the known H1/H2 tagging SNP, 
rs17665188 (R
2
 = 0.93 with rs111522045) was used to demonstrate the effect of the 
H2 haplotype on exon 3 expression (as detected by Affymetrix probe set 3723712). 
The H2 haplotype was associated with higher expression of exon 3 in all brain regions 
(all region average P = 5.210-13) except white matter (Figure 5.3.7). The most 
significant association was observed in frontal cortex (P = 8.810-6). In contrast to the 
alternate splicing of exon 10, the alternate splicing of exons 2 and 3, and more 
specifically the role of exon 3 has not been extensively studied.  However, this data 
refine a previous report using cell lines (Caffrey, Joachim et al. 2008) which suggested 
that H2 was associated with increased inclusion of exons 2 and 3, though the former 
was not observed (P > 0.01 for all tissues for exon 2, as measured by Affymetrix probe 
set 3723710).  
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Figure 5.3.7:  
The effect of the H1/H2 haplotypes (tagged by rs17665188) on the 
expression of MAPT exon 3. FCTX = frontal cortex, TCTX = temporal 
cortex, OCTX = occipital cortex, HIPP = hippocampus, THAL = 
thalamus, CRBL = cerebellum, SNIG = substantia nigra, PUTM = 
putamen, MEDU = medulla and WHMT = white matter. 
MAPT exon 3 expression (Affymetrix probe set 3723712) stratified by 
genotype at rs17665188 for ten brain regions. Increased exon 3 expression 
was associated with the homozygous major allele (CC). A similar 
association pattern was observed in all brain regions except for WHMT  
(P = 0.03). All ten brain regions shown as well as combined mean across 
region (aveALL) (Trabzuni, Wray et al. 2012). 
  MAPT genetics, expression and splicing in human brain 
 
 189 
  
5.3.4 H1c haplotype (rs242557) effect on MAPT mRNA expression 
Determining the effect of the H1c haplotype on both MAPT mRNA expression 
and splicing was performed using the Affymetrix exon arrays on the UKBEC data set 
and NABEC data set combined together in order to increase the number of samples for 
this analysis. The expression data that were derived from 390 individuals (FCTX and 
CRBL regions) and generated by the NABEC using the Illumina HumanHT-12 v3 
Expression BeadChips were used.  This Illumina expression array contains four probes 
mapping to the MAPT transcript, of which only two were detected in control human 
brain, ILMN_2310814 and ILMN_1710903. As previously described, in order to avoid 
the detection of false expression QTLs arising from the presence of SNPs within the 
probe sequences, both Illumina probes for SNPs and indels using the most recent 
release of the 1000 Genomes Project (March 2012: Integrated Phase I haplotype 
release version 3) were checked. This detailed quality control process helped to 
identify a two base pair deletion (rs67759530, MAF = 23% in Europeans) in the target 
sequence of Illumina probe, ILMN_1710903, specifically within the MAPT H2 
haplotype.   
However, removal of H2 haplotype-carrying individuals did allow using the 
data generated by both MAPT probes to investigate the effects of rs242557 in the 
remaining 222 H1/H1 individuals. This SNP defines the H1c sub-haplotype within the 
H1 clade and has also been shown to be a significant risk SNP for PSP (risk allele = A, 
P = 9.510-18 from the relevant GWAS) (Hoglinger, Melhem et al. 2011). In fact, the 
H1c haplotype (tagged by rs242557) was not significantly associated with increased 
mRNA expression of MAPT, as measured with Illumina probes ILMN_1710903 (P = 
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0.957 in FTCX, P = 0.825 in CRBL) and ILMN_2310814 (P = 0.975 in FTCX, P = 
0.768 in CRBL).  
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5.4 Discussion 
This analysis, was based on multiple analyses with a minimum of 780 brain 
samples used in any single analysis (originating from 390 individuals), provides the 
most comprehensive dataset on the regional mRNA expression, splicing and regulation 
of MAPT available to date.  Thorough quality control steps have been used to ensure 
that in particular the effects of the H1/H2 and H1c haplotypes on MAPT mRNA 
expression and splicing were as accurate as possible. Thus, the results reveal 
significant regional variation in MAPT mRNA expression and splicing, validated using 
Quantigene and TaqMan assays, and that at the gene level, MAPT mRNA expression 
and total tau protein are highly correlated. In addition, the effect of the reported H1/H2 
effect on MAPT mRNA gene level expression is likely to be a technical artefact; as this 
polymorphism is associated with the expression of exon 3-containing isoforms in 
control human brain. These findings would suggest that genetic risk factors for 
neurodegenerative diseases at the MAPT locus are likely to operate by changing the 
balance of mRNA splicing in different brain regions, as opposed to the overall 
expression of the MAPT gene (Caffrey and Wade-Martins 2012). 
Profiling mRNA and protein expression in control human brain demonstrated 
significant regional variation. MAPT mRNA expression was 1.5 fold higher in the 
neocortex, as compared to white matter and cerebellum. Total tau protein expression 
level had a similar regional pattern of expression to that for mRNA.  Since the frontal 
and temporal cortex are amongst the brain regions most affected by tangle pathology 
in AD, these findings support the concept that despite high ubiquitous expression of 
MAPT in human brain, regional variation in basal MAPT expression might predispose 
  MAPT genetics, expression and splicing in human brain 
 
 192 
  
some brain regions to tangle pathology and explain the regional specificity of disease 
in AD at least. 
Comparable profiling of MAPT mRNA splicing and protein isoform expression 
presents a more complex task. While regional splicing of exon 2 containing mRNA 
isoforms was confirmed and validated using TaqMan assays, at the protein level this 
observation was not replicable. The only significant regional difference in tau protein 
isoform expression was the reduced levels of 0N3R in cerebellum as compared to 
other regions. This finding was in agreement with previous studies that have observed 
decreased 0N3R in the cerebellum of control (Boutajangout, Boom et al. 2004) and 
PSP (Gibb, de et al. 2004) patients. However, the absence of any clear relationship 
between mRNA splicing and tau protein isoform production is difficult to interpret. 
One possible reason for this is that altered splicing of exon 2 would be shared across 
four tau protein isoforms (1N3R, 1N4R, 2N3R and 2N4R), thus a sizeable change 
would be needed to allow detection by a semi-quantitative technique such as Western 
blotting. 
Finally, the effects of the H1/H2 and H1c haplotypes on MAPT mRNA 
expression and splicing were investigated. In the case of the former, the statistical 
power was insufficient to use the exon-specific and region-wide expression data 
provided by the UKBEC. Thus, for the first time the effect of the H1/H2 inversion 
polymorphism on MAPT splicing were assessed.  These data showed that the under-
represented, protective H2 haplotype is associated, in all grey matter brain regions, 
with more expression of exon 3 and that this effect is most prominent in cortical 
regions.  This finding is consistent with previous allele-specific expression studies 
(Caffrey, Joachim et al. 2008). Interestingly, no association was seen in white matter, 
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where in fact there was a trend in the opposite direction (P = 0.03).  These data suggest 
that the inclusion of exon 3 in grey matter is protective in PSP, CBD and PD. Since 
several physiological roles for the amino-terminal inserts coded by exons 2 and 3 have 
been suggested, these might help explain this finding. For example, it has been 
suggested that the amino-terminal inserts could regulate the spacing between 
microtubules (Chen, Kanai et al. 1992; Frappier, Georgieff et al. 1994). Alternatively, 
since the amino-terminal region of tau has also been shown to interact with the plasma 
membrane where it can in turn interact with src-family kinases, it could be involved in 
signal transduction (Lee, Newman et al. 1998; Lee 2005). Moreover, it has been 
recently shown that the exon 2- and 10-encoded inserts increase aggregation 
propensity whereas the exon 3-encoded insert decreases aggregation (Zhong, Congdon 
et al. 2012; Zhong, Congdon et al. 2012).  The latter could in part explain the 
protective function of H2 with its increased inclusion of exon 3. Interestingly, this 
function has recently been shown to be important in mediating amyloid-beta toxicity in 
a mouse model of Alzheimer’s disease (Ittner, Ke et al. 2010).  
The brain mRNA expression data (FCTX and CRBL) that were generated by 
the NABEC (n = 222) were used to investigate the effects of the H1c haplotype 
(tagged by rs242557) on MAPT expression. Using the most recent release of the 1000 
Genomes Project (Interim phase I haplotypes, June 2011), quality control procedures 
identified a two base pair deletion (rs67759530) in the target sequence of 
ILMN_1710903 within the H2 haplotype. It is now well recognised that such sequence 
polymorphisms can result in hybridization artefacts, which in turn cause reporting of 
false cis-acting expression QTLs (Alberts, Terpstra et al. 2007; Benovoy, Kwan et al. 
2008). Since the signals produced by Illumina probe ILMN_1710903 in mixed H1/H2 
sample sets are responsible for the widely reported cis-acting MAPT expression QTL 
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(characterised by lower expression of MAPT in H2 individuals) (Myers, Gibbs et al. 
2007; Gibbs, van der Brug et al. 2010; Nalls, Plagnol et al. 2011), this finding would 
suggest that this gene level mRNA expression QTL is a technical artefact. However, 
restricting the analysis to H1 homozygotes to explore the impact of the H1c haplotype 
on gene expression was performed. Unfortunately, this analysis did not demonstrate a 
significant association between the H1c haplotype (tagged by rs242557) and MAPT 
mRNA expression, as measured with Illumina probes ILMN_1710903 and 
ILMN_2310814. This does not exclude the possibility that this haplotype could affect 
MAPT mRNA splicing patterns. 
In conclusion, the regional expression patterns of MAPT at the exon and gene 
mRNA and protein levels were examined in this study on the largest control human 
brain data set.  This enhanced the establishment of a valuable reference of normal 
regional MAPT mRNA and protein isoforms expression levels. In addition, this study 
stresses the importance of exon-specific analysis as indicated by the association of 
exon-3 inclusion mRNA transcript expression with the H1/H2 inversion 
polymorphism. Exon-specific analysis may prove particularly significant in elucidating 
pathogenic mechanisms in neurodegenerative diseases that belong to a similar 
proteinopathy group but differ in their clinical-pathological profile.  
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The results of the work described in this chapter were published in Human Molecular 
Genetics:  
Trabzuni, D., Wray, S., Vandrovcova, J., Ramasamy, A., Walker, R., Smith, C., Luk, 
C., Gibbs, J.R., Dillman, A., Hernandez, D.G. et al. (2012) MAPT expression and 
splicing is differentially regulated by brain region: relation to genotype and implication 
for tauopathies. Human Molecular Genetics, 21, 4094-4103. 
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6 Characterization of LRRK2 mRNA expression and splicing in 
multiple control human brain regions: its relevance to human disease 
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6.1 Summary 
Common and rare mutations at the LRRK2 (Leucine-rich repeat kinase 2) locus 
have been identified in Parkinson’s disease (PD), Crohn’s disease (CD) and leprosy. 
However, little is known about the molecular mechanisms underlying these disease 
associations.  
To further characterize this locus, the expression and splicing profiles of 
UKBEC, 134 control individuals, from ten brain regions were used for this analysis.  
The regional variation, splicing and regulation of LRRK2 mRNA and protein levels 
(MJFF2 antibody) were studied in detail.   
The results showed that the mRNA expression levels were highest in cortical 
regions and lowest in cerebellum. Novel splicing events involving exons 32-33 (COR 
and kinase domain) and exon 42 (kinase domain) were identified and confirmed. In 
addition, LRRK2 protein expression was demonstrated in multiple cell types, including 
neurons, glia and endothelial cells as demonstrated by immunohistochemistry (IHC). 
An exon quantitative trait locus (QTL) in brain that regulates the splicing of exons 32-
33 and which is in strong linkage disequilibrium with CD associated non-synonymous 
SNP rs3761863 (M2397T) was identified; suggesting a possible molecular mechanism 
for CD association at this locus.   
The results characterize the LRRK2 locus and highlight the importance and 
difficulties of fine-mapping and integration of multiple datasets to delineate pathogenic 
variants and thus develop an understanding of disease molecular mechanisms.  
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6.2 Introduction 
The role of LRRK2 (Leucine-rich repeat kinase 2) in human disease was first 
recognised in 2004 when dominant mutations in the LRRK2 gene were linked to PD 
(Paisan-Ruiz, Jain et al. 2004; Zimprich, Biskup et al. 2004). Rare genetic variants 
located in the LRRK2 gene contribute to a significant fraction of familial clustering of 
the disease (Ross, Soto-Ortolaza et al. 2011). In particular, heterozygous carriers of the 
non-synonymous change G2019S have an estimated PD lifetime risk close to 50% 
(Melrose, Kent et al. 2007; Healy, Falchi et al. 2008), which directly implicates the 
LRRK2 gene in the aetiology of PD.  In addition, recent GWAS results suggest that 
common variants with a more modest effect on PD risk also exist at this locus (Nalls, 
Plagnol et al. 2011). Intriguingly, GWAS have implicated LRRK2 in the pathogenesis 
of CD and leprosy (Zhang, Huang et al. 2009; Franke, McGovern et al. 2010; Lewis 
and Manzoni 2012). However, the mechanisms linking the LRRK2 gene and human 
disease remain largely unknown and are the focus of an intense research effort. 
The LRRK2 gene spans 1.4 Mb and is made up of 51 exons. It produces a 2,527 
amino acid protein with multiple functional domains, including leucine-rich repeats 
(LRR), a GTPase domain (Ras of Complex proteins or ROC domain), a domain of 
unknown function termed the C-terminal of ROC (COR) domain, a kinase domain and 
a WD40 domain (Cookson 2010). Coding changes causative for PD are located within 
the enzymatic core of LRRK2, namely the ROC-COR-Kinase triad of domains, and 
several of the mutations described in this region disrupt the enzymatic activities of the 
protein, strongly implicating the enzymatic function of LRRK2 in the pathogenesis of 
PD (West, Moore et al. 2005; Lewis, Greggio et al. 2007; Greggio and Cookson 2009). 
Existing data demonstrate ubiquitous expression of LRRK2 in human brain in addition 
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to liver, kidney and thymus (Paisan-Ruiz, Jain et al. 2004; Zimprich, Biskup et al. 
2004). A number of studies have been undertaken to investigate the function, 
expression and cellular localization of LRRK2 in the human brain (Galter, Westerlund 
et al. 2006; Higashi, Biskup et al. 2007; Vitte, Traver et al. 2010; Sharma, 
Bandopadhyay et al. 2011), however, these findings have been based on relatively 
small numbers of individuals. Consequently, much of the biology of this gene remains 
unknown. Very little is known about the pattern of LRRK2 gene expression across the 
human brain, to what extent it is the subject of alternative splicing, whether splicing is 
region-specific, and how the expression of LRRK2 is regulated. Understanding the 
mRNA and protein processing is critical for deciphering how LRRK2 dysfunction 
results in disease. 
A key area of research is the identification of the molecular mechanisms 
linking variants in the LRRK2 region with modified risk for PD, CD and leprosy 
(Barrett, Hansoul et al. 2008; Zhang, Huang et al. 2009; Franke, McGovern et al. 2010; 
Nalls, Plagnol et al. 2011; Ross, Soto-Ortolaza et al. 2011). The hypothesis is that 
some of these effects are mediated by genetic control of the expression and/or splicing 
or LRRK2 mRNA. This hypothesis can be tested by comparing disease GWAS results 
with expression datasets and by investigating whether these association signals are 
compatible with shared causal variants (Plagnol, Smyth et al. 2009). In addition to 
suggesting causal mechanisms, this analysis can point to tissue types involved in 
disease pathogenesis. For example, based upon the premise that PD is driven by 
pathophysiological processes resulting in the death of neuronal cell populations, there 
is considerable interest in dissecting the genetic basis of PD susceptibility at the 
LRRK2 locus by analysing this phenotype in the context of results in parallel with 
expression QTL studies conducted in multiple human tissues.  
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Here, the genotyped information that was generated using a custom array 
(Immunochip) as well as the Illumina Omni-1M Quad chip and imputation techniques 
(Howie, Fuchsberger et al. 2012) were used to provide dense genetic coverage at the 
LRRK2 locus. This data was then compared with gene, exon-specific LRRK2 mRNA 
expression profiles of UKBEC from ten brain regions: FCTX, n = 127, TCTX, n = 
119, OCTX, n = 129, HIPP, n = 122, THAL, n = 124, PUTM, n = 129, SNIG, n = 
101, MEDU, n = 119, CRBL, n = 130 and WHMT, n = 131 (1,231 Affymetrix exon 
arrays). Of these, SNIG and PUTM are relevant to PD pathophysiology (Wszolek, 
Vieregge et al. 1997). Moreover, these results were compared with published GWAS 
and  expression QTL findings using imputation techniques (Howie, Fuchsberger et al. 
2012) in order to obtain insights into the molecular mechanisms of LRRK2 disease 
associations. Using immunohistochemistry, the cell types that express LRRK2 protein 
in the human brain of controls were also investigated.  
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6.3 Results 
6.3.1 Regional expression of LRRK2 mRNA in multiple control human brain regions 
The array results showed evidence of regional variability in mRNA expression 
patterns. LRRK2 mRNA levels were three fold higher in OCTX (P < 10
-20
), the region 
expressing the highest LRRK2 levels, as compared to CRBL and WHMT (Figure 
6.3.1). The LRRK2 expression level in SNIG and PUTM, the brain regions most 
implicated in the pathophysiology of PD, were unremarkable (Figure 6.3.1). 
QuantiGene (Chapter 3, Figure 3.3.7) and real-time qRT-PCR (Figure 6.3.2) were 
used to confirm the array results and demonstrated similar regional mRNA expression 
patterns in a subset of brain samples within four selected regions. As previously 
documented in Chapter 2 (Trabzuni, Ryten et al. 2011), a very good agreement 
between the different gene expression quantification methods was observed.   
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Figure 6.3.1:  
Regional Distribution of LRRK2 mRNA expression. OCTX = occipital 
cortex, TCTX = temporal cortex, FCTX = frontal cortex, PUTM = putamen, 
SNIG = substantia nigra, THAL = thalamus, MEDU = medulla, HIPP = 
hippocampus, WHMT = white matter and CRBL = cerebellum. 
Boxplot of mRNA expression levels for LRRK2 in 10 brain regions, from 
microarray experiments on a log2 scale (y-axis). This plot shows the 
regional variation in LRRK2 transcript expression across all the regions. 
Whiskers extend from the box to 1.5 times the inter-quartile range. 
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Figure 6.3.2:  
Dot plot of mRNA expression levels for LRRK2 based on TaqMan 
qRT-PCR validation. OCTX = occipital cortex, WHMT = white matter 
and CRBL = cerebellum. 
The expression levels were normalized to the geometric mean of three 
housekeeping genes. The graph shows higher expression in OCTX 
compared with WHMT and CRBL. These data confirm the array results 
((Data produced by Dr Jana Vandrovcova). 
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6.3.2 Regional splicing of LRRK2 mRNA in multiple control human brain regions 
The analysis of the brain expression data at the exon level and across the ten 
brain regions, demonstrated that exons 32-33 (coding for part of the COR and kinase 
domains), display the highest expression variability between regions (Figure 6.3.3), 
with lower expression in cerebellum and higher in occipital cortex. A similar pattern 
for exon 42-43 was also observed (Figure 6.3.4), of particular interest owing to its 
location in the kinase domain (Lewis 2009). This suggestive evidence of alternative 
splicing of these exons was further confirmed by an analysis of variance on the 
splicing index (Kang, Kawasawa et al. 2011) of these exons to test for differences 
across the ten brain regions (P = 2.46×10
-5 
for exon 32 and P < 10
-25 
for exons 33, 42 
and 43). 
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Figure 6.3.3:  
Exon array expression data at the probe set level suggesting alternative 
splicing by brain region of the LRRK2 transcript. CRBL = cerebellum, 
OCTX = occipital cortex, PUTM = putamen, SNIG = substantia nigra and 
WHMT = white matter. 
Mean expression levels (y-axis) plotted for each probe set (x-axis) covering 
exon 27 to 37 of the LRRK2 gene in CRBL, OCTX, PUTM, SNIG and 
WHMT. Non-parallel probe set expression levels suggest differential 
expression and splicing of exons 28, 31, 32 and 33 in different regions. 
Selected exons are indicated by black arrow (▲). Partek alternative splicing 
ANOVA P value is < 1.0×10
-45
). Plot was generated in Partek Genomics 
Suite software. 
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Figure 6.3.4:  
Exon array expression data at the probe set level suggesting alternative 
splicing by brain region of the LRRK2 transcript. CRBL = cerebellum, 
OCTX = occipital cortex, PUTM = putamen, SNIG = substantia nigra and 
WHMT = white matter.  
Mean expression levels (y-axis) plotted for each probe set (x-axis) covering 
exon 38 to 51 of the LRRK2 gene in CRBL, OCTX, PUTM, SNIG and 
WHMT. Non-parallel probe set expression levels suggest differential 
expression and splicing of exons 41, 42 and 43 in different regions. 
Selected exons are indicated by black arrow (▲). Plot was generated in 
Partek Genomics Suite software. 
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Given this evidence, junction and exon-specific primers, and reverse 
transcriptase PCR (RT-PCR) in 12 brain samples and four brain regions were 
performed to further explore the splicing patterns of exons 32-33 and 42-43.  The 
splicing of exons 32-33 in SNIG as compared to OCTX, CRBL and MEDU was 
confirmed (Figure 6.3.5, A). This analysis revealed extensive splicing complexity 
around exons 31-33 (Figure 6.3.5, A and B). Exon 42 showed a high expression in 
OCTX, but low levels of expression or complete splicing out in SNIG and CRBL in 8 
out of 12 individuals (Figure 6.3.5, C). The corresponding functional domains in 
LRRK2 protein are shown in Figure 6.3.5, D.  
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Figure 6.3.5:  
RT-PCR results confirming regional differences in the splicing of targeted 
exons in the LRRK2 transcript in selected brain regions. OCTX = occipital 
cortex, SNIG = substantia nigra, MEDU = medulla and CRBL = cerebellum. 
(A) RT-PCR results confirming the splicing out of exons 31-32 in SNIG, compared 
with the other brain regions tested. The expected band size for the isoform with 
exon 31- 32 included is 470 bp, whereas that for the isoform with exon 32 alone 
spliced out is 270 bp.  These results show splicing out of exons 31-32 in SNIG and 
the existence of an isoform with exon 32 alone spliced out in OCTX, MEDU and 
CRBL. In addition, the difference in the band intensity between the two observed 
isoforms, suggests that the isoform with exon 32 spliced out is expressed at lower 
levels than the isoform with exon 31-32 included. (B) RT-PCR results further 
confirm the splicing out of exon 32 in SNIG. While OCTX, MEDU and CRBL 
show the expected band size of 195 bp suggesting that exon 32-33 is not spliced 
out in these regions, SNIG does not. (C) RT-PCR results confirming that exons 42-
43 are present and have high expression in OCTX in all individuals but are spliced 
out in SNIG and CRBL in eight out of twelve individuals. The expected band size 
for the isoform with exon 42-43 included is 200 bp and 100 bp when exon 43 alone 
is spliced out. OCTX expressed the two isoforms of LRRK2, that contain exons 42-
43 and the additional isoform with exon 43 spliced out (faint band). Dark blue, 
orange and green arrows indicate the locations of the exon-specific RT-PCR 
primers. (D) Schematic view shows the functional domains that targeted exons 
corresponding to in LRRK2 protein.  
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6.3.3 Regional expression of LRRK2 protein in multiple control human brain regions 
In order to investigate whether the trends that were observed at the mRNA 
level could also be observed at the protein level, Western blot and 
immunohistochemistry (IHC) techniques were applied using the MJFF2 antibody 
(validated using tissue LRRK2 knockout mice (Lin, Parisiadou et al. 2009) (Figure 
6.3.6). This antibody was raised against recombinant protein covering residues 970-
2575. LRRK2 protein levels were shown to exhibit a similar pattern to the mRNA 
expression levels in five selected regions using Western blots of control tissue from 
five individuals (Figure 6.3.7). A number of specific LRRK2 immunoreactive bands 
were identified, which may be the product of proteolytic processing or alternative 
splicing events. 
    
 
 
 
 
 
 
 
 
Figure 6.3.6:  
Western blot of mouse brain with MJJF2 antibody. 
Western blot of wild type and knock out mouse brain 
probed with anti-LRRK2 MJFF2 antibody (upper band) 
and beta actin loading control (lower band) 
demonstrating specificity of MJFF2 antibody (Lin, 
Parisiadou et al. 2009). 
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Figure 6.3.7:  
LRRK2 protein levels in selected regions using Western blots of control 
tissue. CRBL = cerebellum, FCTX = frontal cortex, OCTX = occipital 
cortex, PUTM = putamen and WHMT = white matter. 
(A) mRNA expression levels for LRRK2 in five brain regions, CRBL, 
FCTX, OCTX, PUTM and WHMT for one individual. (B) The Western blot 
for the LRRK2 protein, showing that the highest expression was in OCTX 
as a faint band can be observed at the right size of 260 kDa. (C) Graph 
showing the protein level for LRRK2 in the same five brain regions to 
demonstrate the constant pattern between the array results at the mRNA and 
the protein level of LRRK2 (Data produced by Dr Patrick Lewis). 
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IHC was applied to determine the cellular distribution of LRRK2 in control 
human brain tissue from FCTX, OCTX, CRBL, SNIG and striatum (caudate and 
PUTM) (Figure 6.3.8 and summary in Table 6.3.1). The results revealed LRRK2 
expression to be highest in the cerebellar purkinje cells, both in the neuronal perikarya 
and also in the processes (Fig 5A and B for negative control pre-absorbed antibody). 
Low levels of LRRK2 immunoreactivity were detected within neurons in FCTX, in the 
neuronal perikarya of OCTX (Figure 6.3.8, C-D). Low or background levels of 
LRRK2 staining were noted in the cytoplasm of neuromelanin-positive SNIG neurons 
(Figure 6.3.8, E) and in the medium spiny neurons within the striatum (data not 
shown). All regions showed LRRK2 immunoreactivity in the smooth muscle and 
endothelium of blood vessels. Interestingly, some astroglia (Figure 6.3.8, F) were 
positive for LRRK2 and were seen both in the grey and white matter of all regions 
studied. Although no LRRK2 immunoreactivity could be detected within microglia, it 
should be noted that the control brain tissue used would not be expected to contain 
activated microglia, which could have a very different expression profile. A summary 
of relative staining intensity obtained with the MJFF2 antibody is described in Table 
6.3.1. 
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Figure 6.3.8:  
Immunohistochemical distribution of LRRK2 in control human brain 
visualized by rabbit monoclonal MJFF2 antibody. 
(A) Cerebellar purkinje neurons (black arrow) and processes (green arrows) 
display strong labelling for LRRK2. (B) Cerebellar section probed with pre-
absorbed antibody shows complete absence of LRRK2 labelling in purkinje 
neurons (black arrows). (C) Larger neurons (black arrows) in the deep layer of 
frontal cortex show low levels of LRRK2 immunoreactivity. (D) Neurons in the 
occipital cortex show low levels of immunoreactivity for LRRK2. (E) Melanised 
nigral neurons from the substantia nigra show minimal LRRK2 immunoreactivity. 
(F) Astrocytes positive for LRRK2 immunoreactivity in the grey matter of frontal 
cortex. Scale bar: 20 µm in A, B, C, F and 10 µm in D and E (Data produced by Dr 
Rina Bandopadhyay). 
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Table 6.3.1: Relative intensity of LRRK2 immunohistochemistry in various cell 
types of the control human brain. 
 
Key:  +, background expression; + low expression, ++ mild expression; +++ 
high expression. CRBL = Cerebellum, SNIG = Substantia nigra, PUTM = 
Caudate+Putamen, FCTX = Frontal cortex and OCTX = Occipital cortex. 
 
  
Region Neuronal LRRK2 Glial LRRK2 Blood vessels 
CRBL Purkinje cells +++ Astrocytes ++ Endothelial cells ++ 
CRBL Granule cells + + + 
SNIG DA neurons + Astrocytes ++ Endothelial cells  ++ 
PUTM Neurons  + Astrocytes ++ Endothelial cells ++ 
FCTX Neurons + Astrocytes ++ Endothelial cells ++ 
OCTX Neurons + Astrocytes ++ Endothelial cells ++ 
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6.3.4 Relevance of genetic control of expression for PD, CD and leprosy 
Using the publically available association data from GWA results for PD, CD 
and leprosy and UKBEC expression profiles in human brain, the question as to 
whether the association of LRRK2 with these diseases is compatible with shared causal 
expression variant(s) was assessed (Table 6.3.2).  
The analysis identified an exon expression QTL linking the levels of exons 32 
and 33 with SNP rs10784486 (rs118049839) at genomic position chr12:40677029 (In 
the intron 18-19 of the LRRK2 gene) (Table 6.3.3 and Figure 6.3.9) that was 
consistent with a shared causal variant. The secondary LRRK2 CD association (lead 
SNP rs3761863) was strongly correlated with LRRK2 mRNA expression of exons 32 
and 33 in control human brain (Figure 6.3.10). The minor allele T of rs3761863 
increases CD risk and is associated with a decrease in LRRK2 expression (Table 6.3.2 
and Figure 6.3.10). While the summary statistic level of the latest CD meta-analysis 
(for the rs3761863/CD exon expression QTL) does not enable a formal test of co-
localization between disease and expression QTL signals (Plagnol, Smyth et al. 2009), 
these results suggest plausible mRNA mechanisms to mediate this secondary CD 
association signals.  
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Table 6.3.2: Common variant associations in the LRRK2 region for PD, CD and leprosy.  
 
 
 
 
 
 
For each disease association the P-values in the expression datasets were listed. 
a: See Figure 6.3.10. 
 PD CD, 1
st 
signal CD, 2
nd
 signal Leprosy 
SNP rs117762348 rs11564258 rs3761863
a rs1491938 
Position chr12:40,597,612 chr12:40,792,300 chr12:40,758,652 chr12:40,645,630 
Alleles (major > minor) A > G G > A C > T T > C 
MAF 0.076 0.034 0.32 0.396 
Odds ratio for minor allele (95% CI) 0.85 (0.80-0.91) 1.74 (1.55–1.95) 1.1 ( 1.05-1.15) 0.86 (0.80-0.92) 
P-value brain dataset 9.6×10
-01
  0.081 2×10
-08
 8.7×10
-03
 
Expression effect on LRRK2 mRNA 
(for the minor allele) 
Not detected Not detected Decrease Not detected 
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Table 6.3.3: Information on the identified LRRK2 exon expression QTL in the UKBEC (n = 134). 
 
 
 
For the P-value computations in brain samples, LRRK2 expression values are averaged across all 10 brain regions.  
MAF: minor allele frequency. a: See Figure 6.3.9.  
Lead SNP Position Alleles MAF Probe location P-value 
Direction of effect 
(for minor allele) 
rs10784486
a chr12:40,677,029 C > A 0.33 exons 32 and 33 5.1E-10 Decrease 
LRRK2 genetics, expression and splicing in human brain 
217 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.9:  
The effect of rs10784486 on the expression of LRRK2 exon 33. OCTX = 
occipital cortex, TCTX = temporal cortex, FCTX = frontal cortex, PUTM = 
putamen, SNIG = substantia nigra, THAL = thalamus, MEDU = medulla, 
HIPP = hippocampus, WHMT = white matter and CRBL = cerebellum. 
LRRK2 exon 33 expression (Affymetrix probe set 3411379) stratified by 
rs10784486 for ten brain regions in 134 brain samples. Decreased exon 33 
expression was associated with the homozygous minor allele (AA). A 
similar association pattern was observed in all brain regions. All ten brain 
regions shown as well as combined mean across region (aveALL). 
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Figure 6.3.10:  
The effect of rs3761863 on the expression of LRRK2 exon 33. OCTX = 
occipital cortex, TCTX = temporal cortex, FCTX = frontal cortex, PUTM = 
putamen, SNIG = substantia nigra, THAL = thalamus, MEDU = medulla, 
HIPP = hippocampus, WHMT = white matter and CRBL = cerebellum. 
LRRK2 exon 33 expression (Affymetrix probe set 3411379) stratified by 
rs3761863 for ten brain regions in 134 brain samples. Decreased exon 33 
expression was associated with the homozygous minor allele (TT). A 
similar association pattern was observed in all brain regions. All ten brain 
regions shown as well as combined mean across region (aveALL). 
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6.4 Discussion 
 The key role of the LRRK2 locus in Parkinson’s disease was the motivation 
for fine-mapping this locus in the UKBEC individuals.  The analysis of the gene/exon 
expression dataset highlighted the complexity of the genetic control of LRRK2 in the 
human brain. A significant exon expression QTL was reported in the brain tissue that 
involves exons 32 and 33 of LRRK2 but does not co-localize with the PD association. 
The most recent meta-analysis results for CD indicated a secondary association 
for CD, for which the non-synonymous SNP rs3761863 is a leading associated variant 
(P = 3.0×10
-6
) (Franke, McGovern et al. 2010). SNP rs3761863 is also strongly 
associated with the exon 32-33 brain exon expression QTL (SNP rs10784486) that was 
identified (P = 2×10
-8
, Table 6.3.3). These results suggest a potential mechanism to 
mediate the CD association. CD may involve any part of the gastrointestinal tract, but 
most frequently the terminal ileum or any region of the intestine (Bernstein, Wajda et 
al. 2005) and since the human intestine is heavily innervated with nerve endings, the 
findings in brain tissue may be relevant to CD. It is therefore possible that the 
exon/expression correlation may be shared across other tissue types and so analysis of 
expression in intestinal tissue is warranted. Moreover, additional CD fine-mapping will 
be required to test whether the CD and brain exon expression QTL datasets are fully 
consistent with a shared variant. Furthermore, a previous study has associated the 
nsSNP rs3761863/M2397T with LRRK2 protein stability (Liu, Lee et al. 2011). 
These results highlight several factors that complicate the follow-up of 
associated variants at the LRRK2 locus in all diseases and in particular PD: the 
existence of multiple LRRK2 isoforms, variability in mRNA expression and splicing 
across brain regions, and localisation of LRRK2 protein to both neuronal and non-
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neuronal cell types. On the basis of both exon array and RT-PCR data there is a 
prediction that at least two further isoforms exist in addition to full-length LRRK2: an 
isoform that lacks exon 32 and an isoform that lacks one or both of exon 42-43. Given 
that exons 32 and 42-43 all map to functional domains of the LRRK2 protein (COR 
and kinase domains) these splicing events are likely to have functional consequences 
upon complex formation and/or enzymatic function. In fact, data from a number of 
groups have demonstrated that expression of truncated forms of LRRK2 has a major 
impact on the enzymatic functions of this protein, although these studies have – to date 
– examined only artificial truncation constructs (Jaleel, Nichols et al. 2007; Luzon-
Toro, Rubio de la Torre et al. 2007; Klein, Rovelli et al. 2009). As a result, it is very 
important to note that future characterization of the regional splicing isoforms of 
LRRK2 must include not only mRNA analysis, but also cDNA and amino acid 
sequencing to ensure that as many variants as possible are captured. Understanding the 
range of different protein isoforms will be critical to understanding the physiological 
functions of LRRK2. 
The analysis of gene expression in ten brain regions, including PD-relevant 
tissues such as the substantia nigra and putamen, also provided insights into the wide 
regional variation in gene expression within the human brain. These differences were 
in some cases large, with a 3.0 fold change in expression between the occipital cortex 
and cerebellum. Furthermore, regional LRRK2 protein expression measured by 
Western blotting correlated well with mRNA levels simplifying the interpretation of 
mRNA-based exon expression QTLs. The use of a recently well-characterised 
monoclonal antibody (Mandemakers, Snellinx et al. 2012) also showed that LRRK2 
expression is not restricted to neurons in the control human brain. Even amongst the 
neuronal population LRRK2 staining levels were variable, with higher 
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immunoreactivity in purkinje cells of the cerebellum as compared to neurons of the 
cortical regions, basal ganglia and dopaminergic substantia nigra neurons.  These 
immunohistochemistry results are broadly concordant with previously reported 
LRRK2 localisation data in rodent and human brain (Greggio, Jain et al. 2006; 
Higashi, Moore et al. 2007; Melrose, Kent et al. 2007; Vitte, Traver et al. 2010; 
Sharma, Bandopadhyay et al. 2011). These results were extended by demonstrating 
that LRRK2 protein expression in glial cells is more widespread than was originally 
thought.  While this may be due to the use of polyclonal antibodies recognising 
different epitopes of the LRRK2 protein, recent evidence proposes that LRRK2 is 
expressed in monocytes and in activated microglia implying a role for LRRK2 in the 
immune system and in PD (Hakimi, Selvanantham et al. 2011; Thevenet, Pescini 
Gobert et al. 2011; Moehle, Webber et al. 2012).  
Furthermore, it is important to realize that the amino acid epitope which the 
antibody binds to is not known. For example, if the antibody binds to the epitope that 
is presented by exon 32 or any other spliced exons, a specific protein isoform will not 
be detected in the Western blot even if it is expressed in the cell/tissue. Therefore, 
epitope mapping for this antibody is needed to detect and identify different isoforms of 
LRRK2 protein in further investigations. 
In summary, this study provides novel insights into LRRK2 expression, splicing 
and regulation with a potential link to the aetiology of CD. It also highlights the 
relevance of imputation techniques to provide the dense coverage required to integrate 
multiple disease association and gene expression studies. The localization of the 
common variant PD association outside of the coding region of LRRK2 suggests that it 
is likely that the effect on disease risk is mediated by control of mRNA expression. 
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These data, together with the recent analysis of the MAPT locus, illustrate the 
complexities of defining precisely how risk loci contribute to disease and illustrate that 
there is as much work required to dissect a locus as to identify it in the first place 
(Trabzuni, Wray et al. 2012).  In addition, gene expression studies are required to 
increase the quality and quantity of data to maximize the power to dissect the genetic 
control of LRRK2 expression in all those diseases in which it is implicated. 
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7 Discussion and future recommendations 
  
The first aim for this thesis was to generate a genome-wide and large scale 
genetic-phenotypic data set that will advance neuroscience research in the field. The 
information obtained from the multiple CNS regions that were dissected from 137 
control human post-mortem brains will be a publicly available reference data set, to be 
used to assess specific hypotheses in various projects in the future.  
The data set resulting from this study will complement the other data sets that 
were generated for the same purpose, either from human brain or different human 
tissues using different sample sizes, different CNS regions and different expression and 
genotyping platforms (Gardina, Clark et al. 2006; Roth, Hevezi et al. 2006; Myers, 
Gibbs et al. 2007; Wang, Sandberg et al. 2008; Johnson, Kawasawa et al. 2009; 
Webster, Gibbs et al. 2009; Gibbs, van der Brug et al. 2010; Kang, Kawasawa et al. 
2011; Nica, Parts et al. 2011; Hawrylycz, Lein et al. 2012; Hernandez, Nalls et al. 
2012). Data from this study demonstrates that 70 to 80% of transcript/gene expression 
and splicing profiles from human post-mortem frozen brain regions are reproducibly 
recoverable to improve our understanding of the genetic regulation of the transcriptome 
architecture of the human brain in specific tissues, and eventually in specific cell types.  
 The identification of the expression and splicing patterns in the human CNS 
was performed to achieve the second aim of this project. Results revealed that the 
alternative splicing pattern is the main pattern in the human CNS between the 12 
regions, particularly in cortical regions (OCTX, FCTX and TCTX). Furthermore, there 
was a specific expression signature for certain regions such as CRBL and WHMT.  
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Lastly, this thesis demonstrates that this resource permits the start of the 
exploration of the functional effects of the genetic variants on the brain transcriptome 
in specific CNS regions focusing on targeted genes. The primary advantage of this type 
of data is that further advanced analyses can be undertaken, using different 
bioinformatics tools and this can be followed up with bench experiments depending on 
specific hypotheses that the researchers are posing.  This is important as new 
bioinformatic and molecular biology tools become available in the future.  
Recently, not only have new techniques been developed in the field to 
maximize the probability of producing high quality and reliable data from partially 
degraded RNA and precious tissue samples such as human brain tissues, but also the 
sensitivity and specificity of isoforms predicting algorithms have been improved 
(Anton, Aramburu et al. 2010; Chow, Li et al. 2011).  
The logical step forward is to perform second stage analyses (Stage II) of the 
data to address the challenges raised through Stage I analyses of this project.  These are 
outlined as follows.  
Firstly, integrating the expression, splicing and expression QTLs resulting from 
this study into functional databases. The results from this study revealed regional 
specific differential expression patterns especially in the cerebellum and white matter. 
Furthermore, the alternative splicing patterns were the leading pattern in the cortical 
regions and this matches the expression QTL results where the exon level expression 
QTLs were the dominant signals. The application of weighted gene co-expression 
network analysis (WGCNA) (Zhang and Horvath 2005) will help to identify network 
connectivity modules in specific regions or between all regions (Johnson, Kawasawa et 
al. 2009). Other tools can be used in parallel to integrate the results with the Database 
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for Annotation, Visualization and Integrated Discovery (DAVID) (Huang da, Sherman 
et al. 2009)  to identify enriched biological themes such as functional and clustering 
classification using gene ontology (GO). Identification of over-represented 
transcription factor binding sites (TFBS) in targeted modules is also applicable (Ho Sui, 
Mortimer et al. 2005). A recent study demonstrated a very specific example for distinct 
cortical areas in two individuals. By using the combination of some of the mentioned 
tools and RNA sequences, the link between the cognitive function and the 
transcriptome of these cortical regions was established (Naumova, Palejev et al. 2012). 
The use of these bioinformatic tools does not exclude the importance of molecular and 
cellular biology experiments that are required to validate the results further. 
Secondly, it is crucial to follow up and validate the gene and exon expression 
QTLs using specific cellular modules to perform experiments and advanced 
bioinformatic tools. To date, GWAS results have provided an extended list of coding 
and non-coding SNPs that are associated with neurological diseases. Moving beyond 
that type of information is vital, as the successful identification of variants that 
contribute functionally to complex traits is highly dependent on the type and reliability 
of the assay (Stranger, Forrest et al. 2005). In a heterogeneous organ such as the brain, 
it is challenging to evaluate the effect of the expression QTLs on the transcriptome. The 
presence of different types of neurons and glial cells at different ratios, in different 
regions complicate the interpretation of the results. It will be difficult to be certain on 
which cell type the expression QTL is acting. Moreover, it cannot be confirmed that 
this expression QTL is the associated biomarker with the investigated disease. At this 
end to consider these QTLs as functional biomarkers, further validations and 
integration of these results with different and advanced techniques are important. 
Induced pluripotent stem (iPS) cell technology is an advanced technique (Takahashi, 
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Tanabe et al. 2007) that scientists are using to generate specific types of human 
neurons. This technique is suggested as a future approach to overcome the challenge of 
mixed cell populations. The Encyclopaedia of DNA Elements (ENCODE) Consortium 
is also one of the main bioinformatic tools that can be used to identify functional and 
regulatory elements in the human genome (Dunham, Kundaje et al. 2012; Harrow, 
Frankish et al. 2012), in addition to all the bioinformatic and molecular biology tools 
described above.  
The experience that was earned from this project has taught us that the 
distribution patterns and the resulting effects of brain expression QTLs are not fully 
understood. This was demonstrated by the analysis of two examples, specifically the 
genes MAPT and LRRK2 that were covered comprehensively in this study. There is still 
a pressing need to investigate further some of the findings in order to have conclusive 
results. For MAPT for example, further investigations are needed taking into 
consideration the existence of antisense RNA molecules and how that can affect the 
splicing and regulate the transcriptional processing of the MAPT mRNA in the cell 
(Peacey, Rodriguez et al. 2012). Regarding LRRK2, future work is required to 
investigate the novel isoform presence in different brain regions by combining cDNA 
and protein sequences from brain tissues and connecting this to the expression QTLs 
detected. Moreover, improving the quality of the immune detection method is also 
required.  
Thirdly, RNA sequencing is becoming the method of choice. It will help to 
overcome some of the limitations of previous technologies by avoiding the biases 
presented in hybridization, allowing strand specific detection, novel isoforms detection 
and having a higher resolution than the exon arrays in particular, particularly if it is 
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applied at the cell level such as neurons and astrocytes. In addition, RNA sequencing 
will provide information about the non-coding RNA such as microRNA and this is 
important for neurodegenerative diseases (Baginsky, Hennig et al. 2010; Salta and De 
Strooper 2012). However, the analyses and the volume of the data that are generated 
from this complex technique are computationally challenging. To date, there is no 
standard protocol available to normalize, process the raw data from these experiments 
in to a manageable format that can then be further interrogated on a personal computer 
and to align and assemble the data to a reference genome (Auer, Srivastava et al. 2012). 
RNA sequencing can detect newly discovered RNA species such as antisense 3' RNA 
that we do not understand the function of yet (Ozsolak and Milos 2011).  
Finally, the main challenge in the field of neuroscience after generating and 
analyzing such genome-wide and large scale data sets, is the ability to integrate 
different data into higher dimensional data sets. This will be achieved by linking the 
genetic, functional genomic, network analysis, cellular biology and proteomic data to 
the central nervous system functions (Geschwind and Konopka 2009; Sanderson 2009; 
Lewis, Schramm et al. 2010). As a result, novel hypotheses will be generated to be 
tested in more advanced levels in the field (Hawkins, Hon et al. 2010; Lewis, Schramm 
et al. 2010) to provide more conclusive answers. 
Over the last decade, the fields of genomics and transcriptomics have developed 
rapidly to routinely use digital platforms, as compared to the progress of other fields of 
science. For example, the development of biochemical, cellular and functional biology 
tools are at least two decades behind (Dr Patrick Lewis, personal communication); this 
may due to the constantly changing factors that influence experiments in these other 
fields of science.   
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In conclusion, this project provides a reference dataset and remarkable results to 
be used as a resource for further functional biology investigations. It can be used to 
initiate new follow up research areas in various directions and to encourage researchers 
in the biochemistry, cellular and functional biology fields to develop more advanced 
and higher throughput tools. This research can be applied in targeted areas and a 
pipeline established to transfer these results into a solid functional framework. 
Integrating data from different research areas will ultimately lead to the dissemination 
of the scientific findings to the health industry and the field of drug discovery to 
achieve a long term beneficial impact on the clinical management of neurodegenerative 
diseases in the future. 
 
 
 
 
 
“Have you noticed how the more you learn, the more you 
realize how little you know” 
Plato 
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